[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"RAYSEARCH LABORATORIES AB\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":411},{"warningLetters":4,"total":410},[5,32,54,80,101,123,145,166,184,203,223,242,261,280,297,320,339,358,373,390],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},722,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-12T04:00:00Z\">08\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-06T04:00:00Z\">08\u002F06\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbe-laboratories-inc-708309-08062025\">ABBE Laboratories, Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-98\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul A. Iannuzzo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ABBE Laboratories, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1095 Route 110, Suite E, F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Farmingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11735-4815\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-98\u003C\u002Fp>\u003Cp>August 6, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Iannuzzo:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ABBE Laboratories, Inc., FEI 3004433842, located at 1095 Route 110, Suite E, F, Farmingdale, New York, from February 24 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 11, 2025, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. In your response, you commit to the creation of standard operating procedures (SOPs) and work instructions to comply with CGMP regulations; however, no details were provided on the content of these documents.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures and repackages over-the-counter (OTC) drug products, including topical liquids and ointments, without adequate assurance of the quality of components used in their manufacture. For example, you failed to adequately test your incoming components, including identity testing for each shipment of each component lot used in the manufacture of your OTC drug products. Instead, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing High-Risk Drug Components\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test for identity each shipment of every lot of propylene glycol and glycerin, components at higher risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, received at your facility. Identity testing for propylene glycol, glycerin, and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document: Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your 2009 cleaning validation study for the Kettle \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment is inadequate to ensure your cleaning procedures are effective for the multiple OTC drug products your firm manufactures. For example, the cleaning validation study did not include a determination of the worst-case drug product for this shared equipment and lacked the identity of the drug product cleaned during the study. You also failed to perform a new cleaning validation study when you began manufacturing a new drug product, End Zit Acne Drying Lotion, which you determined to be the most difficult to clean product due to the titanium dioxide active ingredient, on shared equipment.\u003C\u002Fp>\u003Cp>In addition, the cleaning validation study for your kettle lacked analysis for API residues.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Cleaning Documentation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Although your procedures define the cleaning steps, you lacked documented evidence that you performed each step of the cleaning process as required. Your procedure, ABBE-010, requires that you document all cleaning and sanitization information into the cleaning and sanitizing logbooks; however, you stopped documenting cleaning activities in your logbooks and status of the equipment around 2020.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment and disinfection cleaning. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum dirty and clean hold times before cleaning\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\u003Cul>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate you adequately validated the manufacturing processes for your OTC drug products. You stated that you validated the process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sunscreen, \u003Cstrong>(b)(4)\u003C\u002Fstrong> SPF 30, \u003Cstrong>(b)(4)\u003C\u002Fstrong> SPF 30, and End Zit Acne Drying Lotion; however, you were unable to provide a validation protocol and corresponding report with established parameters (e.g., mixing speeds, temperature, hold times prior to filling) to demonstrate process control for each product you manufacture.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>This is a repeat finding from your 2018 inspection when you committed to initiate process validation by September 2018 and forward final reports to FDA upon completion. The current inspection found that you failed to fulfill this commitment.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked adequate oversight for the manufacture and repackaging of your OTC drug products. For example, you failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of suitable quality oversight procedures (e.g., investigations, returns\u002Fcomplaints, CAPA, and label reconciliation).\u003C\u002Fli>\u003Cli>Implementation of adequate documentation practices. For example, we collected documents, including batch records and an out-of-specification investigation record, that were incomplete (e.g., documents had blank spaces, missing signatures), although the OTC drug products were released by your quality unit (QU).\u003C\u002Fli>\u003Cli>Performance of an appropriate periodic (at least annual) review of drug product production. For example, you failed to perform annual product reviews of your OTC drug products since at least 2018.\u003C\u002Fli>\u003Cli>Adherence to procedures for batch release. For example, you failed to complete the Finished Product Final Release Checklist for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of OTC drug products already distributed to the market.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous inspection, dated August 7 to 10, 2018, FDA cited similar CGMP violations for the lack of process validation and lack of annual product review. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004433842 and ATTN: Vilmary Negrón Rodríguez.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-98\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paul A. Iannuzzo\n\nRecipient Title\n\nManaging Director\n\nABBE Laboratories, Inc.\n\n1095 Route 110, Suite E, F\n\nFarmingdale, NY 11735-4815\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-98\nAugust 6, 2025\nDear Mr. Iannuzzo:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ABBE Laboratories, Inc., FEI 3004433842, located at 1095 Route 110, Suite E, F, Farmingdale, New York, from February 24 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 11, 2025, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. In your response, you commit to the creation of standard operating procedures (SOPs) and work instructions to comply with CGMP regulations; however, no details were provided on the content of these documents.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures and repackages over-the-counter (OTC) drug products, including topical liquids and ointments, without adequate assurance of the quality of components used in their manufacture. For example, you failed to adequately test your incoming components, including identity testing for each shipment of each component lot used in the manufacture of your OTC drug products. Instead, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nProducts Containing High-Risk Drug Components\nYou also failed to adequately test for identity each shipment of every lot of propylene glycol and glycerin, components at higher risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, received at your facility. Identity testing for propylene glycol, glycerin, and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document: Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn response to this letter provide:\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products.\nInadequate Cleaning Validation\nYour 2009 cleaning validation study for the Kettle (b)(4) equipment is inadequate to ensure your cleaning procedures are effective for the multiple OTC drug products your firm manufactures. For example, the cleaning validation study did not include a determination of the worst-case drug product for this shared equipment and lacked the identity of the drug product cleaned during the study. You also failed to perform a new cleaning validation study when you began manufacturing a new drug product, End Zit Acne Drying Lotion, which you determined to be the most difficult to clean product due to the titanium dioxide active ingredient, on shared equipment.\nIn addition, the cleaning validation study for your kettle lacked analysis for API residues.\nInadequate Cleaning Documentation\nAlthough your procedures define the cleaning steps, you lacked documented evidence that you performed each step of the cleaning process as required. Your procedure, ABBE-010, requires that you document all cleaning and sanitization information into the cleaning and sanitizing logbooks; however, you stopped documenting cleaning activities in your logbooks and status of the equipment around 2020.\nIn response to this letter provide:\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment and disinfection cleaning. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum dirty and clean hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to demonstrate you adequately validated the manufacturing processes for your OTC drug products. You stated that you validated the process for (b)(4) Sunscreen, (b)(4) SPF 30, (b)(4) SPF 30, and End Zit Acne Drying Lotion; however, you were unable to provide a validation protocol and corresponding report with established parameters (e.g., mixing speeds, temperature, hold times prior to filling) to demonstrate process control for each product you manufacture.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nThis is a repeat finding from your 2018 inspection when you committed to initiate process validation by September 2018 and forward final reports to FDA upon completion. The current inspection found that you failed to fulfill this commitment.\nIn response to this letter provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n4. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYou lacked adequate oversight for the manufacture and repackaging of your OTC drug products. For example, you failed to ensure:\nEstablishment of suitable quality oversight procedures (e.g., investigations, returns\u002Fcomplaints, CAPA, and label reconciliation).\nImplementation of adequate documentation practices. For example, we collected documents, including batch records and an out-of-specification investigation record, that were incomplete (e.g., documents had blank spaces, missing signatures), although the OTC drug products were released by your quality unit (QU).\nPerformance of an appropriate periodic (at least annual) review of drug product production. For example, you failed to perform annual product reviews of your OTC drug products since at least 2018.\nAdherence to procedures for batch release. For example, you failed to complete the Finished Product Final Release Checklist for at least (b)(4) batches of OTC drug products already distributed to the market.\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nRepeat Violations at Facility\nIn a previous inspection, dated August 7 to 10, 2018, FDA cited similar CGMP violations for the lack of process validation and lack of annual product review. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004433842 and ATTN: Vilmary Negrón Rodríguez.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","ABBE Laboratories, Inc.","abbe-laboratories-inc-708309-08062025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbe-laboratories-inc-708309-08062025","2026-10-26T08:07:48.589769+00:00","Warning Letter","Issued","2025-08-12","708309","Drugs Over-the-Counter Drugs","Mr. Paul A. Iannuzzo","2026-08-19T16:30:16.873+00:00","VIA EMAIL WITH READ RECEIPT","320-25-98","2025-08-06",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1092,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-06T05:00:00Z\">12\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frandox-laboratories-limited-696569-12062024\">Randox Laboratories Limited\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Peter FitzGerald\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Randox Laboratories Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>30 Randalstown Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Antrim\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>BT41 4FL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:peter.fitzgerald@randox.com\"> peter.fitzgerald@randox.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 6, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Steven Peter FitzGerald:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Antrim, United Kingdom on August 5, 2024 through August 8, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the RX series test systems, including the RX daytona, the RX daytona + (plus), and the RX imola test systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Linda A Magee, Chief Operating Officer dated August 29. 2024, and Oisin Quinn, Quality Improvement Manager dated November 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for validating device design, including appropriate risk analysis, as required by 21 CFR 820.30(g). For example, your firm has initiated five Class II Recalls, beginning in 2018 (Event IDs 81746, 86236, 91097, 92650, 93775), related to assay reagents from the previously used assays carrying over to the subsequent assay test, which caused erroneous results of the subsequent assay conducted on your RX series analyzers, including RX daytona and RX imola. Your firm’s procedure, Risk Management, RQA-1707, Revision O, drafted on June 6, 2023, section 5.1.3.4 Post Market surveillance, states “The Risk Management Report must be updated with any new hazards or hazardous situations identified and or any additional control measures that are required”. Additionally, section 5.2.4 Risk Control requires that control measures should be implemented using “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” in that order of priority. However, your firm has not conducted adequate risk analysis nor identified adequate control measures to address the risks of reagents from the precedent assays carrying over to the subsequent assay conducted on the RX series analyzers to ensure the devices (i.e., manufactured assays tested on RX series analyzers) meet their intended use.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified that the root cause is related to ambiguity in your risk analysis procedures, lack of clear responsibility for the activities, and that maintenance of the risk management files and not been effective. Your firm states that you have reviewed and updated the risk management files for the recalled products, however, copies of those files were not provided for review because they are currently under review by specified teams at your firm. An estimated date of completion was not provided.\u003C\u002Fp>\u003Cp>Your firm also provided Risk Management Report for RX Series Analyzers – Automated RX modena, RX daytona+, RX daytona, RX imola, RX monaco, dated September 30, 2024 and Risk Analysis for RX Series Analyzers – Automated, revision number 4, approved on September 30, 2024. A carryover and contamination category was added to analyzer risk analysis. The risk evaluation before \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, no information was provided to support \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required by RQA-1707.\u003C\u002Fp>\u003Cp>Your firm provided a revised job description for the Device Documentation Specialist (JD1402), who is within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of RQA-1707, revision Q, drafted September 20, 2024. The procedure has been revised to require the Quality Assurance department to review \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Post Market Surveillance, RQA-1664, revision M, drafted September 20, 2024 was revised to, among other things, define that the Quality Assurance Department is responsible \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024 was revised to include responsibility for Quality Assurance Department for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, RQA-1707, RQA-1664, and RGP-2032 do not reference the Device Documentation Specialist. Therefore, it is unclear how the revised job description will prevent similar failures in the future. Your firm stated retraining on RQA-1707, RQA-1664, and RGP-2032 was completed and provided examples for how a completion of training event was documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided. Your firm plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, evidence that appropriate control measures will be applied has not been provided. Your firm should provide an update on this review and any remediation efforts needed. You firm also stated that RGP-1002 has been updated but FDA was unable to open this file to review and therefore the Agency unable is unable to determine whether this action is effective.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA NCP INC612, was initiated on October 16, 2023, due to a customer complaint related to issues when running Copper assay on a RX daytona + analyzer. Your firm confirmed the testing of total protein carried over to the subsequent copper assay, causing falsely elevated Copper results. The root cause description states, “Carryover from both cuvettes and pipettes,” but fails to identify the underlying cause of why the reagent from the previously used assay carried over to the subsequent assay. The CAPA was closed on May 20, 2024, with the correction, “Technical bulletin RXTB-0121 to be updated with as a result of the testing recommending that Copper and Total protein on the same machine.” Since December 2018, your firm has initiated five US market Class II Recalls (Event IDs 81746, 86236, 91097, 92650, 93775) due to erroneous results caused by reagent carryover and, in each your firm has issued an updated Technical Bulletin for carryover avoidance (RXTB-0083, issued February 16, 2018 and RXTB-0098, issued November 20, 2018; RXTB-0121, issued July 31, 2020; RXTB-0136, issued September 22, 2022; RXTB-0148, issued June 6, 2023; RXTB-0148, issued November 22, 2023). The bulletin currently includes a list of over 50 combinations of assays to avoid running in sequence. CAPA #NCP INC612 fails to identify the action(s) needed to correct and prevent recurrence of carryover of assays run on the RX series analyzers. Additionally, activities to ensure the effectiveness of the corrective actions were not identified. Your firm states “Confirm no further complaints since bulletin” but fails to verify or validate the corrective and preventive action to ensure that such action is effective.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified the root cause is related to inadequate procedure and absence of dedicated training resources on root cause analysis for the staff to perform root cause analysis adequately and effectively. Your firm determined the actual root cause for the carryover event from CAPA #NCP INC612 is because of inadequate cleaning of the pipette\u002Fcuvette after programmed cleaning on the automated analyzer so the remaining residue of the reagents from Total Protein assay, which contains copper, impacted the subsequent Copper assay. Your firm has not identified corrective and prevention actions for CAPA #NCP INC612 and has not provided information on how you will verify or validate the corrective and preventive action is effective.\u003C\u002Fp>\u003Cp>Your firm has updated the CAPA procedure “Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024” to include reference to root cause analysis training material and created training slides “QAT 2.17.pptx” for performing root-cause analysis. Your firm stated training on RGP-2032 and QAT 2.17 was completed and provided an example for how the completion of training event documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided.\u003C\u002Fp>\u003Cp>Your firm proposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm should provide an update on this review and any remediation efforts needed.\u003C\u002Fp>\u003Cp>Your firm initiated a CAPA (qNCP 1394) dated August 29, 2024 to determine \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm has yet identified the root cause for causing the inadequate cleaning which your firm stated in an email dated November 8, 2024, is the common root cause of all the initiated recalls related to carryover on the RX series instruments. Your firm has yet to define actions to prevent recurrence.\u003C\u002Fp>\u003Cp>Your firm plans to review CAPAs and root cause \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm should provide an update on this review and any remediation efforts needed.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Additionally, based on information provided to the investigator during and following the inspection, it appears that your establishment registrations and device listings are incorrect and should be further clarified. During teleconferences following the inspection with the investigator on September 5 and 11, 2024, you promised to evaluate \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, as of the date of this letter your registration and listing data remains unchanged.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. \u003Cstrong>Refer to CMS case #696569 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: I-Lin Wu at i-lin.wu@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Cheryl OHagan\u003Cbr>US Agent\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteven Peter FitzGerald\n\nRecipient Title\n\nFounder and Managing Director\n\nRandox Laboratories Limited\n\n30 Randalstown Road\n\nAntrim\n\nBT41 4FL\n\nUnited Kingdom\n\npeter.fitzgerald@randox.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nDecember 6, 2024\nDear Mr. Steven Peter FitzGerald:\nDuring an inspection of your firm located in Antrim, United Kingdom on August 5, 2024 through August 8, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the RX series test systems, including the RX daytona, the RX daytona + (plus), and the RX imola test systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Linda A Magee, Chief Operating Officer dated August 29. 2024, and Oisin Quinn, Quality Improvement Manager dated November 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for validating device design, including appropriate risk analysis, as required by 21 CFR 820.30(g). For example, your firm has initiated five Class II Recalls, beginning in 2018 (Event IDs 81746, 86236, 91097, 92650, 93775), related to assay reagents from the previously used assays carrying over to the subsequent assay test, which caused erroneous results of the subsequent assay conducted on your RX series analyzers, including RX daytona and RX imola. Your firm’s procedure, Risk Management, RQA-1707, Revision O, drafted on June 6, 2023, section 5.1.3.4 Post Market surveillance, states “The Risk Management Report must be updated with any new hazards or hazardous situations identified and or any additional control measures that are required”. Additionally, section 5.2.4 Risk Control requires that control measures should be implemented using “(b)(4),” in that order of priority. However, your firm has not conducted adequate risk analysis nor identified adequate control measures to address the risks of reagents from the precedent assays carrying over to the subsequent assay conducted on the RX series analyzers to ensure the devices (i.e., manufactured assays tested on RX series analyzers) meet their intended use.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified that the root cause is related to ambiguity in your risk analysis procedures, lack of clear responsibility for the activities, and that maintenance of the risk management files and not been effective. Your firm states that you have reviewed and updated the risk management files for the recalled products, however, copies of those files were not provided for review because they are currently under review by specified teams at your firm. An estimated date of completion was not provided.\nYour firm also provided Risk Management Report for RX Series Analyzers – Automated RX modena, RX daytona+, RX daytona, RX imola, RX monaco, dated September 30, 2024 and Risk Analysis for RX Series Analyzers – Automated, revision number 4, approved on September 30, 2024. A carryover and contamination category was added to analyzer risk analysis. The risk evaluation before (b)(4).” However, no information was provided to support (b)(4) as required by RQA-1707.\nYour firm provided a revised job description for the Device Documentation Specialist (JD1402), who is within the (b)(4) of RQA-1707, revision Q, drafted September 20, 2024. The procedure has been revised to require the Quality Assurance department to review (b)(4). Post Market Surveillance, RQA-1664, revision M, drafted September 20, 2024 was revised to, among other things, define that the Quality Assurance Department is responsible (b)(4). Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024 was revised to include responsibility for Quality Assurance Department for (b)(4). However, RQA-1707, RQA-1664, and RGP-2032 do not reference the Device Documentation Specialist. Therefore, it is unclear how the revised job description will prevent similar failures in the future. Your firm stated retraining on RQA-1707, RQA-1664, and RGP-2032 was completed and provided examples for how a completion of training event was documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided. Your firm plans to (b)(4). However, evidence that appropriate control measures will be applied has not been provided. Your firm should provide an update on this review and any remediation efforts needed. You firm also stated that RGP-1002 has been updated but FDA was unable to open this file to review and therefore the Agency unable is unable to determine whether this action is effective.\n2. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA NCP INC612, was initiated on October 16, 2023, due to a customer complaint related to issues when running Copper assay on a RX daytona + analyzer. Your firm confirmed the testing of total protein carried over to the subsequent copper assay, causing falsely elevated Copper results. The root cause description states, “Carryover from both cuvettes and pipettes,” but fails to identify the underlying cause of why the reagent from the previously used assay carried over to the subsequent assay. The CAPA was closed on May 20, 2024, with the correction, “Technical bulletin RXTB-0121 to be updated with as a result of the testing recommending that Copper and Total protein on the same machine.” Since December 2018, your firm has initiated five US market Class II Recalls (Event IDs 81746, 86236, 91097, 92650, 93775) due to erroneous results caused by reagent carryover and, in each your firm has issued an updated Technical Bulletin for carryover avoidance (RXTB-0083, issued February 16, 2018 and RXTB-0098, issued November 20, 2018; RXTB-0121, issued July 31, 2020; RXTB-0136, issued September 22, 2022; RXTB-0148, issued June 6, 2023; RXTB-0148, issued November 22, 2023). The bulletin currently includes a list of over 50 combinations of assays to avoid running in sequence. CAPA #NCP INC612 fails to identify the action(s) needed to correct and prevent recurrence of carryover of assays run on the RX series analyzers. Additionally, activities to ensure the effectiveness of the corrective actions were not identified. Your firm states “Confirm no further complaints since bulletin” but fails to verify or validate the corrective and preventive action to ensure that such action is effective.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified the root cause is related to inadequate procedure and absence of dedicated training resources on root cause analysis for the staff to perform root cause analysis adequately and effectively. Your firm determined the actual root cause for the carryover event from CAPA #NCP INC612 is because of inadequate cleaning of the pipette\u002Fcuvette after programmed cleaning on the automated analyzer so the remaining residue of the reagents from Total Protein assay, which contains copper, impacted the subsequent Copper assay. Your firm has not identified corrective and prevention actions for CAPA #NCP INC612 and has not provided information on how you will verify or validate the corrective and preventive action is effective.\nYour firm has updated the CAPA procedure “Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024” to include reference to root cause analysis training material and created training slides “QAT 2.17.pptx” for performing root-cause analysis. Your firm stated training on RGP-2032 and QAT 2.17 was completed and provided an example for how the completion of training event documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided.\nYour firm proposed (b)(4). Your firm should provide an update on this review and any remediation efforts needed.\nYour firm initiated a CAPA (qNCP 1394) dated August 29, 2024 to determine (b)(4). Your firm has yet identified the root cause for causing the inadequate cleaning which your firm stated in an email dated November 8, 2024, is the common root cause of all the initiated recalls related to carryover on the RX series instruments. Your firm has yet to define actions to prevent recurrence.\nYour firm plans to review CAPAs and root cause (b)(4). Your firm should provide an update on this review and any remediation efforts needed.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nAdditionally, based on information provided to the investigator during and following the inspection, it appears that your establishment registrations and device listings are incorrect and should be further clarified. During teleconferences following the inspection with the investigator on September 5 and 11, 2024, you promised to evaluate (b)(4). However, as of the date of this letter your registration and listing data remains unchanged.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #696569 when replying. If you have any questions about the contents of this letter, please contact: I-Lin Wu at i-lin.wu@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nCheryl OHagan\nUS Agent","Randox Laboratories Limited","randox-laboratories-limited-696569-12062024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frandox-laboratories-limited-696569-12062024","2026-10-26T08:09:47.070417+00:00","2025-01-14","696569","Medical Devices","Steven Peter FitzGerald","2026-08-19T17:05:02.173+00:00","VIA Electronic Mail","2024-12-06",{"id":55,"raw":56,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":19,"letter_url":69,"updated_at":70,"action_type":22,"case_status":71,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":75,"issuing_office":60,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},1784,[57,58,59,60,61,13,62,13],"\u003Ctime datetime=\"2023-10-25T18:45:00Z\">10\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-24T04:00:00Z\">10\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-10242023\">Abbott Laboratories\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Dietary Supplement\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-12122024\">\u003Ctime datetime=\"2025-01-21T05:00:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Dietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert B. Ford\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abbott Laboratories\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>100 Abbott Park Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Abbott Park\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:robert.ford@abbott.com\"> robert.ford@abbott.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: October 24, 2023\u003C\u002Fp>\n\n\u003Cp>Warning Letter #669353\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ford:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s websites at www.abbottnutrition.com, www.abbott.com, and www.pediatricproconnect.com in October 2023 and your company’s marketing materials for Similac® Probiotic Tri-Blend (hereinafter Similac Probiotic Supplement or your product), which contains instructions on where to buy your product. The marketing materials FDA reviewed include one handout that bears the heading “Probiotics and Preterm Infants: Clinical Evidence” and another that bears the heading “The Promise of Similac Another Innovation Only From Similac,” which your sales representatives provided together to hospital staff. You refer to your product as a probiotic and offer it for sale to health care professionals in the United States. Your product is labeled as containing, among other ingredients, \u003Cem>Bifidobacterium infantis\u003C\u002Fem> (Bb-02) and&nbsp;\u003Cem>Streptococcus thermophilus\u003C\u002Fem> (TH-4®), otherwise known as \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) and \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), and you sell it for use in preterm infants.\u003C\u002Fp>\n\n\u003Cp>Based on the statements on your website and your marketing materials, your product is an unapproved new drug and unlicensed biological product that you introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. Your Similac Probiotic Supplement is also adulterated under section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)] because it contains \u003Cem>B. infantis\u003C\u002Fem> (Bb-02), an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act [21 U.S.C. §§321(s) and 348]; and \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, when used in preterm infants. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&amp;C Act and the PHS Act. You can find the FD&amp;C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Probiotics and Preterm Infants: Clinical Evidence” handout provided by your sales representative to hospital staff has a section with the heading “Probiotics in the NICU: Clinical Evidence” that states, “Probiotics have shown to significantly improve outcomes” for “All-cause mortality,” “Necrotizing enterocolitis (NEC),” “Late-onset sepsis,” and “Feeding tolerance,” and that represents “Benefits of probiotics on NEC,” as “significantly reduc[ing] incidence of NEC in clinical studies.” The other marketing handout with the heading “The Promise of Similac Another Innovation Only From Similac” states that Similac® Probiotic Supplement undergoes safety testing to “ensure the probiotic is ready for hospital use,” (emphasis omitted).\u003C\u002Fp>\n\n\u003Cp>Your website at www.pediatricproconnect.com (last visited in October 2023), includes a link to an Abbott infographic entitled “The Microbiome &amp; The Preterm Infant: Gut Immaturity &amp; Dysbiosis,” which states, “Importantly, giving probiotics to preterm infants can reduce the incidence of NEC.” As noted above, your www.abbottnutrition.com website and documents accessed from it further state that your product is available for “Hospitals and institutions,” and your Pediatric Product Nutrition Guide categorizes the product as for “Premature\u002F Low-Birth-Weight Infants.”\u003C\u002Fp>\n\n\u003Cp>Because these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to your Similac Probiotic Supplement being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Unsafe Food Additive: Bifidobacterium infantis (Bb-02)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your Similac Probiotic Supplement is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because, when used in food for preterm infants,&nbsp;\u003Cem>B. infantis\u003C\u002Fem> (BB-02) is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act [21 U.S.C. §§321(s) and 348(a)].\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any substance added or intended for addition to food must have premarket approval by FDA as a food additive for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at section 201(s)(1)-(6) of the FD&amp;C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. There is no food additive regulation that authorizes the use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02). In addition, as discussed below, we are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or in conventional foods, nor are we aware of a basis to conclude that any use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or otherwise in food for preterm infants is generally recognized as safe (GRAS).\u003C\u002Fp>\n\n\u003Cp>We are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. infantis\u003C\u002Fem> (BB-02) in dietary supplements or in conventional foods. Section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. The label of your Similac Probiotic Supplement declares \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) as a dietary ingredient. However, the ingredient \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) does not meet the definition of a dietary ingredient. Under section 201(ff)(1) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) does not fall within any of these categories. Therefore, the ingredient \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) used in your product is a non-dietary ingredient added to a dietary supplement and must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\u003C\u002Fp>\n\n\u003Cp>We are not aware of a basis to conclude that any use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or food for preterm infants is GRAS. GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”), such as \u003Cem>B. infantis\u003C\u002Fem> (Bb-02), by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous&nbsp;subpopulation of varying ages (&lt;37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight &lt;1000 grams.”\u003C\u002Fp>\n\n\u003Cp>Although your Similac Probiotic Supplement label states that the product is “not intended for infants with compromised intestinal permeability,” and your Pediatric Product Nutrition Guide states that your product is “not intended for infants with intestinal permeability,” other marketing materials of yours directly contradict these statements. For example, your infographic titled, “How Probiotics Can Help My Preterm Infant, Infancy is an Important Time in Developing a Healthy Gut Microbiome,” acknowledges that the “[g]ut is not fully developed” in many preterm infants and nonetheless recommends your product be administered to this population because probiotics “increase the number of good bacteria in the gut, promoting a healthy microbiome.” Moreover, you categorize your product as a dietary supplement for premature\u002Flow-birth-weight infants in your Pediatric Product Nutrition Guide, and in your “Probiotics and Preterm Infants: Clinical Evidence” marketing handout that your sales representatives distribute to NICU dieticians, you have indicated that this product is designed specifically for preterm infants. Furthermore, statements on the product page of your website indicate your product is available for “Hospitals and institutions” and your “The Promise of Similac: Another Innovation Only From Similac” information sheet describes product testing to ensure it is “ready for hospital use.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is not GRAS for use in food for preterm infants. Because \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is not a dietary ingredient and is not GRAS or otherwise exempt from the food additive definition, and because your Similac Probiotic Supplement is intended to be added to food for preterm infants, your Similac Probiotic Tri-Blend product is adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act because \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is an unsafe food additive for use by premature infants within the meaning of sections 201(s) and 409 of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Section 402(f)(1)(B) Adulteration: Streptococcus thermophilus\u003C\u002Fem> (TH-4®)\u003C\u002Fp>\n\n\u003Cp>The label of your Similac Probiotic Supplement declares \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) as a dietary ingredient.\u003Cem> S. thermophilus\u003C\u002Fem> (TH-4®) is a dietary ingredient under section 201(ff)(1)(F) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)(F)]. \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) is also a new dietary ingredient under section 413(d) of the FD&amp;C Act [21 U.S.C. § 350b(d)], in that it is a dietary ingredient that was not marketed in the United States before October 15, 1994.\u003C\u002Fp>\n\n\u003Cp>A dietary supplement is adulterated under section 402(f)(1)(B) of the FD&amp;C Act if it contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. The available scientific information regarding the safety of S. thermophilus (TH-4®), when intended for consumption by preterm infants, indicates that there is inadequate information to provide reasonable assurance that \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) does not present a significant or unreasonable risk of illness or injury. In fact, as noted above, available information on the use of microorganisms in products intended for preterm infants raises serious safety concerns. Therefore, your Similac Probiotic Supplement is an adulterated dietary supplement under section 402(f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(f)(1)(B)] because it contains a new dietary ingredient, \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury when used in preterm infants. Introduction of this product into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your product in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector, Office of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nBiologics\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert B. Ford\n\nRecipient Title\n\nCEO\n\nAbbott Laboratories\n\n100 Abbott Park Road\n\nAbbott Park, IL 60064\n\nUnited States\n\nrobert.ford@abbott.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nDate: October 24, 2023\n\nWarning Letter #669353\n\nDear Mr. Ford:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s websites at www.abbottnutrition.com, www.abbott.com, and www.pediatricproconnect.com in October 2023 and your company’s marketing materials for Similac® Probiotic Tri-Blend (hereinafter Similac Probiotic Supplement or your product), which contains instructions on where to buy your product. The marketing materials FDA reviewed include one handout that bears the heading “Probiotics and Preterm Infants: Clinical Evidence” and another that bears the heading “The Promise of Similac Another Innovation Only From Similac,” which your sales representatives provided together to hospital staff. You refer to your product as a probiotic and offer it for sale to health care professionals in the United States. Your product is labeled as containing, among other ingredients, Bifidobacterium infantis (Bb-02) and Streptococcus thermophilus (TH-4®), otherwise known as B. infantis (Bb-02) and S. thermophilus (TH-4®), and you sell it for use in preterm infants.\n\nBased on the statements on your website and your marketing materials, your product is an unapproved new drug and unlicensed biological product that you introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. Your Similac Probiotic Supplement is also adulterated under section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)] because it contains B. infantis (Bb-02), an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act [21 U.S.C. §§321(s) and 348]; and S. thermophilus (TH-4®), a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, when used in preterm infants. These violations are described in more detail below.\n\nAs explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&C Act and the PHS Act. You can find the FD&C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drug and Unlicensed Biological Product\n\nYour “Probiotics and Preterm Infants: Clinical Evidence” handout provided by your sales representative to hospital staff has a section with the heading “Probiotics in the NICU: Clinical Evidence” that states, “Probiotics have shown to significantly improve outcomes” for “All-cause mortality,” “Necrotizing enterocolitis (NEC),” “Late-onset sepsis,” and “Feeding tolerance,” and that represents “Benefits of probiotics on NEC,” as “significantly reduc[ing] incidence of NEC in clinical studies.” The other marketing handout with the heading “The Promise of Similac Another Innovation Only From Similac” states that Similac® Probiotic Supplement undergoes safety testing to “ensure the probiotic is ready for hospital use,” (emphasis omitted).\n\nYour website at www.pediatricproconnect.com (last visited in October 2023), includes a link to an Abbott infographic entitled “The Microbiome & The Preterm Infant: Gut Immaturity & Dysbiosis,” which states, “Importantly, giving probiotics to preterm infants can reduce the incidence of NEC.” As noted above, your www.abbottnutrition.com website and documents accessed from it further state that your product is available for “Hospitals and institutions,” and your Pediatric Product Nutrition Guide categorizes the product as for “Premature\u002F Low-Birth-Weight Infants.”\n\nBecause these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdulterated Dietary Supplement\n\nIn addition to your Similac Probiotic Supplement being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)].\n\nUnsafe Food Additive: Bifidobacterium infantis (Bb-02)\n\nYour Similac Probiotic Supplement is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because, when used in food for preterm infants, B. infantis (BB-02) is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act [21 U.S.C. §§321(s) and 348(a)].\n\nFood additives require premarket approval based on data demonstrating safety. Any substance added or intended for addition to food must have premarket approval by FDA as a food additive for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at section 201(s)(1)-(6) of the FD&C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. There is no food additive regulation that authorizes the use of B. infantis (Bb-02). In addition, as discussed below, we are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. infantis (Bb-02) in dietary supplements or in conventional foods, nor are we aware of a basis to conclude that any use of B. infantis (Bb-02) in dietary supplements or otherwise in food for preterm infants is generally recognized as safe (GRAS).\n\nWe are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. infantis (BB-02) in dietary supplements or in conventional foods. Section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. The label of your Similac Probiotic Supplement declares B. infantis (Bb-02) as a dietary ingredient. However, the ingredient B. infantis (Bb-02) does not meet the definition of a dietary ingredient. Under section 201(ff)(1) of the FD&C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. B. infantis (Bb-02) does not fall within any of these categories. Therefore, the ingredient B. infantis (Bb-02) used in your product is a non-dietary ingredient added to a dietary supplement and must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\n\nWe are not aware of a basis to conclude that any use of B. infantis (Bb-02) in dietary supplements or food for preterm infants is GRAS. GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”), such as B. infantis (Bb-02), by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (\u003C37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight \u003C1000 grams.”\n\nAlthough your Similac Probiotic Supplement label states that the product is “not intended for infants with compromised intestinal permeability,” and your Pediatric Product Nutrition Guide states that your product is “not intended for infants with intestinal permeability,” other marketing materials of yours directly contradict these statements. For example, your infographic titled, “How Probiotics Can Help My Preterm Infant, Infancy is an Important Time in Developing a Healthy Gut Microbiome,” acknowledges that the “[g]ut is not fully developed” in many preterm infants and nonetheless recommends your product be administered to this population because probiotics “increase the number of good bacteria in the gut, promoting a healthy microbiome.” Moreover, you categorize your product as a dietary supplement for premature\u002Flow-birth-weight infants in your Pediatric Product Nutrition Guide, and in your “Probiotics and Preterm Infants: Clinical Evidence” marketing handout that your sales representatives distribute to NICU dieticians, you have indicated that this product is designed specifically for preterm infants. Furthermore, statements on the product page of your website indicate your product is available for “Hospitals and institutions” and your “The Promise of Similac: Another Innovation Only From Similac” information sheet describes product testing to ensure it is “ready for hospital use.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\n\nB. infantis (Bb-02) is not GRAS for use in food for preterm infants. Because B. infantis (Bb-02) is not a dietary ingredient and is not GRAS or otherwise exempt from the food additive definition, and because your Similac Probiotic Supplement is intended to be added to food for preterm infants, your Similac Probiotic Tri-Blend product is adulterated under section 402(a)(2)(C)(i) of the FD&C Act because B. infantis (Bb-02) is an unsafe food additive for use by premature infants within the meaning of sections 201(s) and 409 of the FD&C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nSection 402(f)(1)(B) Adulteration: Streptococcus thermophilus (TH-4®)\n\nThe label of your Similac Probiotic Supplement declares S. thermophilus (TH-4®) as a dietary ingredient. S. thermophilus (TH-4®) is a dietary ingredient under section 201(ff)(1)(F) of the FD&C Act [21 U.S.C. § 321(ff)(1)(F)]. S. thermophilus (TH-4®) is also a new dietary ingredient under section 413(d) of the FD&C Act [21 U.S.C. § 350b(d)], in that it is a dietary ingredient that was not marketed in the United States before October 15, 1994.\n\nA dietary supplement is adulterated under section 402(f)(1)(B) of the FD&C Act if it contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. The available scientific information regarding the safety of S. thermophilus (TH-4®), when intended for consumption by preterm infants, indicates that there is inadequate information to provide reasonable assurance that S. thermophilus (TH-4®) does not present a significant or unreasonable risk of illness or injury. In fact, as noted above, available information on the use of microorganisms in products intended for preterm infants raises serious safety concerns. Therefore, your Similac Probiotic Supplement is an adulterated dietary supplement under section 402(f)(1)(B) of the FD&C Act [21 U.S.C. § 342(f)(1)(B)] because it contains a new dietary ingredient, S. thermophilus (TH-4®), for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury when used in preterm infants. Introduction of this product into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nWe advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your product in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector, Office of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nCc:\n\n(b)(4)","Abbott Laboratories","abbott-laboratories-669353-10242023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-10242023","2026-10-26T08:07:48.691438+00:00","Closed Out","2023-10-25","669353","BiologicsDietary SupplementsDrugs","2025-01-21","Robert B. Ford","2026-08-20T00:34:47.53+00:00","VIA UPS and Electronic Mail","2023-10-24",{"id":81,"raw":82,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":44,"fei_number":19,"letter_url":92,"updated_at":93,"action_type":22,"case_status":23,"posted_date":94,"marcs_cms_no":95,"product_type":96,"closeout_date":19,"issuing_office":86,"recipient_name":97,"body_fetched_at":98,"delivery_method":99,"recipient_title":19,"reference_number":19,"action_taken_date":100,"medical_device_id":19,"response_letter_date":19},1376,[83,84,85,86,87,13,13,13],"\u003Ctime datetime=\"2024-07-16T13:20:00Z\">07\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-11T04:00:00Z\">06\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Farg-laboratories-inc-670899-06112024\">ARG Laboratories, Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Return Confirmation Requested\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Darin Hoogendoorn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv> President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ARG Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2639 Manana Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75220-1301\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>1201 Main Street, Suite 7200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Case #:&nbsp;&nbsp; &nbsp;670899\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hoogendoorn:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, ARG Laboratories, Inc., FEI 3002556034, at 2639 Manana Drive, Dallas, TX from September 11 to 20, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d). Further, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 4, 2023, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1.&nbsp;&nbsp; &nbsp;Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture topical over-the-counter (OTC) drug products for the U.S. market. Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to establish adequate procedures describing the roles and responsibilities of the QU, including for supplier qualification, change control, investigation of out-of-specification (OOS) results, recalls, and complaint handling. Notably, your QU released Bullfrog Amphibious SPF Lotion that failed your specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the active ingredient octocrylene. FDA also documented multiple other drug product lots that failed your specifications but were released.\u003C\u002Fp>\n\n\u003Cp>Your response states that you intend to create procedures to comply with CGMP and ensure that all active ingredients are within the “required and approved analytic ranges.”\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to address the fundamental deficiencies in your QU that led to these failures. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n•&nbsp;&nbsp; &nbsp;A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory- information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical- current-good-manufacturing-practice-regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2.&nbsp;&nbsp; &nbsp;Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming components for identity before using the components in your OTC drug products, including propylene glycol and active pharmaceutical ingredients such as octocrylene. Additionally, you relied on the certificates of analysis (COA) from your suppliers and failed to establish the reliability of each of your suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Further, identity testing for propylene glycol and certain other high-risk drug components\u003Ca id=\"footnoteref1_4iegz40\" href=\"#footnote1_4iegz40\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>Your response states that you will sample and inspect all incoming raw materials to ensure they are “identified and match the supplier COA,” and that you will validate your suppliers’ test results. Your response is inadequate because it did not include a detailed plan for how raw materials will be tested, including test methods and review of&nbsp;compendial requirements. Your response also lacked sufficient detail on how you plan to establish the reliability of the test results on your suppliers’ COAs at appropriate intervals. Additionally, you did not consider a retrospective review of previously distributed drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples of all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3.&nbsp;&nbsp; &nbsp;Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture&nbsp;have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate your production and process controls. During the inspection, you acknowledged that you did not conduct process validation studies and cleaning validation studies for your non-dedicated equipment. You also failed to validate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system, which supplies water as a component used in your OTC drug products. When requested to provide water quality test results, you failed to provide any test results.\u003C\u002Fp>\n\n\u003Cp>Your response states that validation will be conducted on kettles used in OTC drug product manufacturing, and that the cleaning processes and water system would be validated. Your response is inadequate because it lacks sufficient detail and did not include a risk assessment or identify corrective actions to address drug products manufactured without a validated process currently in distribution.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A timeline for performing PPQ for each of your marketed drug products. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\no&nbsp;&nbsp; &nbsp;Drugs with higher toxicities\u003Cbr>\no&nbsp;&nbsp; &nbsp;Drugs with higher drug potencies\u003Cbr>\no&nbsp;&nbsp; &nbsp;Drugs of lower solubility in their cleaning solvents\u003Cbr>\no&nbsp;&nbsp; &nbsp;Drugs with characteristics that make them difficult to clean\u003Cbr>\no&nbsp;&nbsp; &nbsp;Swabbing locations for areas that are most difficult to clean\u003Cbr>\no&nbsp;&nbsp; &nbsp;Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003Cbr>\n&nbsp;\u003Cbr>\n•&nbsp;&nbsp; &nbsp;A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;monograph specifications and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>Your firm lacks an adequate process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4.&nbsp;&nbsp; &nbsp;Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to follow your written stability procedures for your OTC drug products. During the inspection you stated that you used expiration dates provided by your clients but were unable to provide documentation to support those dates.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you will place process validation batches on stability and assign appropriate expiration dates, unless the stability data is provided by your clients. Your response is inadequate because you did not address the lack of stability data to support the expiration dates for your drug products that are currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\no&nbsp;&nbsp; &nbsp;Stability indicating methods\u003Cbr>\no&nbsp;&nbsp; &nbsp;Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\no&nbsp;&nbsp; &nbsp;An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\no&nbsp;&nbsp; &nbsp;Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;All procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain,” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples from the products’ labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Golden Tiger Natural Pain Relieving Cream”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“DRUG FACTS…Uses:\u003C\u002Fstrong> Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ simple backache ■ arthritis ■ sprains ■ bruises ■ strains” [from the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;“NATURAL PAIN RELIEVING CREAM…Enriched with Capsaicin, Aloe Vera, Willow Bark &amp; MSM” [from the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;“Golden Tiger’s Pain Relief Cream is an ideal remedy for inflammation and pain. With natural botanicals like willow, menthol, capsaicin, and ginger, relief is on the way as soon as you apply it… Golden Tiger Pain Relief Cream offers fast and effective relief from pain and inflammation from arthritis, bursitis, neck aches, headaches, cramps, backaches, bruises, muscle strains and sprains, fibromyalgia, muscle soreness, joint pain, sports injuries, and tendonitis.” [from the product website www.goldentigerusa.com listed on the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;“Other botanicals – ginger, willow, and curcumin – then penetrate and go to work reducing inflammation and relieving pain. . . ”[from the product website www.goldentigerusa.com listed on the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;“. . .ginger and curcumin fight inflammation, willow eases pain, and capsaicin loosens and warms.” [from the product website www.goldentigerusa.com listed on the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;“Golden Tiger Pain Relief Cream works quickly and effectively to relieve pain and inflammation with the power of natural botanicals like ginger, willow, and curcumin, and capsaicin.” [from the product website www.goldentigerusa.com listed on the product label]\u003Cbr>\n&nbsp;\u003Cbr>\n“Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain”\u003Cbr>\n•&nbsp;&nbsp; &nbsp;\u003Cstrong>“DRUG FACTS…Uses:\u003C\u002Fstrong> Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ simple backache ■ arthritis ■ sprains ■ bruises ■ strains” [from your product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Natural Relief for Muscular &amp; Arthritic Pain…Enriched with Capsaicin, Camphor, Menthol &amp; MSM” [from the product label]\u003Cbr>\n•&nbsp;&nbsp; &nbsp;[T]he anti-inflammatory Bromelain, an enzyme found in pineapples; from India came the anti-inflammatory Boswellia, found in the bark of the boswellia tree; from China came the anti-inflammatory, Green Tea Extract, from the leaves of the green tea plant; from Germany came the anti- inflammatory and pain reliever, Arnica, derived from the arnica montana flower; . . . Methyl Sulfonyl Methane (MSM) was added to help deliver these fine ingredients deeper into the tissues. [from the product website painwizard.com listed on your product label]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” are intended for use as counterirritant external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21&nbsp;U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA- approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for the drug products identified above.\u003C\u002Fp>\n\n\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription counterirritant external analgesic drug products, in order to be GRASE and not new drugs, the product must, among other things, conform to the conditions of use in the applicable OTC monograph, here the Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereafter “M017”).\u003Ca id=\"footnoteref2_nd8wyqd\" href=\"#footnote2_nd8wyqd\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> However, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” do not conform to conditions specified in M017 for the reasons described below.\u003C\u002Fp>\n\n\u003Cp>The product labeling for “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” promote several ingredients as “active ingredients” that are not permitted by M017.\u003Ca id=\"footnoteref3_dkie86d\" href=\"#footnote3_dkie86d\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> For example, the product website for “Golden Tiger Natural Pain Relieving Cream” promotes several ingredients as providing pain relieving benefits, e.g., “botanicals like willow, menthol, and ginger, relief is on the way” and “ginger, willow, and curcumin – then penetrate and go to work reducing inflammation and relieving pain.” In addition, we note that the principal display panel of the product, prominently features willow bark. Similarly, the labeling for the “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” product makes several statements about the product’s ingredients, including “. . . (MSM) was added to help deliver these fine ingredients deeper into the tissues,” along with promoting MSM prominently on the principal display panel of the product. While your products are formulated to contain camphor and menthol as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, curcumin, willow bark, ginger, and MSM—in combination or as sole ingredients—are not permitted as active ingredients in M017.\u003Ca id=\"footnoteref4_qmima7u\" href=\"#footnote4_qmima7u\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa> Although the Drug Facts Panels do not specifically list these ingredients as active ingredients, the website’s statements describing the pharmacological activity of ingredients along with the prominence of these specific ingredients demonstrate that they are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because they are intended to furnish pharmacological activity.\u003Ca id=\"footnoteref5_oqej8h9\" href=\"#footnote5_oqej8h9\">\u003Csup>5\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Furthermore, “Golden Tiger Natural Pain Relieving Cream” includes indications that are not consistent with the permitted indications in M017. For example, claims that the product can be used for “relief from...inflammation…fibromyalgia…and tendonitis” do not conform with M017.50(b).\u003C\u002Fp>\n\n\u003Cp>Therefore, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” drug products do not comply with the applicable conditions set forth in M017 and have not otherwise been found GRASE.\u003Ca id=\"footnoteref6_8wupszr\" href=\"#footnote6_8wupszr\">\u003Csup>6\u003C\u002Fsup>\u003C\u002Fa> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21&nbsp;U.S.C. 321(p), and there is no basis under which section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate&nbsp;commerce of this unapproved new drugs violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and neither one is the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent&nbsp;their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>670899\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch at Ronda.Loyd- Jones@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-6104 or Rebecca.Asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMonica R. Maxwell Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_4iegz40\">\u003Ca href=\"#footnoteref1_4iegz40\">1\u003C\u002Fa>Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_nd8wyqd\">\u003Ca href=\"#footnoteref2_nd8wyqd\">2\u003C\u002Fa>M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&amp;C Act; see See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_dkie86d\">\u003Ca href=\"#footnoteref3_dkie86d\">3\u003C\u002Fa>See 21 CFR 201.66(b)(2).\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_qmima7u\">\u003Ca href=\"#footnoteref4_qmima7u\">4\u003C\u002Fa>We note that, in accordance with M017, a counterirritant external analgesic may contain capsaicin at certain strengths. The capsaicin is not identified as an active ingredient in Drug Facts Panel for “Golden Tiger Natural Pain Relieving Cream” or “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain.”\u003C\u002Fli>\n                      \u003Cli id=\"footnote5_oqej8h9\">\u003Ca href=\"#footnoteref5_oqej8h9\">5\u003C\u002Fa>Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fli>\n                      \u003Cli id=\"footnote6_8wupszr\">\u003Ca href=\"#footnoteref6_8wupszr\">6\u003C\u002Fa>FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Golden Tiger Natural Pain Relieving Cream” or “Pain Wizard Natural Relief for Muscular &amp; Arthritic Pain” are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReturn Confirmation Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDarin Hoogendoorn\n\nRecipient Title\n\nPresident\n\nARG Laboratories, Inc.\n\n2639 Manana Drive\n\nDallas, TX 75220-1301\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202\n\nUnited States\n\nCase #: 670899\n\nWARNING LETTER\n\nDear Mr. Hoogendoorn:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, ARG Laboratories, Inc., FEI 3002556034, at 2639 Manana Drive, Dallas, TX from September 11 to 20, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d). Further, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nWe reviewed your October 4, 2023, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\n\nYou manufacture topical over-the-counter (OTC) drug products for the U.S. market. Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to establish adequate procedures describing the roles and responsibilities of the QU, including for supplier qualification, change control, investigation of out-of-specification (OOS) results, recalls, and complaint handling. Notably, your QU released Bullfrog Amphibious SPF Lotion that failed your specification of (b)(4)% for the active ingredient octocrylene. FDA also documented multiple other drug product lots that failed your specifications but were released.\n\nYour response states that you intend to create procedures to comply with CGMP and ensure that all active ingredients are within the “required and approved analytic ranges.”\n\nYour response is inadequate because you failed to address the fundamental deficiencies in your QU that led to these failures. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate.\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\n• A complete and final review of each batch and its related information before the QU disposition decision.\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory- information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical- current-good-manufacturing-practice-regulations.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to adequately test your incoming components for identity before using the components in your OTC drug products, including propylene glycol and active pharmaceutical ingredients such as octocrylene. Additionally, you relied on the certificates of analysis (COA) from your suppliers and failed to establish the reliability of each of your suppliers’ analyses at appropriate intervals.\n\nFurther, identity testing for propylene glycol and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nWithout adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\n\nYour response states that you will sample and inspect all incoming raw materials to ensure they are “identified and match the supplier COA,” and that you will validate your suppliers’ test results. Your response is inadequate because it did not include a detailed plan for how raw materials will be tested, including test methods and review of compendial requirements. Your response also lacked sufficient detail on how you plan to establish the reliability of the test results on your suppliers’ COAs at appropriate intervals. Additionally, you did not consider a retrospective review of previously distributed drug products.\n\nIn response to this letter, provide:\n\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples of all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to adequately validate your production and process controls. During the inspection, you acknowledged that you did not conduct process validation studies and cleaning validation studies for your non-dedicated equipment. You also failed to validate your (b)(4) water system, which supplies water as a component used in your OTC drug products. When requested to provide water quality test results, you failed to provide any test results.\n\nYour response states that validation will be conducted on kettles used in OTC drug product manufacturing, and that the cleaning processes and water system would be validated. Your response is inadequate because it lacks sufficient detail and did not include a risk assessment or identify corrective actions to address drug products manufactured without a validated process currently in distribution.\n\nIn response to this letter, provide:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing PPQ for each of your marketed drug products. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the (b)(4) water system consistently produces water that meets (b)(4) monograph specifications and appropriate microbial limits.\n\nYour firm lacks an adequate process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\n4. Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYou failed to follow your written stability procedures for your OTC drug products. During the inspection you stated that you used expiration dates provided by your clients but were unable to provide documentation to support those dates.\n\nIn your response, you state that you will place process validation batches on stability and assign appropriate expiration dates, unless the stability data is provided by your clients. Your response is inadequate because you did not address the lack of stability data to support the expiration dates for your drug products that are currently on the market.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program\n\nUnapproved New Drug and Misbranding Violations\n\n“Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain,” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\n\nExamples from the products’ labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n\n“Golden Tiger Natural Pain Relieving Cream”\n\n• “DRUG FACTS…Uses: Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ simple backache ■ arthritis ■ sprains ■ bruises ■ strains” [from the product label]\n\n• “NATURAL PAIN RELIEVING CREAM…Enriched with Capsaicin, Aloe Vera, Willow Bark & MSM” [from the product label]\n\n• “Golden Tiger’s Pain Relief Cream is an ideal remedy for inflammation and pain. With natural botanicals like willow, menthol, capsaicin, and ginger, relief is on the way as soon as you apply it… Golden Tiger Pain Relief Cream offers fast and effective relief from pain and inflammation from arthritis, bursitis, neck aches, headaches, cramps, backaches, bruises, muscle strains and sprains, fibromyalgia, muscle soreness, joint pain, sports injuries, and tendonitis.” [from the product website www.goldentigerusa.com listed on the product label]\n\n• “Other botanicals – ginger, willow, and curcumin – then penetrate and go to work reducing inflammation and relieving pain. . . ”[from the product website www.goldentigerusa.com listed on the product label]\n\n• “. . .ginger and curcumin fight inflammation, willow eases pain, and capsaicin loosens and warms.” [from the product website www.goldentigerusa.com listed on the product label]\n\n• “Golden Tiger Pain Relief Cream works quickly and effectively to relieve pain and inflammation with the power of natural botanicals like ginger, willow, and curcumin, and capsaicin.” [from the product website www.goldentigerusa.com listed on the product label]\n\n“Pain Wizard Natural Relief for Muscular & Arthritic Pain”\n\n• “DRUG FACTS…Uses: Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ simple backache ■ arthritis ■ sprains ■ bruises ■ strains” [from your product label]\n\n• Natural Relief for Muscular & Arthritic Pain…Enriched with Capsaicin, Camphor, Menthol & MSM” [from the product label]\n\n• [T]he anti-inflammatory Bromelain, an enzyme found in pineapples; from India came the anti-inflammatory Boswellia, found in the bark of the boswellia tree; from China came the anti-inflammatory, Green Tea Extract, from the leaves of the green tea plant; from Germany came the anti- inflammatory and pain reliever, Arnica, derived from the arnica montana flower; . . . Methyl Sulfonyl Methane (MSM) was added to help deliver these fine ingredients deeper into the tissues. [from the product website painwizard.com listed on your product label]\n\nUnapproved New Drug Violations\n\nBased on the above labeling, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” are intended for use as counterirritant external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA- approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for the drug products identified above.\n\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription counterirritant external analgesic drug products, in order to be GRASE and not new drugs, the product must, among other things, conform to the conditions of use in the applicable OTC monograph, here the Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereafter “M017”).2 However, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” do not conform to conditions specified in M017 for the reasons described below.\n\nThe product labeling for “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” promote several ingredients as “active ingredients” that are not permitted by M017.3 For example, the product website for “Golden Tiger Natural Pain Relieving Cream” promotes several ingredients as providing pain relieving benefits, e.g., “botanicals like willow, menthol, and ginger, relief is on the way” and “ginger, willow, and curcumin – then penetrate and go to work reducing inflammation and relieving pain.” In addition, we note that the principal display panel of the product, prominently features willow bark. Similarly, the labeling for the “Pain Wizard Natural Relief for Muscular & Arthritic Pain” product makes several statements about the product’s ingredients, including “. . . (MSM) was added to help deliver these fine ingredients deeper into the tissues,” along with promoting MSM prominently on the principal display panel of the product. While your products are formulated to contain camphor and menthol as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, curcumin, willow bark, ginger, and MSM—in combination or as sole ingredients—are not permitted as active ingredients in M017.4 Although the Drug Facts Panels do not specifically list these ingredients as active ingredients, the website’s statements describing the pharmacological activity of ingredients along with the prominence of these specific ingredients demonstrate that they are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because they are intended to furnish pharmacological activity.5\n\nFurthermore, “Golden Tiger Natural Pain Relieving Cream” includes indications that are not consistent with the permitted indications in M017. For example, claims that the product can be used for “relief from...inflammation…fibromyalgia…and tendonitis” do not conform with M017.50(b).\n\nTherefore, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” drug products do not comply with the applicable conditions set forth in M017 and have not otherwise been found GRASE.6 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under which section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of this unapproved new drugs violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Drug Violations\n\nAdditionally, “Golden Tiger Natural Pain Relieving Cream” and “Pain Wizard Natural Relief for Muscular & Arthritic Pain” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and neither one is the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 670899.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch at Ronda.Loyd- Jones@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-6104 or Rebecca.Asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell Program Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II\n\n1Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&C Act; see See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n\n3See 21 CFR 201.66(b)(2).\n\n4We note that, in accordance with M017, a counterirritant external analgesic may contain capsaicin at certain strengths. The capsaicin is not identified as an active ingredient in Drug Facts Panel for “Golden Tiger Natural Pain Relieving Cream” or “Pain Wizard Natural Relief for Muscular & Arthritic Pain.”\n\n5Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n6FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Golden Tiger Natural Pain Relieving Cream” or “Pain Wizard Natural Relief for Muscular & Arthritic Pain” are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","ARG Laboratories, Inc.","arg-laboratories-inc-670899-06112024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Farg-laboratories-inc-670899-06112024","2026-10-26T08:07:57.323469+00:00","2024-07-16","670899","Drugs","Darin Hoogendoorn","2026-08-19T23:57:31.412+00:00","VIA Electronic Mail Return Confirmation Requested","2024-06-11",{"id":102,"raw":103,"subject":108,"body_html":109,"body_text":110,"firm_name":111,"letter_id":112,"created_at":113,"fei_number":19,"letter_url":114,"updated_at":115,"action_type":22,"case_status":23,"posted_date":116,"marcs_cms_no":117,"product_type":118,"closeout_date":19,"issuing_office":107,"recipient_name":119,"body_fetched_at":120,"delivery_method":121,"recipient_title":19,"reference_number":19,"action_taken_date":122,"medical_device_id":19,"response_letter_date":19},3260,[104,105,106,107,108,13,13,13],"\u003Ctime datetime=\"2021-07-13T13:20:00Z\">07\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-01T04:00:00Z\">07\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021\">Biomedical Research Laboratories, LLC\u003C\u002Fa>","Office of Human and Animal Food Operations –West Division 5","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher Jacob\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomedical Research Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7590 Fay Ave Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037-4885\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations –West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>July 1, 2021\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 612831\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jacob:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Calm Legs\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Calm Legs product page:\u003Cbr>\n&nbsp; o “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\u003Cbr>\n&nbsp; o “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\u003Cbr>\n&nbsp; o “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\u003Cbr>\n&nbsp; o “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\u003Cbr>\n&nbsp; o “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\u003Cbr>\n&nbsp; o “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\u003Cbr>\n&nbsp; o “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\u003Cbr>\n&nbsp; o “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\u003Cbr>\n• On the blog post “Hope for RLS Sufferers”:\u003Cbr>\n&nbsp; o “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\u003Cbr>\n&nbsp; o “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\u003Cbr>\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\u003Cbr>\n&nbsp; o “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\u003Cbr>\n• On the blog post “How Stress Impacts RLS”:\u003Cbr>\n&nbsp; o “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\u003Cbr>\n• On the blog post “What is Restless Legs Syndrome?”:\u003Cbr>\n&nbsp; o “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\u003Cbr>\nOn your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\u003Cbr>\n• An embedded YouTube video includes the following claims:\u003Cbr>\n&nbsp; o “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\u003Cbr>\n&nbsp; o “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\u003C\u002Fp>\n\n\u003Cp>On the Native Origins Facebook page:\u003Cbr>\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\u003Cbr>\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\u003Cbr>\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\u003Cbr>\n• “Natural Remedy for RLS”\u003Cbr>\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\u003Cbr>\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Flexify\u003C\u002Fstrong>\u003Cbr>\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\u003Cbr>\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\u003Cbr>\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\u003Cbr>\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\u003Cbr>\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\u003Cbr>\n&nbsp; o “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\u003Cbr>\n&nbsp; o “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\u003Cbr>\n&nbsp; o “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\u003Cbr>\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\u003Cbr>\n&nbsp; o “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Collagen Peptides\u003C\u002Fstrong>\u003Cbr>\nOn your product website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Collagen Peptides product page:\u003Cbr>\n&nbsp; o “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\u003Cbr>\n• On the blog post “What Are the Health Benefits of Collagen?”:\u003Cbr>\n&nbsp; o “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\u003Cbr>\n&nbsp; o “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\u003Cbr>\n• On the blog post “4 Ways to Add Collagen to Your Day”:\u003Cbr>\n&nbsp; o “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\u003Cbr>\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\u003Cbr>\n&nbsp; o “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\u003Cbr>\n• On the blog post “Collagen and Joint Health”:\u003Cbr>\n&nbsp; o “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\u003Cbr>\n&nbsp; o “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohemia\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Prohemia product page:\u003Cbr>\n&nbsp; o “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\u003Cbr>\n&nbsp; o “Prohemia contains several potent antioxidants to reduce inflammation . . .”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\u003Cbr>\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Altitude RX\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Altitude RX product page:\u003Cbr>\n&nbsp; o “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\u003Cbr>\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\u003Cbr>\n&nbsp; o “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\u003Cbr>\n&nbsp; o “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\u003Cbr>\n&nbsp; o “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlsports.com:\u003Cbr>\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\u003Cbr>\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\u003Cbr>\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\u003Cbr>\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\u003Cbr>\n\u003Cbr>\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Take Altitude RX for altitude sickness prevention…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Trimmunity\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Trimmunity product page:\u003Cbr>\n&nbsp; o “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\u003Cbr>\n&nbsp; o “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\u003Cbr>\n&nbsp; o “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\u003Cbr>\n&nbsp; o “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\u003Cbr>\n&nbsp; o “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\u003C\u002Fp>\n\n\u003Cp>Your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 612831 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher Jacob\n\nRecipient Title\n\nCEO\n\nBiomedical Research Laboratories, LLC\n\n7590 Fay Ave Suite 202\n\nLa Jolla, CA 92037-4885\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations –West Division 5\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2021\n\nWL 612831\n\nDear Mr. Jacob:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nCalm Legs\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Calm Legs product page:\n\no “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\n\no “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\n\no “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\n\no “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\n\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\n\no “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\n\no “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\n\no “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\n\no “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\n\n• On the blog post “Hope for RLS Sufferers”:\n\no “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\n\no “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\n\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\n\no “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\n\n• On the blog post “How Stress Impacts RLS”:\n\no “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\n\n• On the blog post “What is Restless Legs Syndrome?”:\n\no “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\n\n• An embedded YouTube video includes the following claims:\n\no “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\n\no “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\n\nOn the Native Origins Facebook page:\n\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\n\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\n\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\n\n• “Natural Remedy for RLS”\n\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\n\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\n\nFlexify\n\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\n\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\n\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\n\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\n\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\n\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\n\no “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\n\no “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\n\no “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\n\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\n\no “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\n\nCollagen Peptides\n\nOn your product website https:\u002F\u002Fnativeorigins.com:\n\n• On the Collagen Peptides product page:\n\no “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\n\n• On the blog post “What Are the Health Benefits of Collagen?”:\n\no “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\n\no “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\n\n• On the blog post “4 Ways to Add Collagen to Your Day”:\n\no “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\n\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\n\no “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\n\n• On the blog post “Collagen and Joint Health”:\n\no “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\n\no “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\n\nProhemia\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Prohemia product page:\n\no “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\n\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\n\no “Prohemia contains several potent antioxidants to reduce inflammation . . .”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\n\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\n\nAltitude RX\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Altitude RX product page:\n\no “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\n\no “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\n\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\n\no “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\n\no “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\n\no “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\n\no “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\n\nOn your website https:\u002F\u002Fbrlsports.com:\n\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\n\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\n\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\n\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\n\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Take Altitude RX for altitude sickness prevention…”\n\nTrimmunity\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Trimmunity product page:\n\no “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\n\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\n\no “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\n\no “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\n\no “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\n\no “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\n\no “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\n\nYour Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 612831 when replying.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –West Division 5","Biomedical Research Laboratories, LLC","biomedical-research-laboratories-llc-612831-07012021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021","2026-10-26T08:08:05.137198+00:00","2021-07-13","612831","Food & Beverages","Mr. Christopher Jacob","2026-08-20T02:58:27.948+00:00","United Parcel Service","2021-07-01",{"id":124,"raw":125,"subject":131,"body_html":132,"body_text":133,"firm_name":134,"letter_id":135,"created_at":136,"fei_number":19,"letter_url":137,"updated_at":138,"action_type":22,"case_status":23,"posted_date":139,"marcs_cms_no":140,"product_type":96,"closeout_date":19,"issuing_office":129,"recipient_name":141,"body_fetched_at":142,"delivery_method":143,"recipient_title":19,"reference_number":19,"action_taken_date":144,"medical_device_id":19,"response_letter_date":19},2384,[126,127,128,129,130,13,13,13],"\u003Ctime datetime=\"2022-10-25T13:20:00Z\">10\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-26T04:00:00Z\">09\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022\">Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Kitty Hunter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20550 Prairie Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chatsworth\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91311-6006\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 26, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Hunter:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> Antibacterial Acne Soap, and maintain it in a good state of repair.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Pipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\u003C\u002Fli>\n\t\u003Cli>Numerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\u003C\u002Fli>\n\t\u003Cli>Multiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>It is essential that your facility is in a good state of repair and sanitary conditions are maintained.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Photographic evidence of any repairs made to your facilities and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\u003C\u002Fp>\n\n\u003Cp>For example, regarding your batch record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sunscreen SPF-30 lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Finished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\u003C\u002Fli>\n\t\u003Cli>Out-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\u003C\u002Fli>\n\t\u003Cli>“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\u003C\u002Fp>\n\n\u003Cp>Furthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\u003C\u002Fp>\n\n\u003Cp>Without adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\u003Cbr>\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of labeling claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM\u003Cbr>\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003Cbr>\n\u003Cbr>\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Ms. Celeste Guillen, CEO (via email \u003Cstrong>(b)(6)\u003C\u002Fstrong>)\u003Cbr>\nAdvanced Cosmetic Research Laboratories Inc.\u003Cbr>\n20550 Prairie Street\u003Cbr>\nChatsworth, CA 91311-6006\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Kitty Hunter\n\nRecipient Title\n\nPresident and Owner\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 26, 2022\n\nDear Ms. Hunter:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, (b)(4) 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\n\nYou failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as (b)(4) Antibacterial Acne Soap, and maintain it in a good state of repair.\n\nFor example:\n\nPipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\n\nNumerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\n\nMultiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\n\nIt is essential that your facility is in a good state of repair and sanitary conditions are maintained.\n\nIn response to this letter, provide:\n\nYour corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nPhotographic evidence of any repairs made to your facilities and equipment.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\n\nYour quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\n\nFor example, regarding your batch record for (b)(4) Sunscreen SPF-30 lot (b)(4):\n\nFinished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\n\nOut-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\n\n“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\n\nThe procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\n\nFurthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from (b)(4), where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\n\nWithout adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\n\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nUnapproved New Drug and Misbranding Violations\n\n(b)(4) 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\n\nExamples of labeling claims observed on the (b)(4) 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“(b)(4) 5% LIDOCAINE CREAM\n\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\n\n(b)(4) 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nHowever, (b)(4) 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that (b)(4) 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because (b)(4) 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCC: Ms. Celeste Guillen, CEO (via email (b)(6))\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006","Advanced Cosmetic Research Laboratories Inc.","advanced-cosmetic-research-laboratories-inc-635176-09262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022","2026-10-26T08:07:50.485867+00:00","2022-10-25","635176","Ms. Kitty Hunter","2026-08-20T01:29:18.013+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-09-26",{"id":146,"raw":147,"subject":108,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":136,"fei_number":19,"letter_url":157,"updated_at":158,"action_type":22,"case_status":23,"posted_date":159,"marcs_cms_no":160,"product_type":161,"closeout_date":19,"issuing_office":151,"recipient_name":162,"body_fetched_at":163,"delivery_method":164,"recipient_title":19,"reference_number":19,"action_taken_date":165,"medical_device_id":19,"response_letter_date":19},2341,[148,149,150,151,152,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanabolic-laboratories-inc-636308-11142022\">Anabolic Laboratories Inc\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kyle Brown\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Anabolic Laboratories Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>26021 Commercentre Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lake Forest\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92630-8853\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: CMS # 636308\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kyle Brown:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.anaboliclabs.com\u002FDefault.aspx in August 2022 and has determined that you take orders there for your CoQ10 Ubiquinol Prime and Policosanol Microtabs products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products CoQ10 Ubiquinol Prime and Policosanol Microtabs are intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your CoQ10 Ubiquinol Prime product page at https:\u002F\u002Fwww.anaboliclabs.com\u002FProductDetails.aspx?ID=137:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"In patients undergoing surgery for cardiopulmonary bypass, those receiving CoQ10 treatment were significantly less likely to require inotropic drugs after surgery and to develop ventricular arrhythmias. Also, a randomized controlled multicenter trial evaluated CoQ10 as adjunctive treatment in 420 patients with chronic heart failure. Long- term CoQ10 treatment was found to be safe, improve symptoms, and reduce major adverse cardiovascular events. In another study, the administration of CoQ10 to heart transplant candidates led to significant improvements in functional status, clinical symptoms, and quality of life.\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"[I]mprovement in plasma CoQ10 was correlated with both clinical improvements and improvement in left ventricular function in heart failure patients\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"The ubiquinol form of CoQ10 is beneficial for people who may have increased needs for CoQ10 or who are at high risk for decreased conversion of ubiquinone to ubiquinol, such as those on statins or other CoQ10 depleting medications, older individuals, and those with certain health conditions, especially heart disease.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Policosanol Microtabs product page at https:\u002F\u002Fwww.anaboliclabs.com\u002FProductDetails.aspx?ID=30\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"Contains over 50% Octacosanol, ...found to manage lipid accumulation in fatty tissue and oxidation in the blood stream”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Naturally contains eight other higher primary aliphatic acids that assist in lowering cholesterol”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your CoQ10 Ubiquinol Prime and Policosanol Microtabs products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product CoQ10 Ubiquinol Prime is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, CoQ10 Ubiquinol Prime fails to bear adequate directions for its intended use and, therefore, this product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kyle Brown\n\nAnabolic Laboratories Inc\n\n26021 Commercentre Dr.\n\nLake Forest, CA 92630-8853\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: CMS # 636308\n\nDear Mr. Kyle Brown:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.anaboliclabs.com\u002FDefault.aspx in August 2022 and has determined that you take orders there for your CoQ10 Ubiquinol Prime and Policosanol Microtabs products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products CoQ10 Ubiquinol Prime and Policosanol Microtabs are intended for use as a drug include the following:\n\nOn your CoQ10 Ubiquinol Prime product page at https:\u002F\u002Fwww.anaboliclabs.com\u002FProductDetails.aspx?ID=137:\n\n\"In patients undergoing surgery for cardiopulmonary bypass, those receiving CoQ10 treatment were significantly less likely to require inotropic drugs after surgery and to develop ventricular arrhythmias. Also, a randomized controlled multicenter trial evaluated CoQ10 as adjunctive treatment in 420 patients with chronic heart failure. Long- term CoQ10 treatment was found to be safe, improve symptoms, and reduce major adverse cardiovascular events. In another study, the administration of CoQ10 to heart transplant candidates led to significant improvements in functional status, clinical symptoms, and quality of life.\"\n\n\"[I]mprovement in plasma CoQ10 was correlated with both clinical improvements and improvement in left ventricular function in heart failure patients\"\n\n\"The ubiquinol form of CoQ10 is beneficial for people who may have increased needs for CoQ10 or who are at high risk for decreased conversion of ubiquinone to ubiquinol, such as those on statins or other CoQ10 depleting medications, older individuals, and those with certain health conditions, especially heart disease.\"\n\nOn your Policosanol Microtabs product page at https:\u002F\u002Fwww.anaboliclabs.com\u002FProductDetails.aspx?ID=30\n\n\"Contains over 50% Octacosanol, ...found to manage lipid accumulation in fatty tissue and oxidation in the blood stream”\n\n“Naturally contains eight other higher primary aliphatic acids that assist in lowering cholesterol”\n\nYour CoQ10 Ubiquinol Prime and Policosanol Microtabs products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product CoQ10 Ubiquinol Prime is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, CoQ10 Ubiquinol Prime fails to bear adequate directions for its intended use and, therefore, this product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","Anabolic Laboratories Inc","anabolic-laboratories-inc-636308-11142022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanabolic-laboratories-inc-636308-11142022","2026-10-26T08:07:55.752438+00:00","2022-11-17","636308","Dietary SupplementsDrugs","Mr. Kyle Brown","2026-08-20T01:25:28.557+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":167,"raw":168,"subject":12,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":18,"fei_number":19,"letter_url":176,"updated_at":177,"action_type":22,"case_status":23,"posted_date":178,"marcs_cms_no":179,"product_type":96,"closeout_date":19,"issuing_office":11,"recipient_name":180,"body_fetched_at":181,"delivery_method":52,"recipient_title":19,"reference_number":182,"action_taken_date":183,"medical_device_id":19,"response_letter_date":19},794,[169,170,171,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-08T04:00:00Z\">07\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-27T04:00:00Z\">06\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flibby-laboratories-inc-708259-06272025\">Libby Laboratories, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-87\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Susan Carol Libby  President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Libby Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1700 Sixth Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Berkeley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94710\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-87\u003C\u002Fp>\u003Cp>June 27, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Libby:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Libby Laboratories, Inc., FEI 2912388, at 1700 Sixth Street, Berkeley, California, from March 11 to 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 1, 2025 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) sunscreen and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> antiseptic is labeled for hospital use only and used to prepare skin prior to surgery. You released your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product batches without testing for microbiological quality. For example, the batch record for finished product batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured in September 2024 and distributed to a children’s hospital, only lists finished drug product tests for \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay, color, odor, appearance, and percentage of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\u003C\u002Fp>\u003Cp>In your response, you state that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product contains \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are bactericidal. You indicate that you “think that the requirement to have finished product tested for presence of objectionable microorganisms is not necessary.” You commit to testing your finished drug product for objectionable microorganisms prior to releasing any future batches.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. Additionally, you did not provide any retrospective testing to support the quality of your drug products currently on the market.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before batch disposition decisions.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products distributed in the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also relied on your suppliers’ certificate of analysis (COA) for components, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without establishing the reliability of the suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Furthermore, we note that you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> purchased from a local grocery store as a component in the manufacture of your drug products for which you only conducted organoleptic assessment, including color, odor and appearance. This practice is unacceptable for pharmaceutical manufacturing. At a minimum, you must use purified water (refer to USP General Chapter &lt;1231&gt; \u003Cem>Water for Pharmaceutical Purposes\u003C\u002Fem>) to manufacture your topical, non-sterile drug products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for identity, a component at high-risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4) \u003C\u002Fstrong>or \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of this component for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used as an active pharmaceutical ingredient, for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In your response, you state that you plan to use contract laboratories to perform the identity tests for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also plan to test your drug components in-house or via a contract testing laboratory using compendial test methods or test methods from the manufacturers’ COA.\u003C\u002Fp>\u003Cp>Your response is inadequate because you fail to address the full scope and impact of the CGMP deficiencies as well as the associated risks to drug product quality, including batches already in distribution. Your response also lacked adequate information on how you will evaluate the suitability of your in-house laboratory or contract laboratories to perform testing of your drug components.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>Provide scientific justification to demonstrate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you use is suitable for use in drug manufacturing operations. If you determine the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used to manufacture drugs was not suitable, provide a detailed risk assessment addressing the potential effects on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions you will take in response to the risk assessment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2912388 and ATTN: Emily Wu.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-87\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Susan Carol Libby President\n\nRecipient Title\n\nPresident\n\nLibby Laboratories, Inc.\n\n1700 Sixth Street\n\nBerkeley, CA 94710\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-87\nJune 27, 2025\nDear Ms. Libby:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Libby Laboratories, Inc., FEI 2912388, at 1700 Sixth Street, Berkeley, California, from March 11 to 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 1, 2025 response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\nYou manufacture over-the-counter (OTC) sunscreen and (b)(4) drug products. Your (b)(4) antiseptic is labeled for hospital use only and used to prepare skin prior to surgery. You released your (b)(4) drug product batches without testing for microbiological quality. For example, the batch record for finished product batch (b)(4), manufactured in September 2024 and distributed to a children’s hospital, only lists finished drug product tests for (b)(4) assay, color, odor, appearance, and percentage of (b)(4).\nWithout testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\nIn your response, you state that your (b)(4) product contains (b)(4) and (b)(4), which are bactericidal. You indicate that you “think that the requirement to have finished product tested for presence of objectionable microorganisms is not necessary.” You commit to testing your finished drug product for objectionable microorganisms prior to releasing any future batches.\nYour response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. Additionally, you did not provide any retrospective testing to support the quality of your drug products currently on the market.\nIn response to this letter, provide the following:\nA list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before batch disposition decisions.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products distributed in the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, such as (b)(4) and (b)(4). You also relied on your suppliers’ certificate of analysis (COA) for components, such as (b)(4), and (b)(4), without establishing the reliability of the suppliers’ test analyses at appropriate intervals.\nFurthermore, we note that you used (b)(4) purchased from a local grocery store as a component in the manufacture of your drug products for which you only conducted organoleptic assessment, including color, odor and appearance. This practice is unacceptable for pharmaceutical manufacturing. At a minimum, you must use purified water (refer to USP General Chapter \u003C1231> Water for Pharmaceutical Purposes) to manufacture your topical, non-sterile drug products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n(b)(4)\nYou failed to adequately test each shipment of each lot of (b)(4) for identity, a component at high-risk of (b)(4) or (b)(4) contamination. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of (b)(4) or (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of this component for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) or (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) or (b)(4) contamination at (b)(4)\n(b)(4)\nYou failed to adequately test your incoming (b)(4), used as an active pharmaceutical ingredient, for (b)(4). The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn your response, you state that you plan to use contract laboratories to perform the identity tests for (b)(4) and (b)(4). You also plan to test your drug components in-house or via a contract testing laboratory using compendial test methods or test methods from the manufacturers’ COA.\nYour response is inadequate because you fail to address the full scope and impact of the CGMP deficiencies as well as the associated risks to drug product quality, including batches already in distribution. Your response also lacked adequate information on how you will evaluate the suitability of your in-house laboratory or contract laboratories to perform testing of your drug components.\nIn response to this letter, provide the following:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\nA commitment to provide (b)(4) and (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4) and (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) or (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4) or (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nProvide scientific justification to demonstrate the (b)(4) you use is suitable for use in drug manufacturing operations. If you determine the (b)(4) you used to manufacture drugs was not suitable, provide a detailed risk assessment addressing the potential effects on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions you will take in response to the risk assessment.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2912388 and ATTN: Emily Wu.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Libby Laboratories, Inc.","libby-laboratories-inc-708259-06272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flibby-laboratories-inc-708259-06272025","2026-10-26T08:09:14.167611+00:00","2025-07-08","708259","Ms. Susan Carol Libby President","2026-08-19T16:37:28.172+00:00","320-25-87","2025-06-27",{"id":185,"raw":186,"subject":190,"body_html":191,"body_text":192,"firm_name":193,"letter_id":194,"created_at":195,"fei_number":19,"letter_url":196,"updated_at":197,"action_type":22,"case_status":23,"posted_date":198,"marcs_cms_no":199,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":200,"body_fetched_at":201,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":202,"medical_device_id":19,"response_letter_date":19},2831,[187,188,189,38,190,13,13,13],"\u003Ctime datetime=\"2022-03-08T14:20:00Z\">03\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-17T05:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flusys-laboratories-inc-625807-02172022\">Lusys Laboratories, Inc.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. James Lu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Lusys Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6450 Lusk Blvd. Suite E106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:James.Lu@lusyslab.com\"> James.Lu@lusyslab.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Onestep@lusyslab.com\"> Onestep@lusyslab.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: February 17, 2022\u003C\u002Fp>\n\n\u003Cp>TO: 7220 Trade St. Suite 338\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Lusys Laboratories, Inc., located at 6620 Mesa Ridge Road, Suite 100, San Diego, CA from September 13 through September 24, 2021. During this inspection, FDA investigators determined that your firm is a medical device manufacturer of the COVID-19 IgG\u002FIgM Antibody Test and a COVID-19 Viral Antigen Test (both hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 Test Kits have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate corrective action to prevent the distribution of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to prevent future violations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you distribute are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send emails to\u003C\u002Fstrong> \u003Cstrong>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to prevent future violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to prevent future violations may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to prevent the distribution of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and\u003Cbr>\nRadiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Cem>available at\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaringnational-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaringnational-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca>https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. James Lu\n\nLusys Laboratories, Inc.\n\n6450 Lusk Blvd. Suite E106\n\nSan Diego, CA 92121\n\nUnited States\n\nJames.Lu@lusyslab.com\n\nOnestep@lusyslab.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: February 17, 2022\n\nTO: 7220 Trade St. Suite 338\n\nSan Diego, CA 92121\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Lusys Laboratories, Inc., located at 6620 Mesa Ridge Road, Suite 100, San Diego, CA from September 13 through September 24, 2021. During this inspection, FDA investigators determined that your firm is a medical device manufacturer of the COVID-19 IgG\u002FIgM Antibody Test and a COVID-19 Viral Antigen Test (both hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 Test Kits have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate corrective action to prevent the distribution of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)4” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to prevent future violations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you distribute are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send emails to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to prevent future violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to prevent future violations may result in legal action, including, without limitation, seizure, and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to prevent the distribution of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and\n\nRadiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n____________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaringnational-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Lusys Laboratories, Inc.","lusys-laboratories-inc-625807-02172022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flusys-laboratories-inc-625807-02172022","2026-10-26T08:09:17.170537+00:00","2022-03-08","625807","Mr. James Lu","2026-08-20T02:07:31.671+00:00","2022-02-17",{"id":204,"raw":205,"subject":12,"body_html":209,"body_text":210,"firm_name":211,"letter_id":212,"created_at":213,"fei_number":19,"letter_url":214,"updated_at":215,"action_type":22,"case_status":23,"posted_date":216,"marcs_cms_no":217,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":218,"body_fetched_at":219,"delivery_method":220,"recipient_title":19,"reference_number":221,"action_taken_date":222,"medical_device_id":19,"response_letter_date":19},379,[206,207,208,11,12,13,13,13],"\u003Ctime datetime=\"2026-01-06T05:00:00Z\">01\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftower-laboratories-ltd-717456-12232025\">Tower Laboratories Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Return Receipt Requested\n                                                                          \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-33\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norman Needleman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tower Laboratories Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8060 Whitbeck Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Montague\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49437-1546\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-33\u003C\u002Fp>\u003Cp>December 23, 2025\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Needleman:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Tower Laboratories Ltd., FEI 1823985, at 8060 Whitbeck Road, Montague, from July 8 to 11, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 1, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> medications. You failed to thoroughly investigate several out-of-specification (OOS) laboratory results from October 2024 to June 2025 and lacked corrective action and preventive action (CAPA). For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, failed assay testing at the 9-month stability timepoint. Your retest using additional samples also produced failing results. Your laboratory investigations did not include sufficient details and lacked root causes for the failures. Furthermore, you did not notify your customers about the failing stability results for the distributed lots.\u003C\u002Fp>\u003Cp>In your response, you state that while the above investigations did not identify root causes, the OOS results are “representative of microscopic packaging defects” noted in a previous investigation and “are not formula stability related.” You acknowledge that you did not take market action for the failing batches, despite noting the possibility that the defects may impact drug product effectiveness.\u003C\u002Fp>\u003Cp>Your response is inadequate because your investigation lacked sufficient rigor to show how your “packaging defects” led to a failure in product quality. Additionally, you failed to initiate a CAPA at the conclusion of the investigations. This was a repeat observation from FDA's 2021 inspection where you attributed the root cause of assay failures to packaging defects without providing supporting evidence of how these defects impact your analytical methodology and failed to implement appropriate CAPA.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate that your sample preparation methods are suitable for testing drugs or to account for how these methods could affect test results. For example, you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> to prepare samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets for high-performance liquid chromatography analysis. However, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which can lead to inaccurate results showing OOS levels for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that you did not fully meet the test method validation requirements, and that you will review and re-validate \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your test methods assaying for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your formulations. You commit to updating your analytical method validation master plan to incorporate all current test method validation requirements. You also commit to reviewing all other test methods used to assay your other OTC drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not commit to a retrospective review and risk assessment for all test results generated using these methods. Additionally, you have not established interim controls to use during the review and validation of your test methods.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An evaluation of the adequacy of your analytical sample preparation methods by verifying suitability through documented protocol, analyzing recurring errors throughout the methods’ history, and implementing CAPA measures to address test method deficiencies.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1823985 and ATTN: Renee A. Marcsisin, Ph.D.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReturn Receipt Requested\n\nReference #:\n\n320-26-33\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norman Needleman\n\nRecipient Title\n\nChief Executive Officer\n\nTower Laboratories Ltd.\n\n8060 Whitbeck Road\n\nMontague, MI 49437-1546\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-33\nDecember 23, 2025\n\nDear Mr. Needleman:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Tower Laboratories Ltd., FEI 1823985, at 8060 Whitbeck Road, Montague, from July 8 to 11, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 1, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou manufacture over-the-counter (OTC) drug products, including (b)(4) medications. You failed to thoroughly investigate several out-of-specification (OOS) laboratory results from October 2024 to June 2025 and lacked corrective action and preventive action (CAPA). For example, (b)(4) tablets, lot (b)(4), and (b)(4) tablets, lot (b)(4), failed assay testing at the 9-month stability timepoint. Your retest using additional samples also produced failing results. Your laboratory investigations did not include sufficient details and lacked root causes for the failures. Furthermore, you did not notify your customers about the failing stability results for the distributed lots.\nIn your response, you state that while the above investigations did not identify root causes, the OOS results are “representative of microscopic packaging defects” noted in a previous investigation and “are not formula stability related.” You acknowledge that you did not take market action for the failing batches, despite noting the possibility that the defects may impact drug product effectiveness.\nYour response is inadequate because your investigation lacked sufficient rigor to show how your “packaging defects” led to a failure in product quality. Additionally, you failed to initiate a CAPA at the conclusion of the investigations. This was a repeat observation from FDA's 2021 inspection where you attributed the root cause of assay failures to packaging defects without providing supporting evidence of how these defects impact your analytical methodology and failed to implement appropriate CAPA.\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYou failed to demonstrate that your sample preparation methods are suitable for testing drugs or to account for how these methods could affect test results. For example, you use (b)(4) to prepare samples of your (b)(4) tablets and (b)(4) tablets for high-performance liquid chromatography analysis. However, (b)(4), which can lead to inaccurate results showing OOS levels for (b)(4) content.\nIn your response, you acknowledge that you did not fully meet the test method validation requirements, and that you will review and re-validate (b)(4) of your test methods assaying for (b)(4) in (b)(4) of your formulations. You commit to updating your analytical method validation master plan to incorporate all current test method validation requirements. You also commit to reviewing all other test methods used to assay your other OTC drug products.\nYour response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not commit to a retrospective review and risk assessment for all test results generated using these methods. Additionally, you have not established interim controls to use during the review and validation of your test methods.\nIn response to this letter, provide:\nAn evaluation of the adequacy of your analytical sample preparation methods by verifying suitability through documented protocol, analyzing recurring errors throughout the methods’ history, and implementing CAPA measures to address test method deficiencies.\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1823985 and ATTN: Renee A. Marcsisin, Ph.D.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Tower Laboratories Ltd.","tower-laboratories-ltd-717456-12232025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftower-laboratories-ltd-717456-12232025","2026-10-26T08:10:14.110134+00:00","2026-01-06","717456","Mr. Norman Needleman","2026-08-19T07:18:50.076+00:00","Via Email Return Receipt Requested","320-26-33","2025-12-23",{"id":224,"raw":225,"subject":12,"body_html":230,"body_text":231,"firm_name":232,"letter_id":233,"created_at":213,"fei_number":19,"letter_url":234,"updated_at":235,"action_type":22,"case_status":23,"posted_date":236,"marcs_cms_no":237,"product_type":96,"closeout_date":19,"issuing_office":11,"recipient_name":238,"body_fetched_at":239,"delivery_method":52,"recipient_title":19,"reference_number":240,"action_taken_date":241,"medical_device_id":19,"response_letter_date":19},485,[226,227,228,11,229,13,13,13],"\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-03T05:00:00Z\">11\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiers-laboratories-ltd-715378-11032025\">Miers Laboratories, Ltd\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-13\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Andrew Criglington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Miers Laboratories, Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>32 Waiu Street, Wainuiomata Lower Hutt\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wellington\u003C\u002Fspan> \u003Cspan>5014\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ac@mierslabs.co.nz\"> ac@mierslabs.co.nz\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-13\u003C\u002Fp>\u003Cp>November 3, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Criglington:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Miers Laboratories, Ltd, FEI 3004087508, at 32 Waiu Street, Wainuiomata, Lower Hutt, Wellington, from May 19 to 21, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We have not yet received a response from your firm stating the actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture homeopathic drug products, several of which are intended for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to perform adequate identity testing on incoming components used in the manufacture of your homeopathic drug products. You solely relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform identity testing on a batch of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You used this material as a solvent for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets with homeopathic active pharmaceutical ingredients to manufacture numerous drug product batches for the U.S. market. The United States Pharmacopeia identity test for \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> is unacceptable.\u003C\u002Fp>\u003Cp>You manufacture multiple drugs that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Homeopathic active pharmaceutical ingredients\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to perform adequate testing on homeopathic active pharmaceutical ingredients. For example, you used a batch of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was more than 14 years past its expiration to manufacture numerous batches of finished drug products without determining whether the component continued to meet quality attributes.\u003C\u002Fp>\u003Cp>Without appropriate testing of incoming components, you cannot verify that the identity, purity, strength, quality, and safety of components meet specifications, and cannot confirm their suitability for intended use.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 inspection.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing reserve samples of finished products on the U.S. market for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content. If such testing identifies drug products with unacceptable \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels, take rapid corrective actions such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, our investigator observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your homeopathic drug products. Your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)). This is a repeat violation from your 2014 and 2019 inspections.\u003C\u002Fli>\u003Cli>Establishment of written procedures for managing quality unit functions including deviations, investigations, and corrective actions and preventive actions (21 CFR 211.22(d)). This is a repeat violation from you 2019 inspection.\u003C\u002Fli>\u003Cli>Establishment of an adequate quality control unit to approve or reject components and drug products (21 CFR 211.22(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous inspection, performed June 17 to 21, 2019, FDA cited similar CGMP observations. You acknowledged these observations and informed our investigators that you would correct all observations during the closeout meeting. Despite these commitments, when FDA reinspected your facility, the violations had not been corrected. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on October 27, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Miers Laboratories, Ltd., at 32 Waiu Street, Wainuiomata, Lower Hutt, Wellington, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004087508 and ATTN: Emily Wu.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-13\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Andrew Criglington\n\nRecipient Title\n\nChief Executive Officer\n\nMiers Laboratories, Ltd\n\n32 Waiu Street, Wainuiomata Lower Hutt\n\nWellington 5014\n\nNew Zealand\n\nac@mierslabs.co.nz\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-13\nNovember 3, 2025\nDear Mr. Criglington:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Miers Laboratories, Ltd, FEI 3004087508, at 32 Waiu Street, Wainuiomata, Lower Hutt, Wellington, from May 19 to 21, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe have not yet received a response from your firm stating the actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou manufacture homeopathic drug products, several of which are intended for use in (b)(4). You failed to perform adequate identity testing on incoming components used in the manufacture of your homeopathic drug products. You solely relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n(b)(4)\nYou failed to perform identity testing on a batch of (b)(4) containing up to (b)(4)% (b)(4). You used this material as a solvent for (b)(4) tablets with homeopathic active pharmaceutical ingredients to manufacture numerous drug product batches for the U.S. market. The United States Pharmacopeia identity test for (b)(4) includes a (b)(4) limit of (b)(4) ppm. Your use of (b)(4) with (b)(4) is unacceptable.\nYou manufacture multiple drugs that contain (b)(4). The use of (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See (b)(4)\nHomeopathic active pharmaceutical ingredients\nYou failed to perform adequate testing on homeopathic active pharmaceutical ingredients. For example, you used a batch of (b)(4) that was more than 14 years past its expiration to manufacture numerous batches of finished drug products without determining whether the component continued to meet quality attributes.\nWithout appropriate testing of incoming components, you cannot verify that the identity, purity, strength, quality, and safety of components meet specifications, and cannot confirm their suitability for intended use.\nThis is a repeat violation from your 2019 inspection.\nIn response to this letter, provide:\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing reserve samples of finished products on the U.S. market for (b)(4) content. If such testing identifies drug products with unacceptable (b)(4) levels, take rapid corrective actions such as notifying customers and product recalls.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nDuring the inspection, our investigator observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your homeopathic drug products. Your QU failed to ensure the following:\nAppropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)). This is a repeat violation from your 2014 and 2019 inspections.\nEstablishment of written procedures for managing quality unit functions including deviations, investigations, and corrective actions and preventive actions (21 CFR 211.22(d)). This is a repeat violation from you 2019 inspection.\nEstablishment of an adequate quality control unit to approve or reject components and drug products (21 CFR 211.22(a)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nIn response to this letter, provide the following:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nRepeat Violations at Facility\nIn a previous inspection, performed June 17 to 21, 2019, FDA cited similar CGMP observations. You acknowledged these observations and informed our investigators that you would correct all observations during the closeout meeting. Despite these commitments, when FDA reinspected your facility, the violations had not been corrected. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on October 27, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Miers Laboratories, Ltd., at 32 Waiu Street, Wainuiomata, Lower Hutt, Wellington, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004087508 and ATTN: Emily Wu.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Miers Laboratories, Ltd","miers-laboratories-ltd-715378-11032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiers-laboratories-ltd-715378-11032025","2026-10-26T08:09:25.515624+00:00","2025-11-11","715378","Mr. Andrew Criglington","2026-08-19T15:28:18.885+00:00","320-26-13","2025-11-03",{"id":243,"raw":244,"subject":12,"body_html":249,"body_text":250,"firm_name":251,"letter_id":252,"created_at":68,"fei_number":19,"letter_url":253,"updated_at":254,"action_type":22,"case_status":23,"posted_date":255,"marcs_cms_no":256,"product_type":96,"closeout_date":19,"issuing_office":257,"recipient_name":258,"body_fetched_at":259,"delivery_method":52,"recipient_title":19,"reference_number":256,"action_taken_date":260,"medical_device_id":19,"response_letter_date":19},1891,[245,246,247,248,12,13,13,13],"\u003Ctime datetime=\"2023-08-29T13:20:00Z\">08\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-15T04:00:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgadal-laboratories-inc-655929-08152023\">Gadal Laboratories Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>655929\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Giodardo Del Campo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gadal Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12178 SW 128th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33186-5230\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 8\u002F15\u002F2023\u003C\u002Fp>\n\n\u003Cp>Case #: 655929\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Del Campo:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Gadal Laboratories Inc., FEI 3008611487 at 12178 SW 128th St., Miami, Florida, from February 13 to February 17, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 7, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to qualify your suppliers and adequately test the components used to manufacture your finished drug products, including pediatric over-the-counter (OTC)&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> products. For example,\u003C\u002Fp>\n\n\u003Cp>A. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one of your active ingredients is sourced from an unqualified supplier and was approved for use without establishing the reliability of your suppliers’ certificate of analysis (COA).\u003C\u002Fp>\n\n\u003Cp>In your response you state that assay testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been completed to address the observation, and you will “complete the qualification of this vendor” after receiving the microbiological results.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not provide a detailed plan demonstrating how you will appropriately validate and establish the reliability of your supplier’s COA results. It is unclear if you will validate all tests on the supplier’s COA. Additionally, you do not provide the completed assay results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> with your response, nor address the other active pharmaceutical ingredient (API) and materials you use to manufacture drug products.\u003C\u002Fp>\n\n\u003Cp>B. The microbiological testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> excipient in your supplier qualification document only included a general statement that it should be free from pathogens but lacked any further specificity on microorganisms that your firm considers to be objectionable.\u003C\u002Fp>\n\n\u003Cp>You state in your response that the “last batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong>” were sent for microbiological testing to complete vendor qualification, and you do not have concerns because you did not detect out-of-specification (OOS) microbiological results in your finished drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a known source of \u003Cem>Clostridium botulinum&nbsp;\u003C\u002Fem>spores and has been implicated in cases of infant botulism. \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in preparations for infants should meet the requirements for absence of \u003Cem>Clostridium species\u003C\u002Fem> per United States Pharmacopeia (USP), National Formulary (NF). Your pediatric products (i.e., OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong>) are labeled for use in children younger than two years of age under a doctor’s guidance. It is unclear what specification your firm uses, or microbial identification tests will be performed on each lot, or if any specific objectionable organisms are the focus of testing. You do not propose a revision to this specification or review of other specifications that may be similarly insufficient.\u003C\u002Fp>\n\n\u003Cp>C. You lacked a specific identity test to detect \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>in all shipments, containers, and lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>before use in the manufacturing of drug products. Some of your drug products containing these ingredients are intended for oral use in pediatric populations.\u003Cbr>\n\u003Cbr>\nYour response includes updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications that incorporate \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, and states that analysts must sample each lot for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate, you fail to provide sufficient evidence demonstrating adequate identity testing on all containers of all lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>prior to its use in the manufacture of drug products. Your specifications lack appropriate testing of representative samples of each lot of high-risk components.\u003C\u002Fp>\n\n\u003Cp>After the inspection and after a discussion with FDA on June 1, 2023, you stated you would test and provide your \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> results for your bulk retains of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lots used to manufacture finished drugs. You also provided finished products manufactured with high-risk components that are in distribution and within expiry for analysis of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Based on the provided results, it is unclear what tests were performed to detect \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On August 8, 2023, we requested additional information and specified the testing required to ensure potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination is detected.\u003C\u002Fp>\n\n\u003Cp>In the discussion with FDA, you also stated you would test appropriate representative samples of incoming high-risk component lots for potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> or&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination prior to manufacturing drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results for finished products and for retains of high-risk components no later than 30 calendar days from the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including but not limited to&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A risk assessment of components qualified and released for use in manufacturing without appropriate testing for purity, strength, and quality.\u003C\u002Fli>\n\t\u003Cli>A review of completion status and adequacy of microbial effectiveness testing studies for your multi-use non-sterile drug products. Based on this review, provide a detailed summary and corrective action and preventive action (CAPA), with timelines for completion for any gaps in your studies.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and determine suitability of each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit did not review and approve written procedures for production and process control, including any changes to them, designed to ensure that the drug products you manufacture have the identity, strength, quality, and\u002For purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. You failed to adequately validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing OTC drug products with defined quality attributes. During the inspection, you acknowledged that none of your initial process validation studies (i.e., process performance qualification (PPQ)) were complete.\u003C\u002Fp>\n\n\u003Cp>In your response you commit to review all studies in your process validation program. Your response is inadequate. You do not adequately specify how you will evaluate the information collected and compare it to appropriate predetermined protocol requirements. Your validation studies should document whether your process is reproducible, and your products perform as expected using your actual facility, utilities, equipment, personnel, controls, and other variables unique to your operation.\u003C\u002Fp>\n\n\u003Cp>In addition, your response does not address or otherwise include a risk assessment for any marketed drug products manufactured and distributed with a lack of adequate validation.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>We also note you did not define an assay specification range in your process validation report for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug product. Additionally, you did not investigate multiple out-of-specification assay results in your process validation studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug product.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>B. You also failed to adequately qualify and test your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system to assure the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> produced from the system consistently meets chemical and microbiological standards and is suitable for use as a raw material in drug manufacturing or for cleaning.\u003C\u002Fp>\n\n\u003Cp>In your response you provide the performance qualification protocol for your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>system. You state that you will begin performance qualification with an intermittent sampling frequency described in the protocol.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to describe how your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system maintenance, cleaning process, seasonal variations, and other actual conditions of use are being considered during your “validation” efforts. You do not provide an adequate justification for the performance qualification sampling frequency, the sampling plan in the protocol, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling from only one of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your proposed sampling frequency is not justified for the qualification period.\u003C\u002Fp>\n\n\u003Cp>You are responsible for ensuring the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for equipment cleaning and manufacturing is of suitable quality, reproducibly conforms to \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>standards, and does not potentially contribute microbial contamination to manufacturing processes.\u003Cbr>\n\u003Cbr>\nC. You have not thoroughly validated your cleaning processes and your cleaning verification program does not adequately detect potential cross-contamination between products or microbiological contamination.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to finalizing your cleaning validation reports and continuing cleaning verification.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. You lack a scientific justification for the sole use of pH testing to verify the effectiveness of your cleaning operations. Your cleaning verification lacks the ability to detect cross-contamination from carryover, microbiological contamination, or traces of cleaning solution.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for PPQ, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedure (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example,\u003C\u002Fp>\n\n\u003Cp>A. You replaced the inactive ingredient with another inactive ingredient, without documented scientific rationale and justification, in multiple batches of your OTC drug products. For example, while manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you replaced \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without appropriate documentation or a product risk assessment. Your firm failed to perform adequate change management. You failed to perform stability studies to show equivalency between the original and substituted ingredient. Additionally, you failed to update the product label to list the actual inactive ingredient used.\u003C\u002Fp>\n\n\u003Cp>You also used multiple specification ranges for the same quality attribute in the same OTC drug product.\u003C\u002Fp>\n\n\u003Cp>In your response you state that you will no longer permit ingredient substitution. You note that your previous substitution with \u003Cstrong>(b)(4)\u003C\u002Fstrong> was expected to provide the same emulsifier function. Your response is inadequate. You fail to address if appropriate studies were performed to show equivalency with the substituted ingredient. In addition, your response does not include a risk assessment for any marketed drug products manufactured and distributed with substituted ingredients that lack supportive validation studies.\u003C\u002Fp>\n\n\u003Cp>Your response also commits to perform a detailed investigation and to scientifically determine the correct specification for your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. Your response is inadequate. Your response does not address or otherwise include a risk assessment for the distributed drug products manufactured and tested using different specification ranges. Additionally, your response does not commit to investigate the specification ranges in other drug products.\u003C\u002Fp>\n\n\u003Cp>B. Analysts documented original laboratory data on uncontrolled sheets of paper. Analysts also recorded raw data in pencil and changed written data using correction fluid to obscure the original result.\u003C\u002Fp>\n\n\u003Cp>Your response to the use of uncontrolled sheets, correction fluid, and pencil in the Quality Control (QC) laboratory is inadequate. You do not specify the changes in your procedures you intend to implement to address these deficiencies. Additionally, there is no commitment to perform a retrospective review and risk assessment for potentially impacted data obtained for finished drug products manufactured, tested, and distributed.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality assurance unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of all drug product batch records that included substituted ingredients without appropriate validation (including stability) studies to support the change. Provide a risk assessment for impacted distributed drug products that are within expiry, and your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\n\t\u003Cli>A comprehensive comparison of all drug product specifications defined in your batch records, process validation studies, annual product reviews, and certificates of analysis. This comparison should record any differences in specification ranges for the quality attribute for the same product. Perform a thorough investigation for any inconsistent drug product specifications and include a detailed CAPA plan to remediate the specifications.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter indicate that your quality unit is not fully exercising its authority and\u002For responsibilities. Your firm must provide the quality unit with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>655929\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, DCB at ronda.loyd-jones@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at 787-399-9905 or email at dayna.martinez@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n655929\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGiodardo Del Campo\n\nRecipient Title\n\nPresident\n\nGadal Laboratories Inc.\n\n12178 SW 128th St.\n\nMiami, FL 33186-5230\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 8\u002F15\u002F2023\n\nCase #: 655929\n\nWARNING LETTER\n\nDear Mr. Del Campo:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Gadal Laboratories Inc., FEI 3008611487 at 12178 SW 128th St., Miami, Florida, from February 13 to February 17, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 7, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\n\nYour firm failed to qualify your suppliers and adequately test the components used to manufacture your finished drug products, including pediatric over-the-counter (OTC) (b)(4) products. For example,\n\nA. (b)(4), one of your active ingredients is sourced from an unqualified supplier and was approved for use without establishing the reliability of your suppliers’ certificate of analysis (COA).\n\nIn your response you state that assay testing for (b)(4) has been completed to address the observation, and you will “complete the qualification of this vendor” after receiving the microbiological results.\n\nYour response is inadequate. You do not provide a detailed plan demonstrating how you will appropriately validate and establish the reliability of your supplier’s COA results. It is unclear if you will validate all tests on the supplier’s COA. Additionally, you do not provide the completed assay results for (b)(4) with your response, nor address the other active pharmaceutical ingredient (API) and materials you use to manufacture drug products.\n\nB. The microbiological testing of (b)(4) excipient in your supplier qualification document only included a general statement that it should be free from pathogens but lacked any further specificity on microorganisms that your firm considers to be objectionable.\n\nYou state in your response that the “last batches of (b)(4)” were sent for microbiological testing to complete vendor qualification, and you do not have concerns because you did not detect out-of-specification (OOS) microbiological results in your finished drug product.\n\nYour response is inadequate. (b)(4) is a known source of Clostridium botulinum spores and has been implicated in cases of infant botulism. (b)(4) used in preparations for infants should meet the requirements for absence of Clostridium species per United States Pharmacopeia (USP), National Formulary (NF). Your pediatric products (i.e., OTC (b)(4)) are labeled for use in children younger than two years of age under a doctor’s guidance. It is unclear what specification your firm uses, or microbial identification tests will be performed on each lot, or if any specific objectionable organisms are the focus of testing. You do not propose a revision to this specification or review of other specifications that may be similarly insufficient.\n\nC. You lacked a specific identity test to detect (b)(4) and (b)(4) in all shipments, containers, and lots of (b)(4) and (b)(4) before use in the manufacturing of drug products. Some of your drug products containing these ingredients are intended for oral use in pediatric populations.\n\nYour response includes updated (b)(4) and (b)(4) specifications that incorporate (b)(4) and (b)(4) testing, and states that analysts must sample each lot for (b)(4) and (b)(4) contamination.\n\nYour response is inadequate, you fail to provide sufficient evidence demonstrating adequate identity testing on all containers of all lots of (b)(4) and (b)(4) prior to its use in the manufacture of drug products. Your specifications lack appropriate testing of representative samples of each lot of high-risk components.\n\nAfter the inspection and after a discussion with FDA on June 1, 2023, you stated you would test and provide your (b)(4) or (b)(4) results for your bulk retains of (b)(4) and (b)(4) lots used to manufacture finished drugs. You also provided finished products manufactured with high-risk components that are in distribution and within expiry for analysis of potential (b)(4) or (b)(4) contamination. Based on the provided results, it is unclear what tests were performed to detect (b)(4) or (b)(4). On August 8, 2023, we requested additional information and specified the testing required to ensure potential (b)(4) or (b)(4) contamination is detected.\n\nIn the discussion with FDA, you also stated you would test appropriate representative samples of incoming high-risk component lots for potential (b)(4) or (b)(4) contamination prior to manufacturing drug products.\n\nThe use of ingredients contaminated with (b)(4) or (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for (b)(4) or (b)(4) contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe remaining (b)(4) and (b)(4) test results for finished products and for retains of high-risk components no later than 30 calendar days from the date of this letter.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) or (b)(4) contamination (including but not limited to (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4) or (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA risk assessment of components qualified and released for use in manufacturing without appropriate testing for purity, strength, and quality.\n\nA review of completion status and adequacy of microbial effectiveness testing studies for your multi-use non-sterile drug products. Based on this review, provide a detailed summary and corrective action and preventive action (CAPA), with timelines for completion for any gaps in your studies.\n\nThe chemical and microbiological quality control specifications you use to test and determine suitability of each incoming lot of components for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph. Include your standard operating procedure (SOP) that describes this COA validation program.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm’s quality control unit did not review and approve written procedures for production and process control, including any changes to them, designed to ensure that the drug products you manufacture have the identity, strength, quality, and\u002For purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nA. You failed to adequately validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing OTC drug products with defined quality attributes. During the inspection, you acknowledged that none of your initial process validation studies (i.e., process performance qualification (PPQ)) were complete.\n\nIn your response you commit to review all studies in your process validation program. Your response is inadequate. You do not adequately specify how you will evaluate the information collected and compare it to appropriate predetermined protocol requirements. Your validation studies should document whether your process is reproducible, and your products perform as expected using your actual facility, utilities, equipment, personnel, controls, and other variables unique to your operation.\n\nIn addition, your response does not address or otherwise include a risk assessment for any marketed drug products manufactured and distributed with a lack of adequate validation.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWe also note you did not define an assay specification range in your process validation report for your (b)(4) finished drug product. Additionally, you did not investigate multiple out-of-specification assay results in your process validation studies for (b)(4) finished drug product.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nB. You also failed to adequately qualify and test your (b)(4) system to assure the (b)(4) produced from the system consistently meets chemical and microbiological standards and is suitable for use as a raw material in drug manufacturing or for cleaning.\n\nIn your response you provide the performance qualification protocol for your (b)(4) system. You state that you will begin performance qualification with an intermittent sampling frequency described in the protocol.\n\nYour response is inadequate. You fail to describe how your (b)(4) system maintenance, cleaning process, seasonal variations, and other actual conditions of use are being considered during your “validation” efforts. You do not provide an adequate justification for the performance qualification sampling frequency, the sampling plan in the protocol, (b)(4) sampling from only one of the (b)(4), and your proposed sampling frequency is not justified for the qualification period.\n\nYou are responsible for ensuring the (b)(4) for equipment cleaning and manufacturing is of suitable quality, reproducibly conforms to (b)(4) standards, and does not potentially contribute microbial contamination to manufacturing processes.\n\nC. You have not thoroughly validated your cleaning processes and your cleaning verification program does not adequately detect potential cross-contamination between products or microbiological contamination.\n\nIn your response, you commit to finalizing your cleaning validation reports and continuing cleaning verification.\n\nYour response is inadequate. Your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. You lack a scientific justification for the sole use of pH testing to verify the effectiveness of your cleaning operations. Your cleaning verification lacks the ability to detect cross-contamination from carryover, microbiological contamination, or traces of cleaning solution.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for PPQ, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate PPQ for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\n\no A (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedure (21 CFR 211.22(d)).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example,\n\nA. You replaced the inactive ingredient with another inactive ingredient, without documented scientific rationale and justification, in multiple batches of your OTC drug products. For example, while manufacturing (b)(4) batch (b)(4), you replaced (b)(4) with (b)(4), without appropriate documentation or a product risk assessment. Your firm failed to perform adequate change management. You failed to perform stability studies to show equivalency between the original and substituted ingredient. Additionally, you failed to update the product label to list the actual inactive ingredient used.\n\nYou also used multiple specification ranges for the same quality attribute in the same OTC drug product.\n\nIn your response you state that you will no longer permit ingredient substitution. You note that your previous substitution with (b)(4) was expected to provide the same emulsifier function. Your response is inadequate. You fail to address if appropriate studies were performed to show equivalency with the substituted ingredient. In addition, your response does not include a risk assessment for any marketed drug products manufactured and distributed with substituted ingredients that lack supportive validation studies.\n\nYour response also commits to perform a detailed investigation and to scientifically determine the correct specification for your OTC (b)(4) drug product. Your response is inadequate. Your response does not address or otherwise include a risk assessment for the distributed drug products manufactured and tested using different specification ranges. Additionally, your response does not commit to investigate the specification ranges in other drug products.\n\nB. Analysts documented original laboratory data on uncontrolled sheets of paper. Analysts also recorded raw data in pencil and changed written data using correction fluid to obscure the original result.\n\nYour response to the use of uncontrolled sheets, correction fluid, and pencil in the Quality Control (QC) laboratory is inadequate. You do not specify the changes in your procedures you intend to implement to address these deficiencies. Additionally, there is no commitment to perform a retrospective review and risk assessment for potentially impacted data obtained for finished drug products manufactured, tested, and distributed.\n\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality assurance unit. Your change management program should also include provisions for determining change effectiveness.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nA complete assessment of all drug product batch records that included substituted ingredients without appropriate validation (including stability) studies to support the change. Provide a risk assessment for impacted distributed drug products that are within expiry, and your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recalls.\n\nA comprehensive comparison of all drug product specifications defined in your batch records, process validation studies, annual product reviews, and certificates of analysis. This comparison should record any differences in specification ranges for the quality attribute for the same product. Perform a thorough investigation for any inconsistent drug product specifications and include a detailed CAPA plan to remediate the specifications.\n\nIneffective Quality Systems\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nQuality Unit Authority\n\nSignificant findings in this letter indicate that your quality unit is not fully exercising its authority and\u002For responsibilities. Your firm must provide the quality unit with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 655929.\n\nPlease electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, DCB at ronda.loyd-jones@fda.hhs.gov\n\nIf you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at 787-399-9905 or email at dayna.martinez@fda.hhs.gov\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n__________________________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Gadal Laboratories Inc.","gadal-laboratories-inc-655929-08152023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgadal-laboratories-inc-655929-08152023","2026-10-26T08:08:44.4521+00:00","2023-08-29","655929","Division of Pharmaceutical Quality Operations II","Giodardo Del Campo","2026-08-20T00:43:55.219+00:00","2023-08-15",{"id":262,"raw":263,"subject":12,"body_html":268,"body_text":269,"firm_name":270,"letter_id":271,"created_at":68,"fei_number":19,"letter_url":272,"updated_at":273,"action_type":22,"case_status":23,"posted_date":274,"marcs_cms_no":275,"product_type":96,"closeout_date":19,"issuing_office":276,"recipient_name":277,"body_fetched_at":278,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":279,"medical_device_id":19,"response_letter_date":19},1961,[264,265,266,267,12,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-13T04:00:00Z\">07\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjamol-laboratories-inc-654464-07132023\">Jamol Laboratories, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Emil Scott Lucia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jamol Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 Ackerman Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Emerson\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07630\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 654464\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lucia:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Jamol Laboratories, Inc., FEI 2211383, at 13 Ackerman Avenue, Emerson, New Jersey, from December 5, 2022, to January 12, 2023.\u003C\u002Fp>\n\n\u003Cp>Your drug products are adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(A), in that they have been prepared, packed, or held under insanitary conditions.\u003C\u002Fp>\n\n\u003Cp>This warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 1, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Insanitary Conditions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures an over-the-counter (OTC) drug product, Ponaris® NASAL EMOLLIENT (Ponaris). Your Ponaris drug product is adulterated under section 501(a)(2)(A) of the FD&amp;C Act because it was prepared, packed, or held under insanitary conditions.\u003Cbr>\n\u003Cbr>\nYour drug manufacturing occurs in a multipurpose uncontrolled space used for a variety of activities. FDA investigators observed this space to be in a state of disrepair, poorly cleaned and maintained, as evidenced by a dead insect, exposed ceiling, and inadequate ventilation. For example, you conduct a portion of your manufacturing in a corridor using a stained and debris covered fan surrounded by cardboard. You lack adequate controls in place to maintain a clean production environment and prevent contamination of drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm lacks an adequate quality control unit with adequate facilities and procedures to ensure that drugs are manufactured in compliance with CGMP regulations and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug product. For example, you lacked procedures describing the roles and responsibilities of the QU, investigations of out-of-specification (OOS) and other discrepant results and deviations. Additionally, your QU failed to ensure that all batch records are complete.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to perform a review of your standard operating procedures (SOPs) and other governing documents to identify and address deficiencies in a holistic manner.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment with corrective action and preventive action (CAPA) to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; &nbsp; o A complete assessment of documentation systems used throughout your manufacturing operations to determine where documentation practices are inadequate. Include a detailed CAPA plan that remedies documentation practices and ensures that you retain complete and accurate records.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective evaluation of your drug product in the U.S. market and within expiry to identify and take appropriate action on any product quality or patient safety risks.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches\u003C\u002Fem> to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components conform to appropriate standards of identity, strength, quality, and purity, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.160(b) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish an identification test with adequate specificity to appropriately test incoming lots of Eucalyptus Oil to meet the United States Pharmacopoeia (USP) monograph. Specifically, your test procedure fails to include an appropriate test using infrared spectroscopy for identification.\u003C\u002Fp>\n\n\u003Cp>Your firm also failed to conduct appropriate laboratory testing for each batch of drug product that is required to be free of objectionable microorganisms. Your practice of conducting microbiological testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> of Ponaris selected \u003Cstrong>(b)(4)\u003C\u002Fstrong> is inadequate. Additionally, as your drug product contains ingredients of botanical origin, an assessment for the absence of aflatoxins or other mycotoxins should be conducted.\u003C\u002Fp>\n\n\u003Cp>In your response you state that you will continue to test \u003Cstrong>(b)(4)\u003C\u002Fstrong> of Ponaris for “microcontaminants” and heavy metals \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in addition to the rancidity test you already perform. Your response is inadequate because you did not provide scientific justification for conducting microbiological testing only \u003Cstrong>(b)(4)\u003C\u002Fstrong>, nor recognize the need for conducting analysis showing your products are free of aflatoxins and other mycotoxins.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provide a timeline to complete retroactive identification tests using an appropriate identification method for all potentially compromised batches. Respond promptly with all results. If your data indicates that defective products are in the U.S. marketplace, commit to recall the products.\u003C\u002Fli>\n\t\u003Cli>Determine if all methods used to test your raw and in-process materials and finished drug products use USP-NF, or if not, employ an equivalent or better method. Provide a CAPA to address any inadequate methods that are identified.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate the processes used to manufacture Ponaris, and do not have an ongoing program for monitoring process control, to ensure stable manufacturing operations and consistent drug quality.\u003Cbr>\n\u003Cbr>\nFor example, you have not identified the component attributes (e.g., solubility, viscosity, and density) and the process parameters (e.g., speed, temperature, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) that are important to produce this product with a consistent quality.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response you state that you will begin recording mixing times for each lot that is manufactured to ensure consistency and quality of the product. Your response is inadequate because recording mixing times or performing a single “Uniformity in Drum” test does not itself provide adequate evidence of process control at each step of the manufacturing process and show lot-to-lot consistency.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Your process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations exist at your facility You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Identify your response with FEI 2211383 and Warning Letter 654464.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer, Barbara Wilimczyk-Macri, at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Emil Scott Lucia\n\nRecipient Title\n\nCo-Owner\u002FPresident\n\nJamol Laboratories, Inc.\n\n13 Ackerman Avenue\n\nEmerson, NJ 07630\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter 654464\n\nJuly 13, 2023\n\nDear Mr. Lucia:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Jamol Laboratories, Inc., FEI 2211383, at 13 Ackerman Avenue, Emerson, New Jersey, from December 5, 2022, to January 12, 2023.\n\nYour drug products are adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(A), in that they have been prepared, packed, or held under insanitary conditions.\n\nThis warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 1, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nInsanitary Conditions\n\nYour firm manufactures an over-the-counter (OTC) drug product, Ponaris® NASAL EMOLLIENT (Ponaris). Your Ponaris drug product is adulterated under section 501(a)(2)(A) of the FD&C Act because it was prepared, packed, or held under insanitary conditions.\n\nYour drug manufacturing occurs in a multipurpose uncontrolled space used for a variety of activities. FDA investigators observed this space to be in a state of disrepair, poorly cleaned and maintained, as evidenced by a dead insect, exposed ceiling, and inadequate ventilation. For example, you conduct a portion of your manufacturing in a corridor using a stained and debris covered fan surrounded by cardboard. You lack adequate controls in place to maintain a clean production environment and prevent contamination of drug products.\n\nCGMP Violations\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm lacks an adequate quality control unit with adequate facilities and procedures to ensure that drugs are manufactured in compliance with CGMP regulations and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug product. For example, you lacked procedures describing the roles and responsibilities of the QU, investigations of out-of-specification (OOS) and other discrepant results and deviations. Additionally, your QU failed to ensure that all batch records are complete.\n\nYour response is inadequate because you failed to perform a review of your standard operating procedures (SOPs) and other governing documents to identify and address deficiencies in a holistic manner.\n\nIn response to this letter, provide:\n\nA comprehensive assessment with corrective action and preventive action (CAPA) to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no A complete assessment of documentation systems used throughout your manufacturing operations to determine where documentation practices are inadequate. Include a detailed CAPA plan that remedies documentation practices and ensures that you retain complete and accurate records.\n\nA retrospective evaluation of your drug product in the U.S. market and within expiry to identify and take appropriate action on any product quality or patient safety risks.\n\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components conform to appropriate standards of identity, strength, quality, and purity, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.160(b) and 211.165(b)).\n\nYou failed to establish an identification test with adequate specificity to appropriately test incoming lots of Eucalyptus Oil to meet the United States Pharmacopoeia (USP) monograph. Specifically, your test procedure fails to include an appropriate test using infrared spectroscopy for identification.\n\nYour firm also failed to conduct appropriate laboratory testing for each batch of drug product that is required to be free of objectionable microorganisms. Your practice of conducting microbiological testing on (b)(4) of Ponaris selected (b)(4) is inadequate. Additionally, as your drug product contains ingredients of botanical origin, an assessment for the absence of aflatoxins or other mycotoxins should be conducted.\n\nIn your response you state that you will continue to test (b)(4) of Ponaris for “microcontaminants” and heavy metals (b)(4), in addition to the rancidity test you already perform. Your response is inadequate because you did not provide scientific justification for conducting microbiological testing only (b)(4), nor recognize the need for conducting analysis showing your products are free of aflatoxins and other mycotoxins.\n\nIn your response to this letter:\n\nProvide a timeline to complete retroactive identification tests using an appropriate identification method for all potentially compromised batches. Respond promptly with all results. If your data indicates that defective products are in the U.S. marketplace, commit to recall the products.\n\nDetermine if all methods used to test your raw and in-process materials and finished drug products use USP-NF, or if not, employ an equivalent or better method. Provide a CAPA to address any inadequate methods that are identified.\n\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to adequately validate the processes used to manufacture Ponaris, and do not have an ongoing program for monitoring process control, to ensure stable manufacturing operations and consistent drug quality.\n\nFor example, you have not identified the component attributes (e.g., solubility, viscosity, and density) and the process parameters (e.g., speed, temperature, and (b)(4)) that are important to produce this product with a consistent quality.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn your response you state that you will begin recording mixing times for each lot that is manufactured to ensure consistency and quality of the product. Your response is inadequate because recording mixing times or performing a single “Uniformity in Drum” test does not itself provide adequate evidence of process control at each step of the manufacturing process and show lot-to-lot consistency.\n\nIn response to this letter, provide the following:\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing PPQ for each of your marketed drug products.\n\nYour process performance protocols, and written procedures for qualification of equipment and facilities.\n\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations exist at your facility You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Identify your response with FEI 2211383 and Warning Letter 654464.\n\nIf you have any questions, contact Compliance Officer, Barbara Wilimczyk-Macri, at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division I","Jamol Laboratories, Inc.","jamol-laboratories-inc-654464-07132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjamol-laboratories-inc-654464-07132023","2026-10-26T08:09:02.683335+00:00","2023-08-01","654464","Division of Pharmaceutical Quality Operations I","Mr. Emil Scott Lucia","2026-08-20T00:50:07.268+00:00","2023-07-13",{"id":281,"raw":282,"subject":190,"body_html":286,"body_text":287,"firm_name":288,"letter_id":289,"created_at":113,"fei_number":19,"letter_url":290,"updated_at":291,"action_type":22,"case_status":23,"posted_date":292,"marcs_cms_no":293,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":294,"body_fetched_at":295,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":296,"medical_device_id":19,"response_letter_date":19},3402,[283,284,285,38,190,13,13,13],"\u003Ctime datetime=\"2021-04-15T17:00:00Z\">04\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-06T04:00:00Z\">04\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsethi-laboratories-611628-04062021\">Sethi Laboratories\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sameer Sethi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sethi Laboratories\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17290 Preston Road Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75252\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@sethilaboratories.com\"> sales@sethilaboratories.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@sethilabs.com\"> admin@sethilabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 6, 2021\u003Cbr>\n\u003Cbr>\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsethilaboratories.com on March 19, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fsethilabs, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCGC8yKEHXZO, and https:\u002F\u002Ftwitter.com\u002FSethiLabsUS, where you direct consumers to your website, www.sethilaboratories.com, to purchase your products. The FDA has observed that your website offers a “Rapid COVID-19 Antibody Self Test Kit” (which your website also refers to as the “Novel Coronavirus Antibody Test Kit,” “COVID-19 ANTIBODY SELF TEST KIT,” and “AB Rapid Kit”) (hereafter referred to as the “COVID-19 Antibody Self Test Kit”) and a “Rapid COVID-19 Antigen Self Test Kit” (which your website also refers to as the “Novel Coronavirus Antigen Test Kit” and “Sethi Laboratories COVID-19 Antigen test”) (hereafter referred to as the “COVID-19 Antigen Self Test Kit”). Based on our review, the COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are offered for sale in the United States directly to consumers to self-test at home or outside of a healthcare setting without marketing approval, clearance, or authorization from FDA.\u003Csup>\u003Cem>\u003Cstrong>2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Different and potentially serious public health risks are presented with sample collection and testing by lay users at home or outside of a healthcare setting versus collection and testing in a healthcare setting. Such risks include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your website, https:\u002F\u002Fsethilaboratories.com, and social media websites indicate that your firm’s COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit may be purchased directly by consumers to self-test at home or outside of a healthcare setting, including:\u003C\u002Fp>\n\n\u003Cp>• “RAPID COVID-19 ANTIBODY SELF TEST KITS…GREAT FOR BUSINESSES…Find out if you have Covid-19 without an appointment from the convenience of your home or business! . . . CONTAINS 25 SELF-ADMINISTERED TESTS” [https:\u002F\u002Fsethilaboratories.com\u002Fnovel-coronavirus-antibody-test-kit\u002F]\u003Cbr>\n• “RAPID COVID-19 ANTIGEN SELF TEST KITS . . . GREAT FOR BUSINESSES . . . Find out if you currently have Covid-19 without an appointment from the convenience of your home or business! . . . CONTAINS 20 SELF-ADMINISTERED TESTS” [https:\u002F\u002Fsethilaboratories.com\u002Fnovel-coronavirus-antigen-test-kit-new\u002F]\u003Cbr>\n• “Stay one step ahead with our COVID-19 Rapid Self Test Kits. Perfect for employers or families on the go that need to #staysafe...#test #testing #selftest #rapidtest #covid19 #coronavirus…#buynow...#order” [posted Oct. 7, 2020 to https:\u002F\u002Fwww.facebook.com\u002Fsethilabs]\u003Cbr>\n• “RAPID COVID-19 SELF TESTS…KEEP YOUR EMPLOYEES SAFE…TEST WHEN NEEDED AND STAY SAFE AT WORK WITH OUR PACK OF 25 SELF TEST KITS!...www.sethilaboratories.com” [posted Oct. 7, 2020 to https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCGC8yKEHXZO\u002F]\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because your webpage represents that the COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are “FDA Emergency Use Authorized” using the FDA logo. These representations create a false impression that your products have been authorized for emergency use by FDA and are misleading. As discussed above, your products have not been authorized by FDA. In addition, the FDA logo is for the official use of the FDA and not for use on private sector materials. Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”6 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The “COVID-19 Antibody Self Test Kit” offered for sale on your website appears to be the COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) manufactured by Healgen Scientific LLC. On May 29, 2020, FDA issued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Healgen Scientific LLC’s COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests for qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in venous whole blood, plasma (Li+-heparin, K2-EDTA and sodium-citrate), and serum. However, this EUA does not authorize the sale of the Healgen COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) directly to consumers to self-test at home or outside of a healthcare setting.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The “COVID-19 Antigen Self Test Kit” offered for sale on your website appears to be the \u003Cem>CareStart\u003C\u002Fem> COVID-19&nbsp;Antigen test manufactured by Access Bio, Inc. On February 1, 2021, FDA issued an EUA pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Access Bio, Inc.’s \u003Cem>CareStart\u003C\u002Fem> COVID-19 Antigen test by laboratories certified under CLIA that meet the requirements to perform, high, moderate, or waived complexity tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation for qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals suspected of COVID-19 by their healthcare provider within five days of symptom onset. However, this EUA does not authorize the sale of the Access Bio, Inc. \u003Cem>CareStart\u003C\u002Fem> COVID-19 Antigen test directly to consumers to self-test at home or outside of a healthcare setting.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwwwfda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwwwfda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Sameer Sethi\n\nSethi Laboratories\n\n17290 Preston Road Suite 300\n\nDallas, TX 75252\n\nUnited States\n\nsales@sethilaboratories.com\n\nadmin@sethilabs.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: April 6, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsethilaboratories.com on March 19, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fsethilabs, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCGC8yKEHXZO, and https:\u002F\u002Ftwitter.com\u002FSethiLabsUS, where you direct consumers to your website, www.sethilaboratories.com, to purchase your products. The FDA has observed that your website offers a “Rapid COVID-19 Antibody Self Test Kit” (which your website also refers to as the “Novel Coronavirus Antibody Test Kit,” “COVID-19 ANTIBODY SELF TEST KIT,” and “AB Rapid Kit”) (hereafter referred to as the “COVID-19 Antibody Self Test Kit”) and a “Rapid COVID-19 Antigen Self Test Kit” (which your website also refers to as the “Novel Coronavirus Antigen Test Kit” and “Sethi Laboratories COVID-19 Antigen test”) (hereafter referred to as the “COVID-19 Antigen Self Test Kit”). Based on our review, the COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are offered for sale in the United States directly to consumers to self-test at home or outside of a healthcare setting without marketing approval, clearance, or authorization from FDA.2,3 Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nDifferent and potentially serious public health risks are presented with sample collection and testing by lay users at home or outside of a healthcare setting versus collection and testing in a healthcare setting. Such risks include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your website, https:\u002F\u002Fsethilaboratories.com, and social media websites indicate that your firm’s COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit may be purchased directly by consumers to self-test at home or outside of a healthcare setting, including:\n\n• “RAPID COVID-19 ANTIBODY SELF TEST KITS…GREAT FOR BUSINESSES…Find out if you have Covid-19 without an appointment from the convenience of your home or business! . . . CONTAINS 25 SELF-ADMINISTERED TESTS” [https:\u002F\u002Fsethilaboratories.com\u002Fnovel-coronavirus-antibody-test-kit\u002F]\n\n• “RAPID COVID-19 ANTIGEN SELF TEST KITS . . . GREAT FOR BUSINESSES . . . Find out if you currently have Covid-19 without an appointment from the convenience of your home or business! . . . CONTAINS 20 SELF-ADMINISTERED TESTS” [https:\u002F\u002Fsethilaboratories.com\u002Fnovel-coronavirus-antigen-test-kit-new\u002F]\n\n• “Stay one step ahead with our COVID-19 Rapid Self Test Kits. Perfect for employers or families on the go that need to #staysafe...#test #testing #selftest #rapidtest #covid19 #coronavirus…#buynow...#order” [posted Oct. 7, 2020 to https:\u002F\u002Fwww.facebook.com\u002Fsethilabs]\n\n• “RAPID COVID-19 SELF TESTS…KEEP YOUR EMPLOYEES SAFE…TEST WHEN NEEDED AND STAY SAFE AT WORK WITH OUR PACK OF 25 SELF TEST KITS!...www.sethilaboratories.com” [posted Oct. 7, 2020 to https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCGC8yKEHXZO\u002F]\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because your webpage represents that the COVID-19 Antibody Self Test Kit and COVID-19 Antigen Self Test Kit are “FDA Emergency Use Authorized” using the FDA logo. These representations create a false impression that your products have been authorized for emergency use by FDA and are misleading. As discussed above, your products have not been authorized by FDA. In addition, the FDA logo is for the official use of the FDA and not for use on private sector materials. Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”6 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 The “COVID-19 Antibody Self Test Kit” offered for sale on your website appears to be the COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) manufactured by Healgen Scientific LLC. On May 29, 2020, FDA issued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Healgen Scientific LLC’s COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests for qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in venous whole blood, plasma (Li+-heparin, K2-EDTA and sodium-citrate), and serum. However, this EUA does not authorize the sale of the Healgen COVID-19 IgG\u002FIgM Rapid Test Cassette (Whole Blood\u002FSerum\u002FPlasma) directly to consumers to self-test at home or outside of a healthcare setting.\n\n3 The “COVID-19 Antigen Self Test Kit” offered for sale on your website appears to be the CareStart COVID-19 Antigen test manufactured by Access Bio, Inc. On February 1, 2021, FDA issued an EUA pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Access Bio, Inc.’s CareStart COVID-19 Antigen test by laboratories certified under CLIA that meet the requirements to perform, high, moderate, or waived complexity tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation for qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals suspected of COVID-19 by their healthcare provider within five days of symptom onset. However, this EUA does not authorize the sale of the Access Bio, Inc. CareStart COVID-19 Antigen test directly to consumers to self-test at home or outside of a healthcare setting.\n\n4 Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n6 Accessible at https:\u002F\u002Fwwwfda.gov\u002Fmedia\u002F135659\u002Fdownload.","Sethi Laboratories","sethi-laboratories-611628-04062021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsethi-laboratories-611628-04062021","2026-10-26T08:09:55.744876+00:00","2021-04-15","611628","Mr. Sameer Sethi","2026-08-20T03:12:03.356+00:00","2021-04-06",{"id":298,"raw":299,"subject":306,"body_html":307,"body_text":308,"firm_name":309,"letter_id":310,"created_at":113,"fei_number":19,"letter_url":311,"updated_at":312,"action_type":22,"case_status":71,"posted_date":313,"marcs_cms_no":314,"product_type":96,"closeout_date":315,"issuing_office":303,"recipient_name":316,"body_fetched_at":317,"delivery_method":318,"recipient_title":19,"reference_number":19,"action_taken_date":319,"medical_device_id":19,"response_letter_date":19},3078,[300,301,302,303,304,13,305,13],"\u003Ctime datetime=\"2021-10-19T13:20:00Z\">10\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-30T04:00:00Z\">09\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-09302021\">Marcus Research Laboratory, Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-10022024\">\u003Ctime datetime=\"2024-10-04T04:00:00Z\">10\u002F04\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard A. Gilbert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marcus Research Laboratory, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1820 Delmar Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 30, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #615153\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gilbert:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marcus Research Laboratory, Inc., FEI 1950348, at 1820 Delmar Blvd., Saint Louis, Missouri 63103, from May 3, to May 14, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 4, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to have the procedures and processes necessary to ensure the API manufactured at your facility meet established specifications for quality and purity.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures povidone iodine (PVP-I), API which may be used by your customers to produce presurgical preparatory products. During the inspection, we observed that your Quality Unit (QU) released API lots 100017872R and 100017911C without adequate procedures and processes to ensure that critical deviations are investigated and resolved.\u003C\u002Fp>\n\n\u003Cp>During the production of PVP-I lot 100017872R, on March 4, 2020, your production personnel observed PVP-I in reactor cabinet \u003Cstrong>(b)(4)\u003C\u002Fstrong> was smoldering. In response to the risk of imminent fire, production personnel used a fire extinguisher. Due to this incident, production did not proceed as normal. Associated drugs experienced inconsistent temperature exposure and additional processing and hold times. Your firm only tested the affected drums of material for percent of available iodine and released them for further processing.\u003C\u002Fp>\n\n\u003Cp>Similarly, on August 18, 2020 during the production of PVP-I lot 100017911C, your production personnel noted reactor cabinet \u003Cstrong>(b)(4)\u003C\u002Fstrong> was smoking. Production was ceased, and the material was held in unknown conditions. Your firm again, solely tested the affected drums of material for percent available iodine and released them for further processing.\u003C\u002Fp>\n\n\u003Cp>In both instances, your firm created deviation reports but released drugs based solely on composite results of percent available iodine. Your drugs were exposed to excess heat, fire, smoke, and debris. Additional contaminants or other particulates from the use of the fire extinguisher may have also compromised the material. In addition, the associated drugs experienced processing parameters beyond the normal validated state.\u003C\u002Fp>\n\n\u003Cp>Your firm did not perform additional testing on lots 100017872R and 100017911C to confirm that the API was not contaminated with harmful particulate matter or other contamination. Additionally, your firm lacked a risk or impact assessment to evaluate the exposure of the API to the extraneous debris or contamination resulting from the incidents. The QU released lots 100017872R and 100017911C without ensuring the critical deviation was fully resolved, and any residual chemical contaminants and particulate risks were fully addressed.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you are “currently seeking advice from a consultant to determine the best path forward on addressing this matter.” Your response is inadequate. You did not provide any supporting documentation that evaluated the impacted lots that you released. Specifically, you did not provide supporting documentation that would ensure the material was free of potentially harmful particulate matter and other extraneous contamination given the intended use of the API, including the potential for use in sterile drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>o A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fp>\n\n\u003Cp>o Provide concurrent stability data for the affected lots 100017872R and 100017911C.\u003C\u002Fp>\n\n\u003Cp>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fp>\n\n\u003Cp>o A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fp>\n\n\u003Cp>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• Your action plan to address any product quality or patient safety risks for batches of povidone iodine in U.S. distribution, including potential customer notifications and recalls or market withdrawals.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your equipment construction was inadequate because your product contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. During the inspection, we observed that critical povidone iodine manufacturing equipment, such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> blender, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, hoppers, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were discolored and rusty. Furthermore, your firm hired a third party to \u003Cstrong>(b)(4)\u003C\u002Fstrong> your equipment to remove corrosion and rust \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Given that you must \u003Cstrong>(b)(4)\u003C\u002Fstrong> corrosion from product contact surfaces \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your contact surfaces are deficient as they can lead to contamination of your product, specifically, particulate matter (e.g., rust).\u003C\u002Fp>\n\n\u003Cp>Additionally, you use trays to further process your product during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stage. During this processing, you wrap the trays with plastic liners. These plastic liners come into direct contact with povidone. FDA investigators observed the plastic liners were tattered and torn, exposing product to plastic particulate matter.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is adequate to remove corrosion and that you would evaluate the use of plastic liners. Your response is inadequate, because it lacked scientific justification or supportive documentation for your assertion that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is adequate. Furthermore, FDA raised these concerns during the December 2019 inspection and July 2020 regulatory meeting, and you have failed to adequately address them.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Full evaluation of materials of construction of all drug contact surfaces in the facility, with specific focus on additive, absorptive, or reactive factors, and whether they can lead to contamination of the drug distributed.\u003Cbr>\n\u003Cbr>\n• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional API CGMP guidance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca>https:\u002F\u002Fwww.fda.Q:ov\u002Fdownloads\u002FDrugs\u002F...\u002FGuidances\u002Fucm073497.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP consultant recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your product. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter above (WL #615153). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Richard A. Gilbert\n\nRecipient Title\n\nPresident\n\nMarcus Research Laboratory, Inc.\n\n1820 Delmar Boulevard\n\nSaint Louis, MO 63103\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSeptember 30, 2021\n\nWARNING LETTER\n\nWL #615153\n\nDear Mr. Gilbert:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marcus Research Laboratory, Inc., FEI 1950348, at 1820 Delmar Blvd., Saint Louis, Missouri 63103, from May 3, to May 14, 2021.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 4, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to have the procedures and processes necessary to ensure the API manufactured at your facility meet established specifications for quality and purity.\n\nYour firm manufactures povidone iodine (PVP-I), API which may be used by your customers to produce presurgical preparatory products. During the inspection, we observed that your Quality Unit (QU) released API lots 100017872R and 100017911C without adequate procedures and processes to ensure that critical deviations are investigated and resolved.\n\nDuring the production of PVP-I lot 100017872R, on March 4, 2020, your production personnel observed PVP-I in reactor cabinet (b)(4) was smoldering. In response to the risk of imminent fire, production personnel used a fire extinguisher. Due to this incident, production did not proceed as normal. Associated drugs experienced inconsistent temperature exposure and additional processing and hold times. Your firm only tested the affected drums of material for percent of available iodine and released them for further processing.\n\nSimilarly, on August 18, 2020 during the production of PVP-I lot 100017911C, your production personnel noted reactor cabinet (b)(4) was smoking. Production was ceased, and the material was held in unknown conditions. Your firm again, solely tested the affected drums of material for percent available iodine and released them for further processing.\n\nIn both instances, your firm created deviation reports but released drugs based solely on composite results of percent available iodine. Your drugs were exposed to excess heat, fire, smoke, and debris. Additional contaminants or other particulates from the use of the fire extinguisher may have also compromised the material. In addition, the associated drugs experienced processing parameters beyond the normal validated state.\n\nYour firm did not perform additional testing on lots 100017872R and 100017911C to confirm that the API was not contaminated with harmful particulate matter or other contamination. Additionally, your firm lacked a risk or impact assessment to evaluate the exposure of the API to the extraneous debris or contamination resulting from the incidents. The QU released lots 100017872R and 100017911C without ensuring the critical deviation was fully resolved, and any residual chemical contaminants and particulate risks were fully addressed.\n\nIn your response, you stated that you are “currently seeking advice from a consultant to determine the best path forward on addressing this matter.” Your response is inadequate. You did not provide any supporting documentation that evaluated the impacted lots that you released. Specifically, you did not provide supporting documentation that would ensure the material was free of potentially harmful particulate matter and other extraneous contamination given the intended use of the API, including the potential for use in sterile drug products.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provide concurrent stability data for the affected lots 100017872R and 100017911C.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• Your action plan to address any product quality or patient safety risks for batches of povidone iodine in U.S. distribution, including potential customer notifications and recalls or market withdrawals.\n\n2. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\n\nYour equipment construction was inadequate because your product contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. During the inspection, we observed that critical povidone iodine manufacturing equipment, such as the (b)(4) blender, (b)(4), hoppers, and (b)(4), were discolored and rusty. Furthermore, your firm hired a third party to (b)(4) your equipment to remove corrosion and rust (b)(4). Given that you must (b)(4) corrosion from product contact surfaces (b)(4), your contact surfaces are deficient as they can lead to contamination of your product, specifically, particulate matter (e.g., rust).\n\nAdditionally, you use trays to further process your product during a (b)(4) stage. During this processing, you wrap the trays with plastic liners. These plastic liners come into direct contact with povidone. FDA investigators observed the plastic liners were tattered and torn, exposing product to plastic particulate matter.\n\nIn your response, you stated that (b)(4) is adequate to remove corrosion and that you would evaluate the use of plastic liners. Your response is inadequate, because it lacked scientific justification or supportive documentation for your assertion that (b)(4) is adequate. Furthermore, FDA raised these concerns during the December 2019 inspection and July 2020 regulatory meeting, and you have failed to adequately address them.\n\nIn response to this letter, provide:\n\n• Full evaluation of materials of construction of all drug contact surfaces in the facility, with specific focus on additive, absorptive, or reactive factors, and whether they can lead to contamination of the drug distributed.\n\n• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nAdditional API CGMP guidance\n\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.Q:ov\u002Fdownloads\u002FDrugs\u002F...\u002FGuidances\u002Fucm073497.pdf.\n\nCGMP consultant recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your product. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter above (WL #615153). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations III","Marcus Research Laboratory, Inc.","marcus-research-laboratory-inc-615153-09302021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-09302021","2026-10-26T08:09:20.315764+00:00","2021-10-19","615153","2024-10-04","Mr. Richard A. Gilbert","2026-08-20T02:31:11.561+00:00","UPS","2021-09-30",{"id":321,"raw":322,"subject":12,"body_html":326,"body_text":327,"firm_name":328,"letter_id":329,"created_at":213,"fei_number":19,"letter_url":330,"updated_at":331,"action_type":22,"case_status":23,"posted_date":332,"marcs_cms_no":333,"product_type":96,"closeout_date":19,"issuing_office":11,"recipient_name":334,"body_fetched_at":335,"delivery_method":336,"recipient_title":19,"reference_number":337,"action_taken_date":338,"medical_device_id":19,"response_letter_date":19},372,[323,324,325,11,12,13,13,13],"\u003Ctime datetime=\"2026-01-13T05:00:00Z\">01\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-07T05:00:00Z\">01\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwinder-laboratories-llc-718601-01072026\">Winder Laboratories, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-36\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven F. Pressman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Winder Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>716 Patrick Industrial Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winder\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30680\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-36\u003C\u002Fp>\u003Cp>January 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Pressman:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Winder Laboratories, LLC, FEI 3008694072, at 716 Patrick Industrial Lane, Winder, Georgia, from July 14 to August 5, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 26, 2025, response to our Form FDA 483 in detail, and we acknowledge receipt of your subsequent correspondence\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations, including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality of purity of the drug product beyond the official or other established requirements and you failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) and (b))).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Failure to Clean Equipment\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the nondedicated equipment used to manufacture your prescription drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. Multiple pieces of manufacturing equipment, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the Tablet Press, were observed to have drug product residue and oxidized metal surfaces, which were documented as being clean and were released by your quality unit. Additionally, the dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment showed visible product residue, oxidized metal, and foreign material, despite being cleaned and released by your quality unit.\u003C\u002Fp>\u003Cp>Similar equipment cleaning deficiencies were cited during your previous FDA inspections, indicating that your cleaning procedures are insufficient to prevent contamination that could alter the safety, identity, strength, quality, or purity of your drug products.\u003C\u002Fp>\u003Cp>Additionally, your firm's voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg tablets being found inside the bottle could be associated to inadequate line clearance of equipment prior to use.\u003C\u002Fp>\u003Cp>In your response, you state that you have implemented a new procedure requiring the use of a flashlight to detect residues or surface abnormalities not visible to the naked eye, and you provided training on the revised procedures.\u003C\u002Fp>\u003Cp>Your response is inadequate because you do not provide evidence that your cleaning methods are appropriate and effective, nor do you assess the impact of your inadequate cleaning processes on drug product that is currently on the market and within expiry.\u003C\u002Fp>\u003Cp>\u003Cem>Failure to Maintain Equipment\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately maintain your equipment. For example, the metal detection equipment MFG-1276 was found to be nonfunctioning during the inspection. Your preventive maintenance procedures were also inadequate, focusing only on the metal detector’s physical appearance rather than its operational functionality.\u003C\u002Fp>\u003Cp>Additionally, your executed metal detector qualification protocol did not include the qualification of the metal detector MFG-1276.\u003C\u002Fp>\u003Cp>These equipment maintenance failures compromise your ability to detect and prevent contamination. Notably, a metal screw was found in a sealed bottle of \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you stated that you halted all packaging activities and did not resume packaging operations until the metal detectors had been repaired, and preventive maintenance had been performed.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not commit to completing the equipment qualification for the metal detector or describe how you will periodically requalify it. Additionally, you did not commit to conducting a retrospective risk assessment for batches that were processed while the metal detector was not functioning properly.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A corrective actions and preventive actions (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003Cbr>In addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities and your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately maintain your facility in a good state of repair. Specifically, we observed the following deficiencies during the inspection:\u003C\u002Fp>\u003Cul>\u003Cli>Gaps were observed in the protective wall, covering the original underlying wall surface in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine room, thus creating areas that are difficult to clean.\u003C\u002Fli>\u003Cli>An unknown brown-yellow material was visible in the wall gaps located near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, indicating potential contamination risks in the manufacturing environment.\u003C\u002Fli>\u003Cli>A ceiling vent was improperly secured with transparent tape in the tablet room, demonstrating substandard facility maintenance practices.\u003C\u002Fli>\u003Cli>The walls of the room housing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were unfinished and not cleanable.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you immediately halted all manufacturing operations and promptly took corrective actions to address the specific deficiencies. You also indicated that you would not resume manufacturing operations until all repairs were completed, and the rooms met the required standards for cleanliness and maintenance.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide a systemic and comprehensive CAPA plan to ensure that your facility is and remains in a good state of repair.\u003C\u002Fp>\u003Cp>It is essential that your facility be in a good state of repair to prevent contamination and to ensure its ongoing suitability for drug manufacturing.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>Documented evidence (for example, photos) of any repairs made to your facilities and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections, dated July 18, 2018; February 11, 2022; and February 3, 2023, FDA cited similar CGMP observations, and you proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008694072 and ATTN: Chhaya Shetty.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-26-36\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSteven F. Pressman\n\nRecipient Title\n\nCEO\n\nWinder Laboratories, LLC\n\n716 Patrick Industrial Lane\n\nWinder, GA 30680\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-36\nJanuary 7, 2026\nDear Mr. Pressman:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Winder Laboratories, LLC, FEI 3008694072, at 716 Patrick Industrial Lane, Winder, Georgia, from July 14 to August 5, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 26, 2025, response to our Form FDA 483 in detail, and we acknowledge receipt of your subsequent correspondence\nDuring our inspection, our investigators observed specific violations, including but not limited to the following:\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality of purity of the drug product beyond the official or other established requirements and you failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) and (b))).\nFailure to Clean Equipment\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the nondedicated equipment used to manufacture your prescription drug products, including (b)(4) tablets and (b)(4) tablets. Multiple pieces of manufacturing equipment, including the (b)(4) and the Tablet Press, were observed to have drug product residue and oxidized metal surfaces, which were documented as being clean and were released by your quality unit. Additionally, the dedicated (b)(4) equipment showed visible product residue, oxidized metal, and foreign material, despite being cleaned and released by your quality unit.\nSimilar equipment cleaning deficiencies were cited during your previous FDA inspections, indicating that your cleaning procedures are insufficient to prevent contamination that could alter the safety, identity, strength, quality, or purity of your drug products.\nAdditionally, your firm's voluntary recall of (b)(4)mg (b)(4) tablets due to (b)(4) mg tablets being found inside the bottle could be associated to inadequate line clearance of equipment prior to use.\nIn your response, you state that you have implemented a new procedure requiring the use of a flashlight to detect residues or surface abnormalities not visible to the naked eye, and you provided training on the revised procedures.\nYour response is inadequate because you do not provide evidence that your cleaning methods are appropriate and effective, nor do you assess the impact of your inadequate cleaning processes on drug product that is currently on the market and within expiry.\nFailure to Maintain Equipment\nYou failed to adequately maintain your equipment. For example, the metal detection equipment MFG-1276 was found to be nonfunctioning during the inspection. Your preventive maintenance procedures were also inadequate, focusing only on the metal detector’s physical appearance rather than its operational functionality.\nAdditionally, your executed metal detector qualification protocol did not include the qualification of the metal detector MFG-1276.\nThese equipment maintenance failures compromise your ability to detect and prevent contamination. Notably, a metal screw was found in a sealed bottle of (b)(4)mg, lot (b)(4).\nIn your response, you stated that you halted all packaging activities and did not resume packaging operations until the metal detectors had been repaired, and preventive maintenance had been performed.\nYour response is inadequate because you did not commit to completing the equipment qualification for the metal detector or describe how you will periodically requalify it. Additionally, you did not commit to conducting a retrospective risk assessment for batches that were processed while the metal detector was not functioning properly.\nIn response to this letter, provide the following:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA corrective actions and preventive actions (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities and your program for qualification of your equipment and facility.\n2. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\nYou failed to adequately maintain your facility in a good state of repair. Specifically, we observed the following deficiencies during the inspection:\nGaps were observed in the protective wall, covering the original underlying wall surface in the (b)(4) machine room, thus creating areas that are difficult to clean.\nAn unknown brown-yellow material was visible in the wall gaps located near the (b)(4) equipment, indicating potential contamination risks in the manufacturing environment.\nA ceiling vent was improperly secured with transparent tape in the tablet room, demonstrating substandard facility maintenance practices.\nThe walls of the room housing the (b)(4) were unfinished and not cleanable.\nIn your response, you state that you immediately halted all manufacturing operations and promptly took corrective actions to address the specific deficiencies. You also indicated that you would not resume manufacturing operations until all repairs were completed, and the rooms met the required standards for cleanliness and maintenance.\nYour response is inadequate. You did not provide a systemic and comprehensive CAPA plan to ensure that your facility is and remains in a good state of repair.\nIt is essential that your facility be in a good state of repair to prevent contamination and to ensure its ongoing suitability for drug manufacturing.\nIn response to this letter, provide the following:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nDocumented evidence (for example, photos) of any repairs made to your facilities and equipment.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nRepeat Observations at Facility\nIn previous inspections, dated July 18, 2018; February 11, 2022; and February 3, 2023, FDA cited similar CGMP observations, and you proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008694072 and ATTN: Chhaya Shetty.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Winder Laboratories, LLC","winder-laboratories-llc-718601-01072026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwinder-laboratories-llc-718601-01072026","2026-10-26T08:10:32.198019+00:00","2026-01-13","718601","Steven F. Pressman","2026-08-19T07:18:20.8+00:00","Via Email","320-26-36","2026-01-07",{"id":340,"raw":341,"subject":345,"body_html":346,"body_text":347,"firm_name":348,"letter_id":349,"created_at":136,"fei_number":19,"letter_url":350,"updated_at":351,"action_type":22,"case_status":23,"posted_date":352,"marcs_cms_no":353,"product_type":96,"closeout_date":19,"issuing_office":129,"recipient_name":354,"body_fetched_at":355,"delivery_method":356,"recipient_title":19,"reference_number":19,"action_taken_date":357,"medical_device_id":19,"response_letter_date":19},2486,[342,343,344,129,345,13,13,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-17T04:00:00Z\">08\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgordon-laboratories-inc-631432-08172022\">Gordon Laboratories Inc.\u003C\u002Fa>","Drug Product\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Julia A. Christiansen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gordon Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>751 E Artesia Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carson\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90746\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 17, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Christiansen:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the U.S. Food and Drug Administration as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). The FDA conducted testing of a consumer hand sanitizer drug product, labeled as artnaturals SCENT FREE HAND SANITIZER. This drug product was manufactured at your drug manufacturing facility, Gordon Laboratories Inc., FEI 2012546, at 751 E Artesia Blvd., Carson, California, and distributed in the United States.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of artnaturals SCENT FREE HAND SANITIZER in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA inspected your drug manufacturing facility, Gordon Laboratories, Inc., FEI 2012546, at 751 E Artesia Blvd., Carson, California, from February 8 to March 10, 2022. This inspection followed the violative sample results of the consumer hand sanitizer, labeled as artnaturals SCENT FREE HAND SANITIZER.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of CGMP regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FDA Tested Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a contract manufacturer of artnaturals SCENT FREE HAND SANITIZER.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of a batch of artnaturals SCENT FREE HAND SANITIZER in U.S. distribution was found to contain impurities at unacceptable levels\u003Csup>\u003Cstrong>\u003Cem>1\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fsup>. Benzene impurity levels were found to be approximately 15 parts per million (ppm), while acetaldehyde and acetal impurities were found to be approximately 146 ppm and 469 ppm, respectively.\u003C\u002Fp>\n\n\u003Cp>Acetaldehyde appears to be genotoxic, and potentially carcinogenic, when in direct contact with tissues. The FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>On October 4, 2021, the FDA notified the public of the unacceptable impurity results for artnaturals SCENT FREE HAND SANITIZER at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On October 8, 2021, the FDA held a teleconference with you, and your customer, Virgin Scent Inc. (dba Artnaturals), to whom your firm acts as a contract manufacturer for artnaturals SCENT FREE HAND SANITIZER, and we recommended to consider removing the adulterated batch of artnaturals SCENT FREE HAND SANITIZER drug product currently in distribution from the U.S. market.\u003Cbr>\n\u003Cbr>\nOn October 26, 2021, you, and Virgin Scent Inc., issued a voluntary nationwide recall of two batches of artnaturals SCENT FREE HAND SANITIZER due to the presence of benzene, acetaldehyde, and acetal impurities. On April 22, 2022, the scope of the recall of artnaturals SCENT FREE HAND SANITIZER was expanded to include at least 38 additional batches because they were manufactured using some of the same ingredients as the two batches initially recalled. Refer to the following FDA website:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fartnaturalsr-issues-voluntary-recall-limited-batches-8oz-bottles-scent-free-hand-sanitizer-due\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fartnaturalsr-issues-voluntary-recall-limited-batches-8oz-bottles-scent-free-hand-sanitizer-due\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>The contamination with benzene, acetaldehyde, and acetal impurities in a drug product manufactured in your facility, in addition to the significant violations documented in the inspection, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 31, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Hand Sanitizer Drug Product\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate the root cause of the benzene, acetal, and acetaldehyde impurities found in the artnaturals SCENT FREE HAND SANITIZER drug product.\u003C\u002Fp>\n\n\u003Cp>During the inspection, the investigators found that there was a lack of investigation into the failure of the batches that were voluntarily recalled. Furthermore, you failed to identify whether other batches were impacted or initiate testing of the retain samples of other batches that are in U.S. distribution.\u003C\u002Fp>\n\n\u003Cp>In your response, you identify that the “more probable root cause for the introduction of Benzene was from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and that “this was due to the fact that not all grades and all manufacturing processes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> result in the same purity.” However, your response does not provide evidence from the out-of-specification (OOS) investigation or formal risk assessment process which led to this conclusion, nor does the response address the root cause for the unacceptable levels of the acetal and acetaldehyde impurities.\u003C\u002Fp>\n\n\u003Cp>Furthermore, drug products must be tested for identity, strength, quality, and purity prior to release and distribution. Manufacturers are required to establish and validate or verify analytical methods and procedures to ensure the accuracy, sensitivity, specificity, and reproducibility of testing. Considering the known risk of benzene contamination, including the FDA test results demonstrating benzene, a finished product specification for benzene in your hand sanitizers is appropriate under 21 CFR 211.160(b).\u003C\u002Fp>\n\n\u003Cp>As of the date of this letter, you have yet to provide complete impurity results of the other batches in U.S. distribution. We acknowledge that you expanded the voluntary recall to include additional batches of hand sanitizer manufactured with common components used in the recalled batches. However, we remain concerned about the quality of the individual components and the remaining batches of hand sanitizer drug product still in U.S. distribution which lack adequate testing.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You lacked investigations into multiple microbiological monitoring results from your water system that exceed action limits. For example, you did not investigate multiple results above your total aerobic microbial count action limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg. Furthermore, during the inspection, data to support the quality of the water system before July 2021, was not available nor provided.\u003C\u002Fp>\n\n\u003Cp>You acknowledged these deficiencies in your response, but failed to include a risk assessment or retrospective review to determine whether the out-of-limit results and\u002For the lack of water testing results have impacted released drug product; nor did you discuss the impact of the failure to follow your established procedures regarding microbiological events.\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise the ability to produce safe and effective drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>Summary of all available water system results from all parties (whether third party laboratory or in-house testing) including the identification of organism for any results (whether from potable water or points of use ports) above the alert and action levels or for any organism presence detected during the selected indicator organism test.\u003C\u002Fli>\n\t\u003Cli>A summary of all results including methanol, benzene, acetal, and acetaldehyde for all hand sanitizer batches released and distributed. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test incoming components prior to their use in the manufacture of artnaturals SCENT FREE HAND SANITIZER. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, or used incoming components without COAs. For example, one lot of carbomer material was received from an unapproved supplier and a second lot was received without a COA from an unknown supplier. These components were used in the manufacture of hand sanitizer drug products; specifically in two hand sanitizer batches which were subsequently recalled because of the presence of impurities.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your process to manage shipments under quarantine is under revision and that all hand sanitizer batches that were shipped under quarantine had “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, your response does not explain whether product had been distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor was an adequate investigation and retrospective review performed to determine whether other components were received from unapproved suppliers and\u002For with incomplete testing of the incoming component prior to their use in production of drug products. Additionally, your response does not address how you will prevent the use of poor-quality components in future batches.\u003C\u002Fp>\n\n\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications before use in the manufacture of drug products.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Investigation and risk assessment regarding all instances for all drug products where material was received without COA, or where the material may not have been sampled, tested, or released by the quality unit prior to use in production.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You use water as a component in the manufacture of your drug products. You failed to ensure the water system is designed, maintained, and monitored in a validated state. For example, validation of your water system has not been performed and you were unable to provide microbiological monitoring of water system before July 2021.\u003C\u002Fp>\n\n\u003Cp>Your response states that you expect to complete validation (after the systematic review) by the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response is inadequate because you have not provided sufficient details how you will ensure that your current water system design is appropriate for its intended use while the system is being remediated. Furthermore, your sampling frequency and your microbial testing is inadequate since water system samples are not currently monitored for the presence of \u003Cem>Burkholderia Cepacia\u003C\u002Fem> Complex (BCC).\u003C\u002Fp>\n\n\u003Cp>The lack of data regarding the state of control of your water system poses a potential risk objectionable microbiological contamination into your drug products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system including robust monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>Validation report for the water system obtained after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report.\u003C\u002Fli>\n\t\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug products currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of Burkholderia Cepacia Complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and the consultant should also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 631432\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Andrew Haack, Compliance Officer by telephone at 206-340-8212 or email at Andrew.Haack@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lance M. De Souza\u003Cbr>\nActing Director, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n\u003Cbr>\nCC:\u003Cbr>\nMr. Yosef Nourollah\u003Cbr>\nCEO\u003Cbr>\nVirgin Scent Inc. dba Artnaturals\u003Cbr>\n2390 Crenshaw Blvd, PMB #702\u003Cbr>\nTorrance, CA 90501\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Gordon Laboratory hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Julia A. Christiansen\n\nRecipient Title\n\nChief Executive Officer\n\nGordon Laboratories Inc.\n\n751 E Artesia Blvd\n\nCarson, CA 90746\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nAugust 17, 2022\n\nDear Ms. Christiansen:\n\nYour facility is registered with the U.S. Food and Drug Administration as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). The FDA conducted testing of a consumer hand sanitizer drug product, labeled as artnaturals SCENT FREE HAND SANITIZER. This drug product was manufactured at your drug manufacturing facility, Gordon Laboratories Inc., FEI 2012546, at 751 E Artesia Blvd., Carson, California, and distributed in the United States.\n\nThe results of the FDA laboratory testing of batches of artnaturals SCENT FREE HAND SANITIZER in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic (FD&C Act), 21 U.S.C. 351(a)(2)(B)1.\n\nAdditionally, the FDA inspected your drug manufacturing facility, Gordon Laboratories, Inc., FEI 2012546, at 751 E Artesia Blvd., Carson, California, from February 8 to March 10, 2022. This inspection followed the violative sample results of the consumer hand sanitizer, labeled as artnaturals SCENT FREE HAND SANITIZER.\n\nThis warning letter summarizes significant violations of CGMP regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nFDA Tested Samples\n\nYour firm is a contract manufacturer of artnaturals SCENT FREE HAND SANITIZER.\n\nFDA laboratory testing of a batch of artnaturals SCENT FREE HAND SANITIZER in U.S. distribution was found to contain impurities at unacceptable levels1. Benzene impurity levels were found to be approximately 15 parts per million (ppm), while acetaldehyde and acetal impurities were found to be approximately 146 ppm and 469 ppm, respectively.\n\nAcetaldehyde appears to be genotoxic, and potentially carcinogenic, when in direct contact with tissues. The FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\n\nOn October 4, 2021, the FDA notified the public of the unacceptable impurity results for artnaturals SCENT FREE HAND SANITIZER at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn October 8, 2021, the FDA held a teleconference with you, and your customer, Virgin Scent Inc. (dba Artnaturals), to whom your firm acts as a contract manufacturer for artnaturals SCENT FREE HAND SANITIZER, and we recommended to consider removing the adulterated batch of artnaturals SCENT FREE HAND SANITIZER drug product currently in distribution from the U.S. market.\n\nOn October 26, 2021, you, and Virgin Scent Inc., issued a voluntary nationwide recall of two batches of artnaturals SCENT FREE HAND SANITIZER due to the presence of benzene, acetaldehyde, and acetal impurities. On April 22, 2022, the scope of the recall of artnaturals SCENT FREE HAND SANITIZER was expanded to include at least 38 additional batches because they were manufactured using some of the same ingredients as the two batches initially recalled. Refer to the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fartnaturalsr-issues-voluntary-recall-limited-batches-8oz-bottles-scent-free-hand-sanitizer-due\n\nThe contamination with benzene, acetaldehyde, and acetal impurities in a drug product manufactured in your facility, in addition to the significant violations documented in the inspection, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act1.\n\nCGMP Violations\n\nWe reviewed your March 31, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nHand Sanitizer Drug Product\n\nYou failed to adequately investigate the root cause of the benzene, acetal, and acetaldehyde impurities found in the artnaturals SCENT FREE HAND SANITIZER drug product.\n\nDuring the inspection, the investigators found that there was a lack of investigation into the failure of the batches that were voluntarily recalled. Furthermore, you failed to identify whether other batches were impacted or initiate testing of the retain samples of other batches that are in U.S. distribution.\n\nIn your response, you identify that the “more probable root cause for the introduction of Benzene was from the (b)(4)” and that “this was due to the fact that not all grades and all manufacturing processes of (b)(4) result in the same purity.” However, your response does not provide evidence from the out-of-specification (OOS) investigation or formal risk assessment process which led to this conclusion, nor does the response address the root cause for the unacceptable levels of the acetal and acetaldehyde impurities.\n\nFurthermore, drug products must be tested for identity, strength, quality, and purity prior to release and distribution. Manufacturers are required to establish and validate or verify analytical methods and procedures to ensure the accuracy, sensitivity, specificity, and reproducibility of testing. Considering the known risk of benzene contamination, including the FDA test results demonstrating benzene, a finished product specification for benzene in your hand sanitizers is appropriate under 21 CFR 211.160(b).\n\nAs of the date of this letter, you have yet to provide complete impurity results of the other batches in U.S. distribution. We acknowledge that you expanded the voluntary recall to include additional batches of hand sanitizer manufactured with common components used in the recalled batches. However, we remain concerned about the quality of the individual components and the remaining batches of hand sanitizer drug product still in U.S. distribution which lack adequate testing.\n\nWater System\n\nYou lacked investigations into multiple microbiological monitoring results from your water system that exceed action limits. For example, you did not investigate multiple results above your total aerobic microbial count action limit of (b)(4) cfu\u002Fg. Furthermore, during the inspection, data to support the quality of the water system before July 2021, was not available nor provided.\n\nYou acknowledged these deficiencies in your response, but failed to include a risk assessment or retrospective review to determine whether the out-of-limit results and\u002For the lack of water testing results have impacted released drug product; nor did you discuss the impact of the failure to follow your established procedures regarding microbiological events.\n\nInadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise the ability to produce safe and effective drug products.\n\nIn response to this letter, provide:\n\nA comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nSummary of all available water system results from all parties (whether third party laboratory or in-house testing) including the identification of organism for any results (whether from potable water or points of use ports) above the alert and action levels or for any organism presence detected during the selected indicator organism test.\n\nA summary of all results including methanol, benzene, acetal, and acetaldehyde for all hand sanitizer batches released and distributed. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to test incoming components prior to their use in the manufacture of artnaturals SCENT FREE HAND SANITIZER. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, or used incoming components without COAs. For example, one lot of carbomer material was received from an unapproved supplier and a second lot was received without a COA from an unknown supplier. These components were used in the manufacture of hand sanitizer drug products; specifically in two hand sanitizer batches which were subsequently recalled because of the presence of impurities.\n\nIn your response, you stated that your process to manage shipments under quarantine is under revision and that all hand sanitizer batches that were shipped under quarantine had “(b)(4).” However, your response does not explain whether product had been distributed (b)(4) nor was an adequate investigation and retrospective review performed to determine whether other components were received from unapproved suppliers and\u002For with incomplete testing of the incoming component prior to their use in production of drug products. Additionally, your response does not address how you will prevent the use of poor-quality components in future batches.\n\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications before use in the manufacture of drug products.\n\nIn your response to this letter, provide:\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nInvestigation and risk assessment regarding all instances for all drug products where material was received without COA, or where the material may not have been sampled, tested, or released by the quality unit prior to use in production.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\n\nYou use water as a component in the manufacture of your drug products. You failed to ensure the water system is designed, maintained, and monitored in a validated state. For example, validation of your water system has not been performed and you were unable to provide microbiological monitoring of water system before July 2021.\n\nYour response states that you expect to complete validation (after the systematic review) by the (b)(4). However, your response is inadequate because you have not provided sufficient details how you will ensure that your current water system design is appropriate for its intended use while the system is being remediated. Furthermore, your sampling frequency and your microbial testing is inadequate since water system samples are not currently monitored for the presence of Burkholderia Cepacia Complex (BCC).\n\nThe lack of data regarding the state of control of your water system poses a potential risk objectionable microbiological contamination into your drug products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nIn your response to this letter, provide:\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system including robust monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4), United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\n\nValidation report for the water system obtained after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report.\n\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug products currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nObjectionable Organisms\n\nFor further information regarding the significance of Burkholderia Cepacia Complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and the consultant should also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 631432\n\nIf you have questions regarding the contents of this letter, please contact Andrew Haack, Compliance Officer by telephone at 206-340-8212 or email at Andrew.Haack@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLance M. De Souza\n\nActing Director, Division of Pharmaceutical Quality Operations IV\n\nCC:\n\nMr. Yosef Nourollah\n\nCEO\n\nVirgin Scent Inc. dba Artnaturals\n\n2390 Crenshaw Blvd, PMB #702\n\nTorrance, CA 90501\n\n__________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Gordon Laboratory hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Gordon Laboratories Inc.","gordon-laboratories-inc-631432-08172022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgordon-laboratories-inc-631432-08172022","2026-10-26T08:08:48.467031+00:00","2022-08-30","631432","Ms. Julia A. Christiansen","2026-08-20T01:37:38.252+00:00","VIA UPS","2022-08-17",{"id":359,"raw":360,"subject":12,"body_html":363,"body_text":364,"firm_name":365,"letter_id":366,"created_at":113,"fei_number":19,"letter_url":367,"updated_at":368,"action_type":22,"case_status":23,"posted_date":313,"marcs_cms_no":369,"product_type":96,"closeout_date":19,"issuing_office":86,"recipient_name":370,"body_fetched_at":371,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":372,"medical_device_id":19,"response_letter_date":19},3082,[300,361,362,86,12,13,13,13],"\u003Ctime datetime=\"2021-09-21T04:00:00Z\">09\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsircle-laboratories-llc-615098-09212021\">Sircle Laboratories, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bobby J. King, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sircle Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 238\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ridgeland\u003C\u002Fspan>, \u003Cspan>MS\u003C\u002Fspan> \u003Cspan>39158\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 21, 2021\u003C\u002Fp>\n\n\u003Cp>Case #: 615098\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Mr. King:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sircle Laboratories, LLC, FEI 3011772828, at 105 Lexington Drive, Suite J, Madison, Mississippi, from April 13 to 26, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 11, 2021, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks appropriate oversight and procedures to manage contract manufacturing organizations (CMOs) used on behalf of your firm for the manufacturing, packaging, and distribution of your drug products. You are ultimately responsible for CGMP activities you perform.\u003C\u002Fp>\n\n\u003Cp>Your firm has failed to follow your established quality unit (QU) procedures, as well as commitments documented in quality agreements (QA). In your response, you maintained that you have CGMP responsibilities, including, but not limited to, having written procedures for your quality unit, handling of consumer complaints, release of drug products, and qualifying and approving of your CMOs. QU deficiencies include:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate QU oversight of your CMOs\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU lacked adequate oversight and controls for your CMOs, which led to your use of sub-standard CMOs. Since 2017, FDA has taken the following actions in response to CGMP violations found at your CMOs.\u003C\u002Fp>\n\n\u003Cp>For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a Warning Letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that included, but not limited to, violations for the failure to establish appropriate time limits for each stage of production, and failure to thoroughly investigate out-of-specification (OOS) results.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you are in the process of developing procedures that address the approval process for your CMOs. Your response is inadequate because you did not conduct a retrospective review of the lack of QU oversight of your CMOs and product distribution which may impact the identity, strength, quality, and purity of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment plan to ensure that suppliers are suitably qualified and appropriate oversight is maintained. This assessment should include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• Supplier qualification selection and management procedures that encompass all functions of CGMP activities your CMOs perform on your behalf.\u003C\u002Fp>\n\n\u003Cp>• Suitability of your suppliers and key elements of your requalification program (e.g., audit).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Failure to establish and follow QU procedures\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>• Lack of batch release procedures\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish adequate written responsibilities and procedures for reviewing batches made by your CMO. You also failed to review production records for each batch for disposition (i.e., reject or approve) per your QA with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You are ultimately responsible for approving or rejecting drug product batches manufactured for you by a contract facility. Determining the suitability of each batch for release is an essential component of your quality unit responsibility.\u003C\u002Fp>\n\n\u003Cp>In your response, you confirmed that you do not have a written procedure specifying release of drug products from CMOs and stated that you are developing procedures. Your response is inadequate because you did not provide details on what these procedures entail or how they will be applied.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Failure to follow change control procedures\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU failed to ensure your firm follows your change control procedure. For example, since the last FDA inspection in March 2019, your firm implemented changes to your consumer complaints and drug product recalls procedures without following your change control procedure. In addition, you approved changes to your drug product labeling without following your change control procedure. In each of these instances, your firm did not adequately justify or document these changes as required in your change control procedure.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge that you have not been following your change control procedure for the changes your firm has implemented. Your response is inadequate in that the forms provided did not include an assessment of the impact of the changes, including changes to your labeling materials.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not conduct a retrospective review of the failure to establish and follow QU procedures, which may impact the identity, strength, quality, and purity of your drug products.\u003C\u002Fp>\n\n\u003Cp>• In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\no A complete and final review of each batch and its related information before the QU disposition decision. Include a retrospective review of all batches currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis.\u003Cbr>\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to follow establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You acknowledge that while you use CMOs on your behalf, you maintain associated CGMP responsibilities, including, but not limited to, handling customer complaints and inquiries. However, your firm failed to adequately establish and follow your established complaint handling procedure. For example, your procedure stipulated responsibilities for the handling and investigating of consumer complaints to your “Drug Safety Specialist” and “Chief Scientific Officer.” During the inspection, these titles and staff positions did not exist at your firm.\u003C\u002Fp>\n\n\u003Cp>Further, your QA with \u003Cstrong>(b)(4)\u003C\u002Fstrong> states that you will notify \u003Cstrong>(b)(4)\u003C\u002Fstrong> of complaints that are likely to result in a field alert and\u002For recall, and that \u003Cstrong>(b)(4)\u003C\u002Fstrong> will conduct and complete the complaint investigation. All quality-related complaints, beyond those likely to result in a field alert and\u002For recall, must be investigated per 211.198.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you revised the complaint handling procedure by removing the non-existent titles and replacing these job titles to “Chief Operating Officer.” Your response is inadequate because you did not provide evidence demonstrating that this individual follows the complaint handling procedure and performs reviews to determine whether a complaint represents a serious and unexpected adverse drug event.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Your retrospective assessment of complaints received by Sircle that were or should have been shared with your CMOs, including quality-related complaints that may not have been likely to result in a field alert and\u002For recall.\u003C\u002Fp>\n\n\u003Cp>• A list of complaints received by Sircle from all sources, including those received by your CMOs where you handle customer complaints and inquiries.\u003C\u002Fp>\n\n\u003Cp>• Procedure(s) detailing how you will share quality-related complaints with your CMOs\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow written procedures designed to assure that correct labels, labeling, and packaging are used for drug products. (21 CFR 211.130)\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm reviews and approves the labeling for the drug products manufactured by your CMOs. Your procedure for reviewing and approving the labels is inadequate. For example, your procedure does not require the verification of all elements on the labels, such as storage conditions and dispensing volumes. Moreover, your procedure does not include a review or comparison of drug product labels against an approved master or reference label.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you use master labels and that you are in the process of revising your label review procedure by July 1, 2021. Your response is inadequate.\u003Cbr>\nYou did not provide evidence that your firm uses master or reference labels when reviewing and approving your drug product labels. In addition, you have not provided your updated procedure in response to this observation. Further, your response lacks a retrospective review to ensure appropriate labeling is on all products currently in distribution.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Your corrective action and preventive action (CAPA) plan to improve labeling operations including adequate procedures for labeling review and approval, management oversight, and any other needed actions.\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In previous inspections, dated August 2015, and March 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your responses. These repeated violations demonstrate a failure of your executive management to exercise proper oversight and control over the manufacture of drugs. You should immediately and comprehensively assess all of your firm’s manufacturing operations to ensure that systems, processes, and ultimately, products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n\u003Cbr>\n• An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates staff with proper investigation competencies, effectively conducts root cause analysis, assures CAPA effectiveness, regularly reviews investigations trends, implements improvements to the CAPA program when needed, ensures appropriate quality unit decision rights, and is fully supported by executive management.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>As stated in your response, confirm that your CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is performing microbial testing on all batches of drug products manufactured by them for your firm.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>615098\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to John Diehl, Compliance Branch, via john.diehl@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTamala P. Bogan\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBobby J. King, Jr.\n\nRecipient Title\n\nPresident\n\nSircle Laboratories, LLC\n\nP.O. Box 238\n\nRidgeland, MS 39158\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nSeptember 21, 2021\n\nCase #: 615098\n\nWARNING LETTER\n\nMr. King:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sircle Laboratories, LLC, FEI 3011772828, at 105 Lexington Drive, Suite J, Madison, Mississippi, from April 13 to 26, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 11, 2021, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22)\n\nYour firm lacks appropriate oversight and procedures to manage contract manufacturing organizations (CMOs) used on behalf of your firm for the manufacturing, packaging, and distribution of your drug products. You are ultimately responsible for CGMP activities you perform.\n\nYour firm has failed to follow your established quality unit (QU) procedures, as well as commitments documented in quality agreements (QA). In your response, you maintained that you have CGMP responsibilities, including, but not limited to, having written procedures for your quality unit, handling of consumer complaints, release of drug products, and qualifying and approving of your CMOs. QU deficiencies include:\n\nInadequate QU oversight of your CMOs\n\nYour QU lacked adequate oversight and controls for your CMOs, which led to your use of sub-standard CMOs. Since 2017, FDA has taken the following actions in response to CGMP violations found at your CMOs.\n\nFor example, (b)(4), was issued a Warning Letter on (b)(4), that included, but not limited to, violations for the failure to establish appropriate time limits for each stage of production, and failure to thoroughly investigate out-of-specification (OOS) results.\n\nIn your response, you stated that you are in the process of developing procedures that address the approval process for your CMOs. Your response is inadequate because you did not conduct a retrospective review of the lack of QU oversight of your CMOs and product distribution which may impact the identity, strength, quality, and purity of your drug products.\n\nIn response to this letter, provide a comprehensive assessment plan to ensure that suppliers are suitably qualified and appropriate oversight is maintained. This assessment should include, but not be limited to:\n\n• Supplier qualification selection and management procedures that encompass all functions of CGMP activities your CMOs perform on your behalf.\n\n• Suitability of your suppliers and key elements of your requalification program (e.g., audit).\n\nFailure to establish and follow QU procedures\n\n• Lack of batch release procedures\n\nYour firm failed to establish adequate written responsibilities and procedures for reviewing batches made by your CMO. You also failed to review production records for each batch for disposition (i.e., reject or approve) per your QA with (b)(4). You are ultimately responsible for approving or rejecting drug product batches manufactured for you by a contract facility. Determining the suitability of each batch for release is an essential component of your quality unit responsibility.\n\nIn your response, you confirmed that you do not have a written procedure specifying release of drug products from CMOs and stated that you are developing procedures. Your response is inadequate because you did not provide details on what these procedures entail or how they will be applied.\n\nFailure to follow change control procedures\n\nYour QU failed to ensure your firm follows your change control procedure. For example, since the last FDA inspection in March 2019, your firm implemented changes to your consumer complaints and drug product recalls procedures without following your change control procedure. In addition, you approved changes to your drug product labeling without following your change control procedure. In each of these instances, your firm did not adequately justify or document these changes as required in your change control procedure.\n\nIn your response, you acknowledge that you have not been following your change control procedure for the changes your firm has implemented. Your response is inadequate in that the forms provided did not include an assessment of the impact of the changes, including changes to your labeling materials.\n\nIn response to this letter, provide a comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\nYour response is inadequate because you did not conduct a retrospective review of the failure to establish and follow QU procedures, which may impact the identity, strength, quality, and purity of your drug products.\n\n• In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision. Include a retrospective review of all batches currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\n2. Your firm failed to follow establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\n\nYou acknowledge that while you use CMOs on your behalf, you maintain associated CGMP responsibilities, including, but not limited to, handling customer complaints and inquiries. However, your firm failed to adequately establish and follow your established complaint handling procedure. For example, your procedure stipulated responsibilities for the handling and investigating of consumer complaints to your “Drug Safety Specialist” and “Chief Scientific Officer.” During the inspection, these titles and staff positions did not exist at your firm.\n\nFurther, your QA with (b)(4) states that you will notify (b)(4) of complaints that are likely to result in a field alert and\u002For recall, and that (b)(4) will conduct and complete the complaint investigation. All quality-related complaints, beyond those likely to result in a field alert and\u002For recall, must be investigated per 211.198.\n\nIn your response, you stated that you revised the complaint handling procedure by removing the non-existent titles and replacing these job titles to “Chief Operating Officer.” Your response is inadequate because you did not provide evidence demonstrating that this individual follows the complaint handling procedure and performs reviews to determine whether a complaint represents a serious and unexpected adverse drug event.\n\nIn response to this letter, provide the following:\n\n• Your retrospective assessment of complaints received by Sircle that were or should have been shared with your CMOs, including quality-related complaints that may not have been likely to result in a field alert and\u002For recall.\n\n• A list of complaints received by Sircle from all sources, including those received by your CMOs where you handle customer complaints and inquiries.\n\n• Procedure(s) detailing how you will share quality-related complaints with your CMOs\n\n3. Your firm failed to establish and follow written procedures designed to assure that correct labels, labeling, and packaging are used for drug products. (21 CFR 211.130)\n\nYour firm reviews and approves the labeling for the drug products manufactured by your CMOs. Your procedure for reviewing and approving the labels is inadequate. For example, your procedure does not require the verification of all elements on the labels, such as storage conditions and dispensing volumes. Moreover, your procedure does not include a review or comparison of drug product labels against an approved master or reference label.\n\nIn your response, you stated that you use master labels and that you are in the process of revising your label review procedure by July 1, 2021. Your response is inadequate.\n\nYou did not provide evidence that your firm uses master or reference labels when reviewing and approving your drug product labels. In addition, you have not provided your updated procedure in response to this observation. Further, your response lacks a retrospective review to ensure appropriate labeling is on all products currently in distribution.\n\nIn response to this letter, provide the following:\n\n• Your corrective action and preventive action (CAPA) plan to improve labeling operations including adequate procedures for labeling review and approval, management oversight, and any other needed actions.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nRepeat Violations at Facility\n\nIn previous inspections, dated August 2015, and March 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your responses. These repeated violations demonstrate a failure of your executive management to exercise proper oversight and control over the manufacture of drugs. You should immediately and comprehensively assess all of your firm’s manufacturing operations to ensure that systems, processes, and ultimately, products conform to FDA requirements.\n\nIn response to this letter, provide the following:\n\n• Describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates staff with proper investigation competencies, effectively conducts root cause analysis, assures CAPA effectiveness, regularly reviews investigations trends, implements improvements to the CAPA program when needed, ensures appropriate quality unit decision rights, and is fully supported by executive management.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nAs stated in your response, confirm that your CMO, (b)(4), is performing microbial testing on all batches of drug products manufactured by them for your firm.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 615098.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to John Diehl, Compliance Branch, via john.diehl@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Rebecca Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTamala P. Bogan\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II","Sircle Laboratories, LLC","sircle-laboratories-llc-615098-09212021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsircle-laboratories-llc-615098-09212021","2026-10-26T08:09:58.315128+00:00","615098","Bobby J. King, Jr.","2026-08-20T02:31:15.214+00:00","2021-09-21",{"id":374,"raw":375,"subject":12,"body_html":379,"body_text":380,"firm_name":381,"letter_id":382,"created_at":195,"fei_number":19,"letter_url":383,"updated_at":384,"action_type":22,"case_status":23,"posted_date":385,"marcs_cms_no":386,"product_type":96,"closeout_date":19,"issuing_office":86,"recipient_name":387,"body_fetched_at":388,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":389,"medical_device_id":19,"response_letter_date":19},2791,[376,377,378,86,229,13,13,13],"\u003Ctime datetime=\"2022-03-29T13:20:00Z\">03\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-25T04:00:00Z\">03\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagropharma-laboratories-inc-623475-03252022\">Agropharma Laboratories, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jorge Gonzalez Camp\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agropharma Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Urb Industrial Salinas Carr 701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Salinas\u003C\u002Fspan> \u003Cspan>00751\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tato@oleincorp.com\"> tato@oleincorp.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:agropharma_lab@yahoo.com\"> agropharma_lab@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 3\u002F25\u002F2022\u003C\u002Fp>\n\n\u003Cp>Case #: 623475\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gonzalez Camp:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Agropharma Laboratories, Inc., FEI 3000203462, at Carr 701 Km 0.4, Playa Salinas Industrial Park, Salinas, Puerto Rico, from October 21 to November 3, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 6, 2021, response to our Form FDA 483 in detail. Although you mentioned that you engaged the services of a consultant to help you complete a detailed evaluation of the observations and provide responses, you did not provide specific information or evidence of corrective actions to the observations identified during the inspection on our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter antiseptics indicated for open wounds, as well as hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> labeled for use by healthcare personnel. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate testing of your incoming components for identity, purity, strength, and other appropriate quality attributes (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fli>\n\t\u003Cli>Adequate testing and appropriate specifications for your finished drug products (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate procedures describing process validation, investigations, deviations, equipment cleaning, and change management (21 CFR 211.22(d)).\u003C\u002Fli>\n\t\u003Cli>Adherence to your ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\n\t\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\n\t\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fli>\n\t\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition (21 CFR 211.56(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drug manufacturing areas at your facility were in disrepair. For example, our investigator observed facility damage such as broken walls in the production area, filth, and pooling water in close proximity to open manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has not established that your processes used to manufacture drug products are validated. Additionally, your firm uses water from your water system as a component to manufacture your drug products; however, you have not established that the water system is adequately designed, controlled, maintained, and monitored to ensure that it consistently produced water suitable for its intended use.\u003C\u002Fp>\n\n\u003Cp>Your firm lacks a process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of our manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility. A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. However, your firm continues to be registered as a manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\u003Cbr>\n\u003Cbr>\nIf you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations and Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous Untitled Letter (11-SJN-UTL-02) dated October 13, 2010, and in subsequent inspections, FDA cited similar CGMP violations and observations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>623475\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to dayna.matinez@fda.hhs.gov and orapharm2actingdcb@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at (787) 729-8608 or email at dayna.martinez@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>Cc: Ms. Marianela Maldonado\u003Cbr>\nResident Agent\u003Cbr>\nAgropharma Laboratories, Inc.\u003Cbr>\nP.O. Box 1150\u003Cbr>\nSalinas, Puerto Rico 00751-1150\u003Cbr>\nmmaldonado@oleincorp.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Agropharma’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jorge Gonzalez Camp\n\nRecipient Title\n\nPresident\n\nAgropharma Laboratories, Inc.\n\nUrb Industrial Salinas Carr 701\n\nSalinas 00751\n\nPuerto Rico\n\ntato@oleincorp.com\n\nagropharma_lab@yahoo.com\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nDATE: 3\u002F25\u002F2022\n\nCase #: 623475\n\nWARNING LETTER\n\nDear Mr. Gonzalez Camp:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Agropharma Laboratories, Inc., FEI 3000203462, at Carr 701 Km 0.4, Playa Salinas Industrial Park, Salinas, Puerto Rico, from October 21 to November 3, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 6, 2021, response to our Form FDA 483 in detail. Although you mentioned that you engaged the services of a consultant to help you complete a detailed evaluation of the observations and provide responses, you did not provide specific information or evidence of corrective actions to the observations identified during the inspection on our Form FDA 483.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm manufactures over-the-counter antiseptics indicated for open wounds, as well as hand sanitizers1 labeled for use by healthcare personnel. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAdequate testing of your incoming components for identity, purity, strength, and other appropriate quality attributes (21 CFR 211.84(d)(1) and (2)).\n\nAdequate testing and appropriate specifications for your finished drug products (21 CFR 211.165(a)).\n\nAdequate procedures describing process validation, investigations, deviations, equipment cleaning, and change management (21 CFR 211.22(d)).\n\nAdherence to your ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of annual product reviews (21 CFR 211.180(e)).\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include, but not be limited to:\n\nA determination of whether procedures used by your firm are robust and appropriate.\n\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\nA complete and final review of each batch and its related information before the QU disposition decision\n\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\n\n2. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition (21 CFR 211.56(a)).\n\nDrug manufacturing areas at your facility were in disrepair. For example, our investigator observed facility damage such as broken walls in the production area, filth, and pooling water in close proximity to open manufacturing equipment.\n\nIn response to this letter, provide your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm has not established that your processes used to manufacture drug products are validated. Additionally, your firm uses water from your water system as a component to manufacture your drug products; however, you have not established that the water system is adequately designed, controlled, maintained, and monitored to ensure that it consistently produced water suitable for its intended use.\n\nYour firm lacks a process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of our manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility. A comprehensive, independent assessment of your water system design, control, and maintenance.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility. However, your firm continues to be registered as a manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility or another in the future.\n\nIf you plan to resume manufacturing drugs, ensure that adequate corrective actions are in place and notify this office to schedule a meeting before resuming your operations.\n\nBased upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nRepeat Violations and Observations at Facility\n\nIn a previous Untitled Letter (11-SJN-UTL-02) dated October 13, 2010, and in subsequent inspections, FDA cited similar CGMP violations and observations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 623475.\n\nPlease electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to dayna.matinez@fda.hhs.gov and orapharm2actingdcb@fda.hhs.gov\n\nIf you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at (787) 729-8608 or email at dayna.martinez@fda.hhs.gov\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\nCc: Ms. Marianela Maldonado\n\nResident Agent\n\nAgropharma Laboratories, Inc.\n\nP.O. Box 1150\n\nSalinas, Puerto Rico 00751-1150\n\nmmaldonado@oleincorp.com\n\n_____________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Agropharma’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&C Act.","Agropharma Laboratories, Inc.","agropharma-laboratories-inc-623475-03252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagropharma-laboratories-inc-623475-03252022","2026-10-26T08:07:51.24982+00:00","2022-03-29","623475","Mr. Jorge Gonzalez Camp","2026-08-20T02:03:53.387+00:00","2022-03-25",{"id":391,"raw":392,"subject":87,"body_html":396,"body_text":397,"firm_name":398,"letter_id":399,"created_at":400,"fei_number":19,"letter_url":401,"updated_at":402,"action_type":22,"case_status":23,"posted_date":403,"marcs_cms_no":404,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":405,"body_fetched_at":406,"delivery_method":407,"recipient_title":19,"reference_number":408,"action_taken_date":409,"medical_device_id":19,"response_letter_date":19},21703,[393,394,395,11,87,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-17T04:00:00Z\">09\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbentley-laboratories-llc-732028-09172026\">Bentley Laboratories LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-126\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. James Burke\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bentley Laboratories LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>111 Fieldcrest Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Edison\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08837-3622\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:james.burke@bentleylabs.com\"> james.burke@bentleylabs.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 17, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-126\u003C\u002Fp>\u003Cp>To Mr. James Burke:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facilities, and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection and Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Bentley Laboratories LLC, FDA Establishment Identifier (FEI) 2244819, at 111 Fieldcrest Avenue, Edison, from March 16 to 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during a review of product labeling collected during the onsite inspection. Based on our review, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(a) and 331(d).\u003C\u002Fp>\u003Cp>We reviewed your April 21, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cem>CGMP Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to adequately investigate several out-of-specification (OOS) laboratory results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to adequately investigate and scientifically identify the root cause for OOS assay results for lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the 24-month stability timepoint of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also did not adequately evaluate the impact to products on the market.\u003C\u002Fli>\u003Cli>You failed to adequately investigate an OOS result for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for pH at the 36-month stability timepoint. Moreover, as a corrective action and preventive action (CAPA), your firm expanded the pH specification range without scientific justification.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You did not thoroughly investigate these failures of a component or drug product to meet any of its specifications. Your investigations were inadequate because you failed to identify the root cause, implement appropriate CAPA, and expand the investigation to evaluate the impact on other batches or products.\u003C\u002Fp>\u003Cp>In your response, you state the root cause of inadequate investigations was due to deficiencies in your investigation procedures. Your response is inadequate. You fail to include changes to your investigation procedures to require root cause assessment for OOS results. Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\u003Cp>For more information about handling out-of-specification and failing test results, and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating \u003Cstrong>(b)(4)\u003C\u002Fstrong>, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program whenever needed, ensures final QU decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including customer notifications and recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in manufacturing your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, you did not perform adequate identity testing on each shipment of each lot of incoming components (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You manufacture multiple drugs that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). You failed to adequately test your incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you state that you initiated a change control request “to modify the system to ensure \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity testing is included” and tested raw materials for \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurities. Your response is inadequate because you do not provide sufficient detail about your updated raw material specifications and how you will ensure performance of appropriate incoming testing for each component. Also, you failed to indicate whether you lack retain samples of any batches and are therefore unable to test them for impurities. Additionally, you failed to demonstrate that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used as a component to manufacture your drug products met USP monograph specifications including those for impurities (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity before using it in manufacturing your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you state that you initiated a change control request “to modify the test procedure to ensure the inclusion of \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and tested raw materials for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response is inadequate because you do not provide sufficient documentation of your updated raw material specifications and how you will ensure performance of appropriate testing on incoming components. Also, you failed to indicate whether you lack retain samples of any batches and are therefore unable to test them for hazardous impurities.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components, we note that this includes the performance of parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>A commitment to perform reconciliation of retains tested versus all lots used in production. If retain samples are unavailable, a commitment to test finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Also include your analytical methods.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately validate your manufacturing processes for OTC drug products. You did not revalidate your manufacturing processes after making major process changes, nor did you fully execute validation protocols through the completion of all batches. For example, you changed the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to rephase the formulation without revalidation and outside of your change management system. Also, for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your process validation execution deviated from your Validation Master Plan (VMP) which requires validating your manufacturing processes with three batches. Furthermore, you did not retain stability samples from any of the three batches.\u003C\u002Fp>\u003Cp>Your firm also failed to adequately validate your cleaning processes for non-dedicated equipment used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For the two validation batches where cleaning validation swab samples were collected, OOS results for residual of active pharmaceutical ingredients were not adequately investigated.\u003C\u002Fp>\u003Cp>In your response, you state a change control will be conducted for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and, if required, a process validation will be performed for the revised process. You also state you will complete the validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and will update your VMP as well as applicable standard operating procedures (SOPs).\u003C\u002Fp>\u003Cp>Your response is inadequate because you do not commit to revalidating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process. Additionally, you do not evaluate the roles and responsibilities of your QU, including change management and document control, to ensure comprehensive oversight functions.\u003C\u002Fp>\u003Cp>Also, it appears that you used a maximum allowable carryover limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm in your cleaning validation calculations without adequate scientific justification. Without adequate process validation that incorporates all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug products produced using inadequately validated processes.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make their manufacturing equipment difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of the product labeling, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are “drugs” under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Geologie Acne Control Body Wash\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“2% Salicylic Acid…1.5% Glycolic Acid…Clears Skin Fast…Prevents New Breakouts… Drug Facts…Uses…For the treatment of acne. Penetrates pores to eliminate most acne blemishes, whiteheads, &amp; blackheads. Helps prevent new acne blemishes.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>Perricone MD Acne Relief Maximum Strength Spot Gel\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Acne Relief…\u003Cem>Drug Facts\u003C\u002Fem>…\u003Cem>Uses\u003C\u002Fem>…For the treatment of acne…KEY INGREDIENTS Lactic &amp; Succinic Acids: Target Acne-Causing Bacteria…help minimize blemishes…Citrulline: Fight &amp; Visibly Reduce Redness…Tea Tree Oil: Clarify &amp; Soothe… helps soothe the skin &amp; visibly reduce redness.” [from the product label]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are intended for use as acne drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription acne drug products, such as your “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel”, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph(s), here M006 (Topical Acne Drug Products for Over-the-Counter Human Use).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” do not conform to the conditions specified in M006 for the reasons described below.\u003C\u002Fp>\u003Cp>Your product \"Geologie Acne Control Body Wash\" includes the active ingredient Glycolic Acid, which is not a permitted active ingredient under M006.10. 21. CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although the product label does not specifically list Glycolic Acid as an active ingredient in the Drug Facts labeling, your product labeling makes claims such as “1.5% Glycolic Acid…Clears Skin Fast…Prevents New Breakouts” which demonstrates that this is an “active ingredient” in your acne treatment product because it is intended to furnish pharmacological activity. Specifically, the ingredient for this product is not permitted or recognized as an acceptable active ingredient when used under M006. We note that while salicylic acid is a permitted active ingredient under M006, it is not permitted in combination with the above ingredient or other active ingredients.\u003C\u002Fp>\u003Cp>In addition, as labeled, \"Perricone MD Acne Relief Maximum Strength Spot Gel\" includes the active ingredients Lactic &amp; Succinic Acids, Citrulline, and Tea Tree Oil, which are not permitted active ingredients under M006.10. Although the product label does not specifically list Lactic &amp; Succinic Acids, Citrulline, and Tea Tree Oil as active ingredients in the Drug Facts panel. Label claims such as “KEY INGREDIENTS Lactic &amp; Succinic Acids: Target Acne-Causing Bacteria…help minimize blemishes…Citrulline: Fight &amp; Visibly Reduce Redness…Tea Tree Oil: helps soothe the skin &amp; visibly reduce redness” demonstrate that these are “active ingredients” in your acne treatment product because they are intended to furnish pharmacological activity.\u003C\u002Fp>\u003Cp>Thus, the “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” products do not comply with the applicable conditions specified in M006 and have not otherwise been found to be GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of OTC drug products “that do not meet the required testing and systemic rigor” at this facility.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 2244819 and ATTN: Sena G. Dissmeyer in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M006, in the final administrative order, Over-the-Counter Monograph M006: Topical Acne Drug Products for Over-the-Counter Human Use, reflects the conditions in the relevant final order established and in effect under section 505G. See Order ID OTC000013, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\n320-26-126\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. James Burke\n\nRecipient Title\n\nPresident\n\nBentley Laboratories LLC\n\n111 Fieldcrest Avenue\n\nEdison, NJ 08837-3622\n\nUnited States\n\njames.burke@bentleylabs.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nSeptember 17, 2026\nWARNING LETTER\nReference number: 320-26-126\nTo Mr. James Burke:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facilities, and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection and Review\nViolations were observed and documented during an inspection of your drug manufacturing facility, Bentley Laboratories LLC, FDA Establishment Identifier (FEI) 2244819, at 111 Fieldcrest Avenue, Edison, from March 16 to 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during a review of product labeling collected during the onsite inspection. Based on our review, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&C Act, 21 U.S.C. 331(a) and 331(d).\nWe reviewed your April 21, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\nCGMP Violations\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n(b)(4) drug products such as (b)(4). Your firm failed to adequately investigate several out-of-specification (OOS) laboratory results. For example:\nYou failed to adequately investigate and scientifically identify the root cause for OOS assay results for lot (b)(4) at the (b)(4) at the 24-month stability timepoint of (b)(4). You also did not adequately evaluate the impact to products on the market.\nYou failed to adequately investigate an OOS result for (b)(4), lot (b)(4), for pH at the 36-month stability timepoint. Moreover, as a corrective action and preventive action (CAPA), your firm expanded the pH specification range without scientific justification.\nYou did not thoroughly investigate these failures of a component or drug product to meet any of its specifications. Your investigations were inadequate because you failed to identify the root cause, implement appropriate CAPA, and expand the investigation to evaluate the impact on other batches or products.\nIn your response, you state the root cause of inadequate investigations was due to deficiencies in your investigation procedures. Your response is inadequate. You fail to include changes to your investigation procedures to require root cause assessment for OOS results. Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\nFor more information about handling out-of-specification and failing test results, and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating (b)(4), discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program whenever needed, ensures final QU decision authority, and is fully supported by executive management.\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\nYour action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including customer notifications and recalls.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to ensure that components were suitable for use in manufacturing your OTC (b)(4) drug products. For example, you did not perform adequate identity testing on each shipment of each lot of incoming components (e.g., (b)(4)). Additionally, you relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\nProducts Containing (b)(4)\nYou manufacture multiple drugs that contain (b)(4) (e.g., (b)(4)). You failed to adequately test your incoming (b)(4) for (b)(4) contamination. The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you state that you initiated a change control request “to modify the system to ensure (b)(4) impurity testing is included” and tested raw materials for (b)(4) impurities. Your response is inadequate because you do not provide sufficient detail about your updated raw material specifications and how you will ensure performance of appropriate incoming testing for each component. Also, you failed to indicate whether you lack retain samples of any batches and are therefore unable to test them for impurities. Additionally, you failed to demonstrate that the (b)(4) you used as a component to manufacture your drug products met USP monograph specifications including those for impurities (e.g., (b)(4)).\nProducts Containing (b)(4)\nYou also failed to adequately test your incoming components at high risk of (b)(4) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of (b)(4) to determine its appropriate identity before using it in manufacturing your OTC (b)(4) drug products.\nIdentity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for (b)(4) or (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nIn your response, you state that you initiated a change control request “to modify the test procedure to ensure the inclusion of (b)(4)” and tested raw materials for (b)(4). Your response is inadequate because you do not provide sufficient documentation of your updated raw material specifications and how you will ensure performance of appropriate testing on incoming components. Also, you failed to indicate whether you lack retain samples of any batches and are therefore unable to test them for hazardous impurities.\nWithout adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components, we note that this includes the performance of parts (b)(4) of the USP monograph.\nBased on a thorough review, provide a summary of your systems CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\nA commitment to perform reconciliation of retains tested versus all lots used in production. If retain samples are unavailable, a commitment to test finished drug product batches for the presence of (b)(4). Also include your analytical methods.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots.\nIdentify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to adequately validate your manufacturing processes for OTC drug products. You did not revalidate your manufacturing processes after making major process changes, nor did you fully execute validation protocols through the completion of all batches. For example, you changed the manufacturing process for (b)(4) to rephase the formulation without revalidation and outside of your change management system. Also, for (b)(4), your process validation execution deviated from your Validation Master Plan (VMP) which requires validating your manufacturing processes with three batches. Furthermore, you did not retain stability samples from any of the three batches.\nYour firm also failed to adequately validate your cleaning processes for non-dedicated equipment used to manufacture (b)(4). For the two validation batches where cleaning validation swab samples were collected, OOS results for residual of active pharmaceutical ingredients were not adequately investigated.\nIn your response, you state a change control will be conducted for the (b)(4) and, if required, a process validation will be performed for the revised process. You also state you will complete the validation for the (b)(4) and will update your VMP as well as applicable standard operating procedures (SOPs).\nYour response is inadequate because you do not commit to revalidating the (b)(4) process. Additionally, you do not evaluate the roles and responsibilities of your QU, including change management and document control, to ensure comprehensive oversight functions.\nAlso, it appears that you used a maximum allowable carryover limit of (b)(4) ppm in your cleaning validation calculations without adequate scientific justification. Without adequate process validation that incorporates all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\nA risk assessment for the distributed drug products produced using inadequately validated processes.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make their manufacturing equipment difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nA description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nQuality Systems\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nUnapproved New Drug Violations\nBased on a review of the product labeling, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are “drugs” under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as a drug include, but may not be limited to, the following:\nGeologie Acne Control Body Wash\n“2% Salicylic Acid…1.5% Glycolic Acid…Clears Skin Fast…Prevents New Breakouts… Drug Facts…Uses…For the treatment of acne. Penetrates pores to eliminate most acne blemishes, whiteheads, & blackheads. Helps prevent new acne blemishes.” [from the product label]\nPerricone MD Acne Relief Maximum Strength Spot Gel\n“Acne Relief…Drug Facts…Uses…For the treatment of acne…KEY INGREDIENTS Lactic & Succinic Acids: Target Acne-Causing Bacteria…help minimize blemishes…Citrulline: Fight & Visibly Reduce Redness…Tea Tree Oil: Clarify & Soothe… helps soothe the skin & visibly reduce redness.” [from the product label]\nBased on the above labeling evidence, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are intended for use as acne drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription acne drug products, such as your “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel”, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph(s), here M006 (Topical Acne Drug Products for Over-the-Counter Human Use).1 However, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” do not conform to the conditions specified in M006 for the reasons described below.\nYour product \"Geologie Acne Control Body Wash\" includes the active ingredient Glycolic Acid, which is not a permitted active ingredient under M006.10. 21. CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although the product label does not specifically list Glycolic Acid as an active ingredient in the Drug Facts labeling, your product labeling makes claims such as “1.5% Glycolic Acid…Clears Skin Fast…Prevents New Breakouts” which demonstrates that this is an “active ingredient” in your acne treatment product because it is intended to furnish pharmacological activity. Specifically, the ingredient for this product is not permitted or recognized as an acceptable active ingredient when used under M006. We note that while salicylic acid is a permitted active ingredient under M006, it is not permitted in combination with the above ingredient or other active ingredients.\nIn addition, as labeled, \"Perricone MD Acne Relief Maximum Strength Spot Gel\" includes the active ingredients Lactic & Succinic Acids, Citrulline, and Tea Tree Oil, which are not permitted active ingredients under M006.10. Although the product label does not specifically list Lactic & Succinic Acids, Citrulline, and Tea Tree Oil as active ingredients in the Drug Facts panel. Label claims such as “KEY INGREDIENTS Lactic & Succinic Acids: Target Acne-Causing Bacteria…help minimize blemishes…Citrulline: Fight & Visibly Reduce Redness…Tea Tree Oil: helps soothe the skin & visibly reduce redness” demonstrate that these are “active ingredients” in your acne treatment product because they are intended to furnish pharmacological activity.\nThus, the “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” products do not comply with the applicable conditions specified in M006 and have not otherwise been found to be GRASE.2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nYour “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of OTC drug products “that do not meet the required testing and systemic rigor” at this facility.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance.\nIn addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 2244819 and ATTN: Sena G. Dissmeyer in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________________\n1 M006, in the final administrative order, Over-the-Counter Monograph M006: Topical Acne Drug Products for Over-the-Counter Human Use, reflects the conditions in the relevant final order established and in effect under section 505G. See Order ID OTC000013, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Bentley Laboratories LLC","bentley-laboratories-llc-732028-09172026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbentley-laboratories-llc-732028-09172026","2026-11-10T01:02:16.121874+00:00","2026-09-29","732028","Mr. James Burke","2026-10-14T12:34:27.629+00:00","VIA UNITED PARCEL SERVICE","320-26-126","2026-09-17",52,{"510k":412,"classification":413,"enforcement":414,"event":415,"event_backfill":416,"pma":417,"warning_letter":418},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]